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Abstract 
Since the late 1960s the safety of inhaled ~2-agonists has been questioned and the long-
tenn regular use of these drugs has been linked to increasing morbidity and mortality. 
National and international guidelines recommend that short acting inhaled ~2-agonists 
should only be used on an "as needed" basis and yet the e\'idence for these 
recommendations is still unclear, one reason being the lack of common definition for an 
outcome. The Regular Use of Salbutamol Trial (TRUST) was designed to assess the 
risks and benefits of regular versus as needed salbutamol in mild to moderate asthma. 
In order to establish whether a common primary outcome measure could impron~ the 
comparability and interpretation of different trials, a systematic rcyiew of randomised 
controlled trials of long and short acting inhaled ~2-agonists in asthmatic subjects was 
undertaken to identify well designed trials in this field and primary outcome measures 
used. The systematic review identified five different primary outcome measures from 
26 trials of long and short acting inhaled ~2-agonists. The TRUST definition of 
exacerbation was compared with the five primary outcome measures identified using 
the TRUST diary card data. In addition, the diary card variables (changes in PEF, 
symptom scores and medication use) were examined to determine the extent to which 
they predicted exacerbations according to the different definitions. 
The use of additional corticosteroids and an increase in daytime symptoms of two or 
more above baseline were the strongest predictors of all four definitions of 
exacerbation. A fall in morning PEF of 100 lImin was strongly associated with all 
definitions of exacerbation but was not a sensitive measure. 
In conclusion, exacerbations of asthma could be identified by use of additional 
corticosteroids and an increase in two or more of daytime symptoms. The specificity 
could be improved by including morning PEF but this may reduce patient compliance 
\\'ith study protocol in asthma trials. 
Publications arising from this work 
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Chapter 1 - Introduction 
1. 1 Aim of thesis 
Many composite primary outcome measures haye been used to assess the response of 
asthmatic subjects to interventions in clinical trials and one of the common outcomes is 
"exacerbation". However, definitions for an exacerbation in clinical trials have differed 
between studies and it is unclear which components of the composite measures are the 
most sensitive or specific in identifying an exacerbation. The overall aim of this project 
is to compare the outcome measures identified from a systematic reyiew of randomised 
controlled trials of inhaled Pragonists with the TRUST (The Regular Use of 
Salbutamol Trial) definition of exacerbation, using the TRUST dataset. This will clarify 
how the TRUST definition of exacerbation compares with primary outcome measures 
from other trials and to what extent the conclusions of trials may be affected by the 
precise definition of exacerbation used in the study. 
The thesis will present the background to the inhaled Pragonist debate to which 
TRUST contributed. The TRUST results will be reported and discussed. The different 
primary outcome measures identified by the systematic review will then used to re-
analyse TRUST to determine whether the result would have been affected by the choice 
of primary outcome measure. The measurement characteristics of the different primary 
outcome measures will be compared with the TRUST definition of exacerbation. The 
results of the analysis will inform a standard primary outcome measure for use in trials 
of long and short actin~ inhaled P2-agonists that may be relevant to clinical practice. 
1.2 The inhaled P2-agonist debate 
Inhaled Pragonists playa \'ital role in the management of asthma providing rapid relief 
of bronchoconstriction. Since the late 1960s their safety has been brought into question 
and the regular long-term use of these drugs has been linked to increasing morbidity and 
mortality. ;\ational and international guidelines (l-~) now ren)mmend that inhaled P.:-
agonists only be used on an "as needed" basis though the e\idence 1lJr thL'SL' 
recommcndations is still unclear. 
IJ 
An extensive search of the published literature suggested the regular use of inhaled ~::­
agonists has been over re\'iewed and under researched. A thorough search of \ kdline 
and the Cochrane Clinical Trials Register yielded over eighty publications on the ~ubject 
of inhaled P2-agonists and asthma since the paper by Speizer et al (4) was published in 
1968 and first linked the use of adrenergic stimulants with asthma death. 
Many reviews of inhaled Pragonist use in asthma have been published, the majority of 
which concluded that inhaled P2-agonists should be used with caution or that further 
research be undertaken (5-31). Only seven reviewers indicated that the use of inhaled 
P2-agonists is not a cause for concern (32-38). A recently published systematic re\'iew 
(39) suggested that there was no benefit in taking regular P2-agonists and that they may 
have a slight deleterious effect. 
A review of the evidence from retrospective studies yielded 11 / 16 (690/0) supporting a 
link between inhaled ~2-agonist therapy and an increase in morbidity or mortality from 
asthma (4;40-49). However only six of the forty-one (15%) randomised controlled trials 
published since 1968, reported a deleterious effect of inhaled 0~-agonists on asthma 
control (50-55). There is still a case for a well-designed randomised controlled trial to 
detennine whether the regular or prolonged use of inhaled ~2-agonists has a deleterious 
effect on asthma control. 
1.2.1 Evidence from retrospective studies 
Speizer et al reported an increase in asthma deaths in England and Wales between 1959 
and 1966 (56) and also reported on the use of anti-asthma medication prior to death 
from asthma (4). Inhaled isoprenaline, a non-specific adrenoreceptor agonist. was 
introduced in 1960 and oral corticosteroids in 1952; inhaled corticosteroids were not 
introduced until 1971. Speizer et al reported that 84° ° of the cases had used 
isoprenaline before they died. Corticosteroids had been prescribed at some time for 
71~o (123 /173) patients. Howe\,er 25°0 (31/173) of patients \\'ere not prescribed them 
immediately before the fatal episode. The authors concluded that the disease SC\ l'rity 
was undercstimakd in these patients and that there was an OYL'f reliance on iSl)prenaline 
14 
and a failure to recognise the need for corticosteroids. Whilst the eyidence suggested 
that there was a close correlation between adrenoreceptor agonist use and death from 
asthma it could not be said to be causal. Inman and Adelstein (40) also examined the 
details of the epidemic of asthma deaths in England and Wales in the late sixties. They 
reported that the number of patients admitted to hospital because of asilima was 
continuing to rise but ¢at by 1967 there had been no continued increase in the number 
of asthma deaths. They concluded that the increase in asthma deaths may also have 
been associated with an over reliance on the use of isoprenaline especially as it was 
available to buy over the counter until 1968. It is interesting to note that deaths from 
asthma had already begun to decline in 1967 before the publication of the papers by 
Speizer et al (4;56) in 1968. However, the timing of the increase in asthma mortality 
did coincide with the introduction of the high dose isoprenaline inhalers (18) which in 
turn lead to their being linked with an increase in risk of asthma death, see figure 1.1. 
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Figure 1.1 Sales and prescriptions of asthma preparations compared with 
deaths from asthma among people aged 5 - 34 in England and \\" ales, 
1959 - 68 (40). 
There was also an increase in deaths from asthma in Australia at about the same timc. 
Ho\\'e\'t~r the Australian evidence did not scem to support the association betwcen the 
1 :' 
use of isoprenaline inhalers and asthma death (57). The number of asthma death~ 
increased by 13 per 1 000 000 people between 1958-1963 and 1964-1966 before 
subsequently decreasing in spite of the continuing increase in the sales of adrenergic 
agonists including isoprenaline forte which was implicated in the UK epidemic. It is 
likely that something else was involved in the "epidemic" in Australia. Identifying 
trends from a combination of mortality and sales data is difficult and the results are not 
always reliable because they do not provide information on individual patient usage 
prior to death. 
A further increase in asthma mortality was reported in England and Wales between 1974 
and 1984, most apparent in the 5 to 34 year age group, increasing by 4.7° <> per annum (p 
< 0.05) (58). The increase in the rate of death from asthma was greater in males at 6.1 ~'o 
per annum (p < 0.05) than females at 2.1 % per annum (p < 0.05) in spite of the 
improvements in the treatments available for asthma. At this time the prevalence of 
asthma in the population had not been accurately determined which complicated the 
interpretation of the results although it was again postulated that failure to recognise the 
severity and under treatment were contributory factors in spite of rises in sales of all 
anti-asthma medications. 
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Figure 1.2 International patterns of asthma mortality (deaths per 100 000 
persons) aged 5 - 34 years, 1960 - 1994, showing the different trends 
(59). 
Figure l.2 shows the international trends in asthma mortality from asthma from 1960 
until 1995. Whilst the increases in asthma mortality in England and Wales in the mid 
1960s are clearly visible the increase in asthma mortality in New Zealand in the 1970s 
and 1980s is most striking (59). The New Zealand asthma epidemic of the mid 1980s 
renewed interest in the concerns over the use of inhaled ~2-agonists. Until 1989 the 
reviews and the original articles tended to discuss dosing regimens and clinical trials to 
compare new anti-asthma treatments. The publication of the case-control study by 
Crane et al (42) followed by the publication of the results of the case control analysis 
(41) and the cohort analysis (44) from Saskatchewan in Canada reopened the whole 
inhaled ~2-agonist debate. 
A case control study approach to asthma deaths is valuable in order to generate a 
hypothesis because the actual number of asthma deaths in anyone year is relati\'ely 
small. For example, in England and Wales in 1994 there were 1516 asthma deaths 
across all ages (1994 OPCS). This approach should provide infonnation on an 
association between the exposure: the use of p::--agonists. and the outcome of interest: 
\"7 
death from asthma, though the results cannot be used to infer that a relationship i~ 
causal. Crane et al calculated an odds ratio (OR) for asthma death associated with use 
of fenoterol metered dose inhaler (MOl) of l.6 (95% CI 1.04 to 2.3) and 0.7 (95l:~ CI 
0.5 to 1.07) for albuterol. Spitzer et al reported a crude odds ratio of 5.3 for death from 
asthma associated with use of fenoterol MOl, however when this was adjusted for the 
weight of the drug, the odds ratio for death associated with fenoterol was 2.3 (95 0 0 CI 
1.6 to 3.4) and 2.4 (950/0 CI 1.5 to 3.8) for albuterol. The two studies selected controls 
from quite different populations at risk of asthma death. which may have accounted for 
some of the differences in the odds ratios calculated. The controls in the ~e\\' Zealand 
study were asthmatics admitted to hospital with severe &sthma who survived (117 case 
and 468 controls) whereas the controls in the Saskatchewan study were selected from 
the cohort of asthmatics in the Saskatchewan population (129 cases and 655 controls). 
The risk of fatal and non-fatal severe asthma increased in both studies when other risk 
factors were included, such as other hospital admissions, loss of consciousness and 
other anti-asthma medication. In the Saskatchewan study, loss of consciousness OR 
10.6 (950/0 CI 5.2 to 21.5), blood gas data OR 3.0 (95% CI 1.5 to 6.1) and food allergy 
OR 3.8 (95% CI 2.3 to 6.4) all carried greater unadjusted odds ratios as independent risk 
factors than those associated with fenoterol or albuterol use (45). Hospital admission in 
the last year and prescription for oral prednisolone increased the odds ratio for asthma 
death associated with fenoterol to 13.3 (95%> CI 3.5 to 51.2 p<O.O 1) (42). Confounding 
factors such as these are difficult to correct for in a retrospective case-control study, but 
information could be collected in a prospective cohort. 
Suissa et al (44) reported the results from their Saskatchewan asthma cohort from which 
the previous nested case-control had been taken. They reported a rate of death from 
asthma for any exposure to fenoterol MOl of 61.5 per 10 000 asthmatics per year, and 
for albuterol 9.8 per 10 000 per year. They found that fenoterol was a confounding 
factor for albuterol use but not vice versa. and the rate was further confounded hy the 
usc of oral corticosteroids and hospital admissions for asthma in the pre\ious 24 
months. They then calculated the rates associated with the number of canisters of 
albuterol and fenoterol and corrected for the dose of fenoterol (twice that l)f alhutcrol). 
The rate of death from asthma increased with increasing number of canisters per year. 
1 ~ 
However the confidence intervals were large and included zero until 25 or more 
canisters were used. The rate for more than 25 canisters of albuterol was 30.9 (adjusted 
rate difference 20.3 95% CI 1.3 - 39.4) and for the dose equivalence of fenoterol 151 
(adjusted rate difference 129.8 95% CI 61.9 - 197.8). This strengthened the argument 
for the association of increased rate of asthma death and severity of disease. The reason 
for the greater risk associated with the use of fenoterol MDI was unclear though it has 
been speculated that fenoterol was prescribed preferentially to more severe asthmatics. 
Since the publication of these three papers there have been several subsequent 
publications describing further analyses undertaken aI1d examining the question of 
confounding by severity and investigations into the mechanism of action of fenoterol. 
Garret et al (60) repeated the analysis using the data from Crane et al (42). After 
controlling for asthma severity, hospital admission in the previous year and prescribed 
oral corticosteroids, the relative risk of asthma death related to the use of fenoterol 
compared to salbutamol dropped from 2.1 (95% CI 1.4 to 3.1) to 1.5 (95% CI 1.0 to 
2.3). The effect was lost altogether after controlling for other severity markers. They 
concluded that fenoterol was more likely to have been prescribed to more severe 
asthmatics and that if baseline severity was controlled for then fenoterol use could not 
be linked to asthma deaths. Blais et al (61) re-examined the Saskatchewan data and 
assessed the extent to which the results could have been confounded by indication, i.e. 
more severe asthmatics would have their medication changed from salbutamol to 
fenoterol in the belief that fenoterol was more effective in more severe cases of asthma. 
They were able to confirm that patients were switched from salbutamol to fenoterol in 
response to severity markers. Pearce et al (62) disagreed because they felt that the New 
Zealand data suggested too few patients had been switched from salbutamol to fenoterol 
and that more patients had been switched in the opposite direction. Part of the 
misunderstanding arises because of the sources of the data. The Saskatchewan study 
was a cohort study whereas the New Zealand study was a case control study and it is 
more difficult to assess changes over time, such as treatment changes in response to 
severity changes, with a retrospective case control design. 
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In 1996, Bremner et al (63) reported the results of a study to investigate the extra 
pulmonary effects of fenoterol and albuterol in vivo in non-asthmatic subjects. They 
found that, at the high doses required to treat acute severe asthma, fenoterol resulted in 
more adverse cardiac and metabolic effects compared to albuterol at the same doses. 
They concluded that because fenoterol was a full agonist it would result in greater extra 
pulmonary effects per puff than albuterol. The effect of fenoterol's actions as a full 
agonist may explain the increase in asthma deaths associated with its use and why the 
same effect was not seen with salbutamol or terbutaline. The increased potency 
associated with fenoterol may also have been a reason for the preferential prescription to 
more severe asthmatics. 
In 1993, a meta-analysis of case-control studies into the effect of inhaled P2-agonist use 
and death from asthma was published (47). The case control studies meeting the 
inclusion criteria were selected and the data were extracted and X2 for the association 
between Pragonist use and death from asthma was used. The combination of the six 
studies provided 364 cases and 1388 controls (41 ;42;48;49;64;65) and in order to 
perform the analysis the study outcomes were weighted in order to take into account the 
different sample sizes. The association was stronger for nebulised P2-agonists (OR 2.5) 
and reduced for P2-agonist metered dose inhalers (OR 1.3), including fenoterol. This 
again pointed to a link with severity, i.e. those with more severe asthma required more 
treatment and also had a higher risk of asthma death. 
Further attempts have been made to try to understand the reasons for the peaks in 
asthma deaths. Sales data and mortality data for the same country have been plotted on 
the same axes. The sales of inhaled P2-agonists continued to rise yet there was no 
continued increase in asthma deaths (66). The most recent paper reanalysed the New 
Zealand mortality and drug sale data (42) using a Poisson weighted linear regression 
(67). Again the results of this analysis suggested that initial visual method of analysis 
might have oversimplified the explanation for the epidemic overlooking the role that 
inhaled corticosteroids might have played in the epidemic. However these studies are of 
limited value because they are not able to provide insight into patterns of use in 
asthmatics at risk. 
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The most recent paper by Campbell et al (68) examined trends in asthma mortality from 
1983 to 1995 in England and Wales. During this period an annual decline in asthma 
deaths of 6% per annum in people under 65 years of age was reported with an 
accelerated decline in asthma deaths occurring in the 14 to 74 year age group between 
1983 and 1989. They concluded that a greater awareness of asthma and increasing use 
of anti-inflammatory medication might have had some impact on the decline in 
mortality. 
Whilst the results of these retrospective studies provide valuable information on the 
changes over time of asthma mortality and medication use, the results can only be used 
to suggest an association between the use of ~2-agonists and asthma mortality or 
morbidity. These types of studies are subject to potential biases in patient selection and 
problems with retrieving information retrospectively so they cannot be used to confirm 
causality. The only way to attempt to quantify whether the relationship between regular 
inhaled ~2-agonists is causal is to undertake a randomised controlled trial. 
1.2.2 Evidence from randomised controlled trials 
A search of the Cochrane Randomised Controlled Trials Register and of Medline 
yielded 50 randomised controlled trials of inhaled ~2-agonists (50-55;69-112). Many of 
the trials identified were too small to provide conclusive results. 
There have been seventeen randomised controlled trials of short acting inhaled ~r 
agonists (salbutamol, albuterol, terbutaline or fenoterol) since 1968 (50;51 ;53-55;69-
71 ;78;83;87;88;92;94;95; 113; 114), of which ten have reported results in favour of the 
use of regular ~2-agonists with or without the concomitant use of inhaled corticosteroids 
(69-71 ;78;83;85;87;88;92;94). The trials varied in quality and the sample sizes ranged 
from 17 to 341 with follow-up from 15 days to 2.5 years. Five trials reported results 
against the use of regular inhaled ~2-agonists with sample sizes ranging from 8 to 223 
(50;51 ;53-55). Two of these papers were two different analyses of the same trial 
(51 ;54) and the van Schayck trial combined chronic obstructive pUlmonary disease 
(COP D) with asthma and only eight asthmatics were randomised to regular inhaled ~2-
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agonist treatment (53;92). Three recently published trials reported no difference 
between inhaled ~ragonists and placebo in mild to moderate asthmatics over three to 
sixteen weeks (95; I 00; 1 02). The remaining published trials compared long and short 
acting inhaled ~2-agonists with or without placebo. All reported a positive result in 
favour of the use of the long acting inhaled ~2-agonists and in five trials where placebo 
was used the use of short acting inhaled ~2-agonists conferred additional benefit over 
placebo (80;84;91;105;106). For summary information on the randomised controlled 
trials of inhaled ~2-agonists in asthma see Appendices 1.1 and 1.2. 
The earliest randomised controlled trials of salbutamol versus placebo were small and 
reported that patients taking regular salbutamol experienced fewer wheezing episodes or 
lower symptom scores and less seasonal variation than those randomised to an as needed 
treatment (70;71). One of the first trials to suggest that the regular use of inhaled ~2-
agonists may have resulted in a deleterious effect was by Vathenen et al in 1988 (50). 
This trial was particularly interesting because it measured the effect of taking regular 
terbutaline, 500 J,lg or 2000 J,lg or placebo three times daily, on airway 
hyperresponsiveness with a methacholine challenge and the dose needed to produce a 
20% fall (PC20) in forced expiratory volume in one second (FEV 1). The investigators 
found that after 15 days' regular treatment with terbutaline, the ability of a single dose 
of terbutaline to protect against a methacholine challenge was lost. This trial has had an 
impact on the future trials of regular inhaled ~2-agonist use in terms of the length of trial 
required, because the effect of terbutaline on bronchial hyperresponsiveness has been 
used as justification for other trials to be limited to only two weeks follow-up. 
In 1990 three trials investigating the use of inhaled ~2-agonists were published. Two 
involving the use of two new long acting inhaled ~ragonists. These two trials of 
fonnoterol and salmeterol versus salbutamol (73;74) both demonstrated that the long 
acting P2-agonists provided an improvement over the use of short acting inhaled ~2-
agonists alone. In neither trial was there a placebo group, so inferences could not be 
made about the additional benefits of long acting over short acting inhaled P2-agonists 
over placebo. The third trial to be published in 1990 by Sears et al (51) received much 
publicity and an additional paper was published from a further analysis in 1993 (54). 
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Mild to moderate asthmatics were randomised to receive regular versus as needed 
fenoterol for 24 weeks in a crossover design. Sixty-four patients completed the trial and 
they concluded that "asthma control" was improved with as needed fenoterol compared 
to regular use. "Asthma control" was assessed by combining different outcome 
measures to produce an overall score. There were several inconsistencies with the 
method of analysis of this trial. It was not clear what weight was given to the markers 
of asthma severity used in the overall score of asthma control. Evening peak expiratory 
flow (PEF) was much improved on regular treatment and daytime rescue use seemed to 
have been omitted from the presentation of their results. The second paper from the 
same trial reported the differences in exacerbations, PC20, FEV I, PEF and symptoms 
(54). Again the results were significant in favour of the use offenoterol only as needed 
for symptom control, but only for the changes in PEF diurnal variation and pre-
bronchodilator FEV I. 
The next major publication on this theme was by van Schayck et al (53) in 1991. A total 
of 223 patients with asthma or COPD were randomised to receive terbutaline or 
ipratropium bromide. The results suggested that regular treatment with terbutaline 
caused a greater decline in lung function over time. However, only 58 of the 223 
patients were asthmatic and of these only eight were randomised to regular treatment. A 
further follow-up of 83 patients after 4 years demonstrated no deterioration associated 
with the regular use of terbutaline. 
Since 1992 many of the published trials compared the efficacy of inhaled long acting ~2-
agonists with short acting inhaled ~2-agonists and / or placebo. There was a general 
concern that if the deleterious effects of short term inhaled ~ragonists were real then 
they could also occur with the use of long-term inhaled ~ragonists. It was suggested 
that the regular use of inhaled ~2-agonists caused the ~2 adrenoreceptors to down 
regulate; the receptors internalise to avoid further stimulation, but this has not been 
demonstrated in vivo in asthma. It is known that ~2 receptors can be down regulated if 
exposed to continuous stimulation with ~2-agonists in vitro. Since 1992 there have been 
twenty-nine trials investigating the effects of long acting ~2-agonists (salmeterol or 
formoterol) compared to short acting ~2-agonists or inhaled steroids (52:72-77;79-
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82;84;86;89-91 ;96;97;99; 101; 1 03-1 06; 1 08-112). Those trials that haye used a placebo 
group as well as a short acting inhaled Pragonist demonstrated that a long acting P2-
agonist was more effective than a short acting P2-agonist which in tum was more 
effective than placebo (80;84;91; 1 05; 1 06). The benefits associated with the use of long 
acting P2-agonists appear to have increased the uncertainty concerning the safety of 
short acting inhaled P2-agonists. 
Short and long acting P2-agonists exert their effects on the Prreceptor in slightly 
different ways. The long acting P2-agonists possess a longer substitution in the amine 
head, which is highly lipophilic (9). The long tail is thought to bind to an exosite and 
this seems to enable the salmeterol molecule to continue to reassert its effect on the P2 
receptor (115). Computer modelling suggested an interaction with the a helices of the 
receptor itself and forrnoterol might also protect against acetylcholine induced 
bronchoconstriction. There is some evidence that tachyphylaxis is associated with the 
use of long acting P2-agonists (116-118). The downregulation and desensitisation seems 
to affect the bronchoprotective rather than the bronchodilator effects. Long acting Pr 
agonists may antagonise the bronchodilator effect of short acting P2-agonists (119) and 
may have clinical implications in the treatment of acute severe asthma. For the 
molecular structures of salbutamol and salmeterol see figure 1.3. 
Salbutamol OH 
Salmeterol HO 
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Figure 1.3 Structural diagram of salbutamol and salmetcrol. 
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Perhaps the strongest of the most recent e\·idence for the use of inhaled ~2-agonists 
comes from two trials, Chapman (83) and Drazen (95). Chapman (83) carried out a 
short trial of only two weeks and reported an impro\·ement with the regular use of 
salbutamol. Because the intervention period was so short it would be difticult to 
extrapolate the results to determine whether their long-term regular use was appropriate. 
Drazen et al (95) carried out a randomised controlled trial in USA to compare regular 
versus as needed albuterol in mild asthmatics. The trial lasted for sixteen weeks and 
involved 255 patients. They reported no difference between regular and as needed 
treatment. 
The publication of these robustly designed trials, which have failed to repeat the results 
reported by Sears and Taylor et al (51 ;54) has sown the seeds of doubt and reopened the 
debate. Short acting inhaled ~2-agonists are recommended to relieve symptoms and an 
increase in their use indicates that the disease has become more severe and therefore 
additional treatment should be introduced (1). Their use should act as an alarm to 
trigger a change of management. The most recent British Thoracic Society (BTS) 
Guidelines recommend the introduction of long acting inhaled ~ragonists at step three 
(see table 1.2), bringing them forward from previous versions (l; 120). The trend in the 
UK is to introduce inhaled steroids early in the course of the disease and to use short 
acting inhaled ~2-agonists sparingly. Because the research to date has been favourable 
concerning the use of long acting inhaled ~2-agonists it again raises questions as to the 
most appropriate use of inhaled ~ragonists in asthma. 
1.3 Assessment of asthma in clinical trials 
In addition to the methodological problems of study design and statistical power there 
are controversies over what is the most appropriate outcome measure for use in clinical 
trials and this is the purpose of this thesis. The choice of a clinical trial endpoint is 
complicated hecause there is considerable debate on how to define and diagno~e asthma 
eftl'diycly and how to measure change in clinical practice. 
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Several of the clinical trials of inhaled ~2-agonists haye been criticised because of their 
choice of primary outcome measure or patient selection. The trial by Sears et al (51) 
was criticised because it used a measure of asthma control, a combination of morning 
and evening PEF, symptoms and rescue ~2-agonist. but did not clarify the weight that 
was given to each of the components. The trials by van Schayck (53;92) were criticised 
because they included patients with COPD and the number of patients with asthma was 
very small in comparison. Several trials have used definitions of exacerbation 
(54;101;104;105;107;109;111;121-123), that have varied slightly from one another. and 
there is no information as to how their measurement characteristics compare. 
The remainder of this introduction will discuss the problems of definition. diagnosis and 
measurement of asthma with particular reference to the inhaled ~ragonist debate. 
1.3.1 Definition of Asthma 
There is no clear consensus as to the exact definition of asthma. With the advent of 
techniques such as bronchoscopy, asthma has been described increasingly in terms of 
the symptoms and the underlying cellular events. The most recent working definition of 
asthma from the "Global Strategy for Asthma Management" (124) was: 
"Asthma is a chronic inflammatory disorder of the airways, in H'hich many cells 
play a role, in particular eosinophils, mast cells and T lymphocytes. In 
susceptible individuals this inflammation causes recurrent episodes of wheezing, 
breathlessness, chest tightness and cough, particularly at night and in the early 
morning. These symptoms are usually associated It'ith widespread but variable 
ail/low limitation that is at least part~l' reversible, either spontaneous~l' or with 
treatment. The airway inflammation also causes an associated increase ill 
airway responsiveness to a ,'arief)' of stimuli. " 
This \'Cry detailed description of asthma including the underlying cdlular mechanisms 
may not be the most suitable definition for eH?f)' situation. For example. the abo\'e 
definition could not be used to define asthma for the purposes l)f an epidemiological 
survey. For suryeys the following definition may be more appropriate: 
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Asthma is a disease of the airways that makes them prone to narrow excessi\'e~\' 
in response to a variety of provoking stimuli (1 ~ 5). 
Measurement of the patient's bronchial response to histamine was used to validate 
epidemiological questionnaires such as the International Union Against Tuberculosis 
and Lung Disease (IUATLD) Bronchial Symptoms Questionnaire (1984) (126). 
Answers to key questions were likely to predict a positive response to a histamine or 
methacholine challenge. Patients would be classified as asthmatic on the basis of a 
positive questionnaire and bronchial challenge test bur may not have been given a 
clinical diagnosis by their doctor nor be in receipt of anti-asthma treatment. Jarvis et al 
(127) found that 25% of young adults in three East Anglian towns had experienced 
wheeze in the last twelve months yet only 6.6% were receiving anti-asthma medication. 
Crane et al conducted a similar survey in New Zealand and found that 26% of adults 
surveyed experienced wheeze in the last twelve months and only 90/0 were receiving 
anti-asthma treatment (128). Strachan et al conducted a similar study in children and 
found that 23% had "ever" wheezed, 15% of the children surveyed had experienced 
wheeze in the last twelve months and 13.60/0 were currently receiving medication for 
their asthma (129). 
The discrepancy between the prevalence of asthma and the proportion of people 
reCeIVIng treatment may reflect the different definitions of asthma used. 
Epidemiolo.gical surveys were designed to estimate the number of people susceptible to 
provoking stimuli using a combination of specially designed questionnaires and 
bronchial hyperreactivity testing. People with a tendency towards mild bronchial 
hyperreactivity as well as those with established disease recei\'ing medication were 
included. 
Patients studied in the randomised controlled trials or many of the obsenational studies 
cited earlier had been diagnosed or labelled asthmatic by their doctor and were in receipt 
of some combination of anti-asthma therapy before they were included in the trial. The 
inclusion criteria for these trials tended to be based on some fonn of classification of 
asthma so that a specific group of asthmatics were selected and studied. The tenn 
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"asthma" covers a wide spectrum of disease from a mild episodic condition to a ~\?\crc 
and persistent condition and can be classified in several ways. 
In the past, asthmatics have been described as having intrinsic or extrinsic asthma. 
Woolcock and Peat in the Manual of Asthma ~1anagement (130) classit~ .. asthma under 
SIX headings according to the severity of symptoms, degree of aIrway 
hyperresponsiveness (AHR) and medication use~ for details see table 1.1. 
Description Baseline AHR AHR Symptoms Symptoms Medication 
of airway FEY) (direct (indirect of asthm.i of asthma used in 
disease stimuli)* stimuli)* at any time prevIOUS prevIOUS 
year year 
Obstructed Decreased Yes Yes Yes Yes Yes 
asthma 
Persistent Near Yes Yes Yes Yes Yes 
asthma nonnal 
Episodic Nonnal No Yes / 1\0 Yes Yes Yes 
asthma 
Astluna in Nonnal Yes Yes Yes [\;0 No 
remISSIon 
Potential Nonnal Yes ?Yes No 1\0 No 
asthma 
Trivial Nonnal No No Yes ?No 1'\0 
wheeze 
• AHR, aimay hyperresponsiveness; direct stimuli, provocation with histamine or methacholine; IOd:rect stImuli, 
provocation with exercise, hyperventilation or hypertonic saline. 
Table 1.1 Classification of asthma from \\'oolcock and Peat (130). 
The 1997 American National Asthma Education and Prevcntion Guidelincs for the 
Diagnosis and t\1anagcment of Asthma (2) modified the s\?verity classification to include 
tenns for both se\'erity and frequency of symptoms: mild episodil'. mild persistent. 
moderate persistent and Sl'Vl're persistent. 
28 
For the purposes of clinical trials asthma may be classified still further in ord~r to define 
a clear study population. Several trials have used the American Thoracic Soclet\· 
classification to detennine eligibility (53;80;83:84;89;92; 131-133). The criteria used to 
identify the study population were: 
1. An increase in FEV 1 ~ 15%) of the initial value 60 minutes after inhaling 400 ~g 
salbutamol and 80 ~g ipratropium bromide. 
2. Bronchial hyperresponsiveness (PC20 histamine ~ 8 gl). 
3. Dyspnoea. 
4. Allergy (positive test result to specific allergens). 
5. 3 and 4 and / or wheeze. 
This definition may be qualified still further by specifying the level of anti-asthma 
treatment pennitted with or without specifying a period of stability. The BTS Asthma 
Management Guidelines (1; 120; 134) provide a useful method of classification where 
asthmatics could be classified according to the minimum level of treatment required to 
achieve control over their symptoms, for details see table 1.2. A minimum criterion for 
inhaled P2-agonist use could be set to ensure that patients were not included who were 
receiving more treatment than was necessary to control their symptoms. The inclusion 
criteria for TRUST (Ihe Regular Use of Salbutamol Trial) specified steps one to three 
of the 1991 BTS Guidelines (120) excluding patients using long acting P2-agonists. 
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Step Treatment Description Aims of treatment 
1 Occasional use of relief \1inimal symptoms. 
bronchodilators. ~v1inimal exacerbations. 
2 Regular inhaled steroids (or Minimal need for relief 
cromoglycate) plus occasional use bronchodilators. 
of relief bronchodilators. No limitations to exercise. 
Circadian variation in PEF < 
200/0. 
3 High dose inhaled steroids or low PEF ~ 80% predicted or best. 
dose inhaled steroids plus long Minimal adverse events from 
acting inhaled P2 agonists plus medication. 
occasional use of relief 
bronchodilators. 
4 High dose inhaled steroids and Least possible symptoms. 
regular bronchodilators. Least possible need for relief 
bronchodilators. 
Least possible limitation of 
acti\'ity. 
Least variation in circadian PEF. 
5 As for 4 plus oral corticosteroids. Best PEF. 
Least adverse effects. 
Table 1.2 Classification of asthma using the 1995 BTS Guidelines on Asthma 
l\ianagement (1). 
In order to assess whether an intervention has been effecti\'L~ or not a suitable outcome 
measure must be chosen. The choice of a suitable measure may depend on the type of 
intervention to be tested and may be different to the measurements carried out to 
establish an initial diagnosis of asthma. 
1.3.2 Diagnosis of asthma 
The diagnosis of asthma should be confinned in eyer)' individual patient although the 
current American Thoracic Society (A TS) Guidelines, BTS Guidelines and the 
International Consensus Report on Diagnosis and Treatment of Asthma do not discuss 
the minimum requirements for a diagnosis (1: 124: 135). Evidence from an audit of the 
management of newly identified asthmatics in general practice found that only 19% of 
adults had had the results of any diagnostic test recorded in their notes (136). 
Using the detailed definition from the "Global Strategy for Asthma Management"( 124) 
the following aspects should be assessed in order to confinn the diagnosis: 
l. Airway inflammation. 
2. Symptoms: 
• Wheeze. 
• Breathlessness. 
• Chest tightness. 
• Cough. 
• Nocturnal waking. 
3. Airflow limitation. 
4. Increase in airway hyperresponsiveness. 
It is not possible to measure all of these items directly and because of the episodic 
nature of the disease not all the signs and symptoms may be present at anyone time. 
Some of the methods for assessing the signs are not suitable for use in general practice 
where most asthma is diagnosed so indirect measures tend to be used instead. 
Inflammation and the degree of airway hyperresponsiveness are particularly difficult to 
measure safely in general practice. An accurate history should include recording the 
symptoms and the degree of airflow limitation can be measured indirectly using 
spirometry. Taylor suggested that a careful history \\'ith spirometry \\'ould enable the 
diagnosis of asthma to be made (137). If some doubt remained then rEF and 
methacholine challenge could be used; one positin? result confirming the diagnosis, 
Britton et al suggested that this would be insutlicient and that a simple objedin? 
measure should be used but that this simple measure does not yet l'\ist (138). The 2()()2 
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BTS / SIGN (Scottish Intercollegiate Guidelines ~etwork) British Guideline on the 
Management of Asthma (Thorax, in press) recommend that the minimum requirements 
for a diagnosis of asthma in adults are a record of asthma symptoms and the results of an 
objective test such as 20% PEF diurnal variation or a 15% change in FE\, 1 in r('spl)Ib(, 
to treatment or a trigger. 
1.3.3 Measuring change in asthma 
If the diagnosis of asthma was made by confinning the signs and symptoms listed 
above, then it would seem logical to repeat these measurements oyer time to monitor 
change in the condition. In most cases it would not be feasible to assess the extent of 
the inflammation at diagnosis or after treatment unless the patient was taking part in a 
hospital based research project. 
There is no recommended method for assessing symptoms in a clinical trial setting 
although several groups have developed and validated symptoms questionnaires such as 
the St George's Respiratory Questionnaire (139), Asthma Control Questionnaire and 
Asthma Control Diary (140) or the MRC Respiratory Symptoms Questionnaire (141). 
These questionnaires do not simply measure asthma symptoms but also measure the 
impact of these symptoms on the overall health status of the individual. They are often 
complicated to administer and the results difficult to interpret. In a clinical trial setting 
frequent assessments of symptoms may be advantageous because of the fluctuating 
nature of the disease and this could be achieved by using a detailed symptom score at 
each assessment or monitoring daily by diary card. 
Use of inhaled Pragonist is frequently used as an indicator of loss of control of asthma. 
The current BTS guidelines use the use of rescue inhaled Pragonist as an indicator for 
introducing or stepping up preventiye treatment (1). 
Airflow limitation is the fayoured method of measuring change in asthma. Thc best 
single measure for following the changes of airflow limitation is forcl'd cxpiratory 
yolume in one second (FE\' I). which proyides a snapshot of till' degn:l' of airflow 
limitation (142). FEV I is linearly rdated to the sc\erity of th(' aif\\ ays obstructilm 
(142). The forced vital capacity (FVC) is less accurate because the patient may be 
experiencing air trapping behind the bronchoconstriction and the reading would be an 
underestimate of the true value. Both FEV. and FVC can easily be perfonned in general 
practice and reflect the condition of the asthmatic on that day. Measuring the FEV. / 
FVC ratio is a very sensitive test for borderline airways obstruction (142). A more 
useful measure might be to monitor peak expiratory flow (PEF) for two to three weeks 
and assess the degree of circadian variation particularly in those patients with nonna! 
spirometry at the first assessment. 
Peak expiratory flow is a measure of the flow of air during forced expiration. It is very 
effort dependent and has twice the measurement variability of FEV. (142-144). The 
advantages of PEF are that it is extremely cheap to measure and a meter can be given to 
the patient to take home to record more frequent readings, which is particularly useful 
for very mild asthmatics. Ambulatory PEF monitoring allows a more accurate 
assessment of the variable nature of the disease, both within day and between day 
variability. The success of this does depend to an extent on the willingness of the 
patient to co-operate. The disadvantages of ambulatory PEF are poor compliance with 
the measurements and how to handle the large amount of data generated for each 
patient. 
Giannini et al (145) compared PEF and FEV. for their ability to detect changes after 
bronchial provocation tests. They reported that PEF underestimated the change in 
airway calibre by about 10-15% but nevertheless is still correlated with FEV \. A 
significant change in PEF corresponded to a greater change in FEV. (143). PEF seemed 
to have a low sensitivity for detecting small changes in the airways that may be 
important when trying to monitor mild to moderate asthmatics. Troyanov et al (146) 
concluded that PEF was as satisfactory as FEV. for describing circadian variation; in 
this trial the measurements were made every two hours for a two week period. Several 
other groups have concluded that whilst PEF was not reliable as a single measure of 
lung function it was very useful when perfonned frequently over shorter intervals. This 
technique is not without its problems; compliance becomes a factor when asking 
patients to perfonn measurements regularly and it has been estimated that only about 
69% of measurements are perfonned correctly (147). 
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Airway hyperresponsiveness is frequently used in clinical trials to measure the effect of 
an intervention and is widely recommended as a diagnostic test although its use is 
limited to specialist centres. The degree of hyperresponsiveness correlates strongly with 
severity but it is not clear if this technique has any advantages oyer clinical monitoring 
(148). Airway hyperresponsiveness would not be a suitable measure for use in trials in 
pnmary care. 
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The overall outcome of a trial may depend on the primary outcome measure therefore it 
is important to standardise. For example, the Sears trial assessed the change in asthma 
control from baseline and reported a highly significant result (51). \\ben the trial was 
reanalysed using exacerbation as a measure of effect there was no significant difference 
between regular fenoterol and placebo (54). In a trial of 47 asthmatics comparing low 
dose budesonide with placebo two different methods of assessing PEF were used: 
lowest PEF of the morning or evening readings (LPF) and diurnal yariation (DVPF). 
Using LPF there was a significant result in favour of low dose budesonide and using 
DPVF there was no statistically significant difference between the two groups (149). 
1.4 Thesis outline 
The continued uncertainty of the safety of short acting inhaled ~ragonists prompted the 
devclopment of TRUST. The trialists addressed the concerns regarding patient selection 
in an attempt to ensure that the safety of inhaled ~2-agonists was assessed in a 
population representatiye of the majority of the UK asthma population. The definition 
of exacerbation for TRUST was developed during the pilot study to be sure that it 
identitied clinically meaningful exacerbations. 
TRUST was a collaborative trial with a trial steering committee (Appendix 2.1). Dr 
Graham Crompton drafted the outline proposal on behalf of the Therapy \\'orking 
Group of the National Asthma Task Force and Professor Tak Lee was the principal 
investigator. The committee developed the draft into an applicati()n for funding with 
PI"l)fcssors Tak Lce and Peter Barnes and Dr Graham Crompton pnn·iding the clinical 
expertise. ~ 1r Chris Frost pro,·ided the statistical adyice and Dr \ 1adge \' ickcrs and 
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myself provided the trials advice. My role was to develop the protocol and the trial. 
under the close supervision of Dr Madge Vickers. \1y role included designing the trial 
questionnaires, choosing the quality of life tools, writing the standing operating manual. 
training the practices, setting up the quality control procedures and making applications 
to local research ethics committees and the :vledicines Control Agency. I worked 
closely with the statisticians to ensure the integrity of the data. ~lr Stephen Sharp and 
Mr Chris Frost analysed the TRUST data. The first draft of the paper was written hy 
myself, Professor Tak Lee and Mr Stephen Sharp and revised by the members of the 
steering committee. 
In addition to TRUST, a project to determine the measurement characteristics of 
different primary outcome measures compared to TRUST exacerbation was proposed. 
A systematic review was undertaken to identify randomised controlled trials of short and 
long acting Pragonists. A list of the different combinations of primary outcome 
measures used was generated from those trials meeting the inclusion criteria. The 
TRUST data were analysed using the primary outcome measures identified and the 
results compared. I carried out the systematic review and all the statistical analysis, 
including the writing of all the statistical programs, with guidance from Mr Dan 
Altmann and Mr Chris Frost. It was hoped that the results of this study would enable 
trialists to make an informed decision as the most effective means of assessing change 
in asthma in future clinical trials of long or short acting inhaled P2-agonists. 
This thesis details the methods for TRUST with reference to the standard procedures for 
randomised controlled trials in Chapter 2. The main results of TRUST are presented in 
Chapter 3. The systematic review to identify randomised controlled trials of short and 
long acting P2-agonists is described in Chapter 4. Chapters 5 and 6 detail the analyses 
of the comparisons of the primary outcome measures identified in the systematic review. 
Chapter .5 describes the results of TRUST according to the primary outcome measure 
and Chapter 6 describes the comparisons with TRUST exacerbation to identi t~· a 
suitable outcome for further trials. Chapter 7 concludes this thesi~ by ~ummarising the 
current state of the inhaled Pragonist debate and the proposed outcome mea~urc 
resulting from the comparisons with TRUST exacerhation. 
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Chapter 2 - Methods 
Chapter 2 describes the methods used in TRUST in the context of the general principles 
of clinical trials. 
2. 1 Introduction 
TRUST was an initiative of the Therapy Working Group of the National Asthma Task 
Force and its membership included representatives from the BTS. the Royal Colleges. 
the regulatory agencies and the Department of Health. The National Asthma Task Force 
was set up in July 1991, under the auspices of the I\ational Asthma Campaign, in 
response to the concerns over the safety of inhaled ~ragonists and asthma morbidity 
and mortality. The Therapy Working Group approached the \lRC General Practice 
Research Framework (GPRF) to collaborate with them on the trial. The membership of 
the TRUST Steering Committee is listed at Appendix 2.1. The Medical Research 
Council (MRC) funded TRUST. 
2.2 Aims 
TRUST was designed specifically to answer the following questions: 
Does regular inhaled f3_,-agollist therapy result in worse control of asthma than 
when used Oil demand? 
Does concurrent use of regular inhaled corticosteroid therapy influence the 
effects o/regular or on demand inhaled f3ragonists? 
2.3 Method 
TRllST was a randomised. double blind. placebo controlled trial of salbutamol 400 pg 
four times daily for t\\d\'(~ months. 
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Dr G Crompton drafted an outline protocol for a pilot study on behalf of the Therapy 
Working Group of the National Asthma Task Force. The outline of the study was 
turned into an application for a pilot study and my role was to develop the protocol and 
the trial, under the close supervision of Dr \1 R Vickers. Copies of the initial outline 
and final protocol are at Appendices 2.2 and 2.3. Once the final version of the protocol 
had been approved the trial paperwork, procedures and the Standing Operating Manual 
could be written. 
The trial followed the format below for a randomised controlled trial (150; 151): 
1. Define reference population. 
2. Selection of study population. 
Exclude unsuitable individuals. 
3. Selection of suitable subjects: 
Identify those refusing. 
4. Informed consent. 
5. Baseline measurements. 
6. Random allocation: 
Standard or placebo treatments. 
7. Follow up all subjects in both groups: 
Defaulters, losses to follow-up. 
8. Assessment of defined outcome: 
Attention to compliance and losses to follow-up. 
9. Analysis. 
10. Interpretation. ' 
2.3.1 Reference population 
The reference population is the population to which the results of the trial will be 
extrapolated (150). In the case of TRUST the reference population was all adults 
eighteen years and over, with mild to moderate asthma treated according tl) steps one tl) 
three of the BTS asthma management guidelines (1) and managed in general practice. 
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2.3.2 Study population 
The study population should be a representatiye sample of the reference population 
(150). In TRUST it was important to exclude patients with suspected COPD and those 
whose asthma was very stable, as they might not be expected to experience an 
exacerbation during the course of the trial. The inclusion criteria for TRUST were: 
1. Males and females aged eighteen years and over. 
2. Asthma of at least one year's duration. 
3. Current use of an inhaled P2-agonist at least twice per week. 
4. No oral steroids or increased dose of inhaled steroids within six weeks of trial 
entry. 
5. Bronchial asthma defined as a PEF greater than 50% of the predicted normal 
with 15% diurnal variability and an absolute minimum PEF variability of 60 
litres per minute. This was confirmed by previous documentation in the medical 
notes or by measurement during the run-in period. 
Patients were excluded if any of the following applied: 
1. Treatment with oral or increased inhaled corticosteroids wi thin six weeks of trial 
entry. 
2. Inhaled steroids at a dose greater than 2 mg per day 
3. Admission to hospital because of asthma within six weeks of trial entry. 
4. A requirement for inhaled Pragonist therapy less than twice per week. 
5. Treatment with sodium cromoglycate, nedocromil sodium, ipratropium bromide, 
oxitropium bromide, theophyllines, long-acting inhaled and any oral P2-agonist 
preparation. 
6. Other significant lung disease or concomitant major illness. 
7. Pregnancy or suspected pregnancy. 
8. Inability to use usual inhaler or trial inhaler correctly. 
9. Inability to lise a peak flow meter or complete a diary card. 
Patients who had experienced an exacerbation requiring additional treatment or hospital 
admission within six weeks of trial entry and who \H?re kCL'1l to participatc in TRuST 
were asked to wait six weeks and were reassessed. They were randomiseJ and 
completed the run-in if they were eligible on reassessment. This may have resulted in 
the exclusion of some patients who could ha\'e contributed to the exacerbation rate in 
TRUST but was required on safety and ethical grounds, 
The results of the pilot study suggested that bet\veen 70 and 80 practices with an 
average list size close to 10 000 would be required to recruit 1000 patients to TRLST. 
with an expected recruitment of 12 to 15 patients per practice. Initially 73 practices 
from throughout the United Kingdom with an average list size of 7683 were recruited to 
TRUST. There were no selection criteria set for recruiting the practices other than an 
interest and willingness to take part although large practices were chosen when possible. 
Practices were selected from the GPRF database if they had previously expressed an 
interest in taking part in an asthma trial or if they had contacted other members of staff 
at MRC EMCU to ask if they could take part in a trial. 
It quickly became apparent that more practices would be needed if the target of 1000 
patients was to be reached. A further 20 practices with a mean list size of 7683 were 
approached and agreed to take part. A final wave of practices was recruited after the 
Trial Steering Committee meeting in November 1996. An additional 38 practices were 
recruited with an average list size of 1132. In total 115 general practices with a mean 
list size of 8218 recruited patients to the trial. To enable these practices to proceed 
required making applications to the Clinical Research Ethics Committee of the Royal 
College of General Practitioners and to 79 Local Research Ethics Committees (LREC) 
of which 78 approved the trial (152). 
An initial note search was carried out once LREC approval had been granted and the 
practice nurse had been trained. The purpose of the note search was to identify the study 
population. The practices used the practice computer to generate a list of all those 
patients eighteen years and oyer who had been prescribed inhaled P2-agonists with or 
without inhaled corticosteroids. In many practices the computer could then be used to 
exclude those patients receiying any of the other anti-asthma medications listed in the 
exclusion criteria. The nurse manually searched the notes of the p3tients remaining on 
the list. The list of names. including those who were excluded. was sent t\) \1RC 
E\ leU where they were entered onto the Cl)mputer. A list of p3tients. study numhers, 
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labels, invitation letters and a very brief questionnaire were then sent to the practices f(lr 
them to send to all those people potentially eligible for TRUST. 
2.3.3 Selection of suitable subjects 
Invitation letters and a brief questionnaire were sent from the practice to all the patients 
identified from the note search (Appendix 2.4). A reminder letter and questionnaire 
were sent to those patients not replying within a month to the first letter. The nurse 
collected the returned questionnaires and identified those patients who still appeared to 
be eligible and invited them to a screening appointment. 
At the screemng interview the research nurse gave an explanation of the trial and 
completed the screening questionnaire (Appendix 2.5) to determine whether the patient 
was still eligible. Patients who were eligible and interested in participating were giyen 
an information sheet (Appendix 2.6) and an appointment was made for at least one 
week's time for the run-in visit. Patients were free to discuss the trial with friends and 
family before making a decision to take part in the trial. 
2.3.4 Informed consent 
Written informed consent was obtained at the run-in assessment, at least one week after 
the screening appointment (Appendix 2.7). 
2.3.5 Baseline measurements 
There was a three-week run-in period when the patients were asked to record their PFF, 
S)l11ptoms and medication use in a diary card (Appendix 2.8). This was used tn 
calculate the patients' baseline yalues for the trial. 
2.3.6 Random allocation 
The research nurse informed EMCU of those patients who were eligible. had giyen their 
nmsent and had started the run-in period. These patients \\ere strati fied into thrl'l' 
groups according to their haseline inhaled corticoster~)id usage: 
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1. Inhaled Pragonists alone. 
2. Inhaled P2-agonists and inhaled corticosteroids up to and including 800 Ilg per 
day. 
3. Inhaled P2-agonists and inhaled corticosteroids from 801 Ilg up to and including 
2000 Ilg per day. 
The details of the total daily dose of inhaled corticosteroids entered onto the 
randomisation fonn was checked against the total daily dose entered on the screening 
fonn. Any discrepancies were checked with the practices before the patient was 
randomised. Patients were randomised to receive either salbutamol 400 Ilg or matched 
placebo four times daily via a Diskhaler. 
The randomisation was carried out centrally and was completely at random until the 
numbers in each b'TOUP became imbalanced overall or within a practice. No account was 
taken of exclusions after randomisation in the randomisation procedure. The underlying 
assumption was that any exclusions would occur equally between the two groups. 
2.3.7 Follow-up 
Once started on trial medication all patients were followed up at monthly intervals for 
twelve months or until they withdrew or were lost to follow-up. At each visit the 
patients returned their completed diary card and the used and unused trial medication, a 
brief assessment fonn was completed (Appendix 2.9), used and unused Diskhaler 
blisters counted to assess compliance and new trial medication and diary card issued. At 
entry, six and twelve months the St George's Respiratory Questionnaire (SGRQ) and the 
SF-36 were completed. 
A fonn was completed for all patients who withdrew from the trial detailing the 
reason(s) for withdrawal (Appendix 2.10). Patients who experienced tl)Ur serious 
exacerbations requiring treatment were withdrawn from the trial as were women who 
became or suspected that they were pregnant. Patients withdrawing from the trial were 
asked to sign a further consent fonn. (Appendix 2.11). gi\'ing pennission to sear(h their 
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notes at the end of the period that they would have been in the trial had they completed 
the full twelve months' follow-up. 
2.3.8 Assessment of defined outcome 
The primary outcome measure for TRUST was exacerbation. The initial definition 
proposed in September 1992, before the start of the pilot study, was anyone of the 
following: 
1. Increased use of rescue P2 - agonist (more than four puffs per 24 hours). 
2. Decreased PEF (more than 30% of baseline or actual decrease of greater than 
50L per minute). 
3. Increased symptoms (greater than one point on a four point scale symptom score 
over one week). 
4. Increase in disease severity which results in the general practitioner prescribing 
extra treatment. 
5. Treatment with oral prednisolone. 
This definition of exacerbation did not identify all clinically meaningful exacerbations 
in the pilot study data. The definition was modified to enable the practices and the 
patients to decide whether they were experiencing an exacerbation and whether the 
patients should be prescribed a short course of oral corticosteroids. The definition used 
for the pilot study and the application for funding to MRC in July 1994 was any of the 
following: 
I. Fall in morning PEF to <700/0 of baseline reading on two or more consecuti\'(~ 
days. 
1 Increase in the need for rescue P2 - agonist to six or more inhalations per 24 
hours on two or more consecutive days. 
3. Wakening due to nocturnal asthma and need for P2 - agonists use on two or more 
consecuti\'e nights. 
4. \\'orsening asthma symptoms during the day on two or more consecuti\'\'? days. 
5. Clinical need for oral corticosteroids. 
Reco\'(~ry from an exacerbation was defined as: 
1. Return to baseline symptom score for se\'en days. 
2. Morning PEF returned to baseline for seven days. 
Exacerbations were initially detected in two ways: the diary card and a question on oral 
steroid use in the past month in the follow - up assessment form. The s) mptom score on 
the diary cards used a six point scale rather than four point scale because it gaye greater 
flexibility and the diary cards were based on those used by the National Heart and Lung 
Institute. Patients were asked to record their PEF as the best of three in the morning and 
the evening before taking any medication. They \\'ere also requested to fill in the 
number of puffs of their rescue Pragonist taken each da) . 
The data from the pilot study diary cards were used to validate the definition of 
exacerbation. The data were entered on to the computer and a programme written. using 
the definition of exacerbation, to identify those patients experiencing a TRUST 
exacerbation. The exacerbations were then presented to the clinicians on the Steering 
Committee who discussed each exacerbation in tum in terms of its clinical significance. 
The data were presented without reference to the treatment allocation of the patients 
concerned. The result was a definition for the start and end of an exacerbation that 
represented a "true and clinically significant" exacerbation. 
The final working definition of an exacerbation for TRUST was: 
1. Use of oral or increased inhaled corticosteroids. 
Or at least two or more of the following: 
2. Fall in PEF to less than 800/0 of median baseline level. 
3. Bronchodilator per 24 hours increased by three or more over median baseline 
Ic\'el. 
4, Symptom score increased during the day or at night. hy t\\/O or more o\'cr median 
baseline levcl. 
Thc end of an cxacerbation was defined as the cessation of oral cortic~)stcn)ids or return 
to original dose of increased inhaled corticosteroids together with all the following 
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criteria on two consecuti\'c days: 
1. PEF '> 800 0 median baseline level. 
2. Bronchodilator inhalations per 24 hours increased by no more than two over 
median baseline level. 
3. Symptom scores increased day and night by no more than one over median 
baseline level. 
The baseline values were calculated using median values rather than mean values to 
reduce the effect of exceptionally high or low values on the average value. Because 
asthma is characterised by fluctuations in PEF and symptoms, using the mean to 
calculate the baseline value could result in a misleading high or low baseline value for 
an individual patient. 
The secondary outcomes were: 
1. Use of rescue inhaled P2-agonist. 
2. Diurnal variation in PEF. 
3. Symptom score. 
4. Days lost from work / normal activities. 
5. Use ofNHS services - including GP and hospital consultations. 
6. Changes in overall score on the quality of life questionnaire. 
2.3.8 Analysis and interpretation 
The results of TRUST will be presented in chapter 3. 
2.4 Summary 
The detailed methods for TRUST have been described \\"ith reference to general 
principles of clinical trials. Throughout the course of the trial there were regular Data 
Monitoring and Ethics Committee (DMEC) meetings and Trial Steering Committee 
meetings. The purpose of these meetings was to monitor the progress of the triaL to 
detennine trial stopping rules and to ensure that the project milestones were achic\l~d on 
time. Unblinded trial data were presented to the O\1EC but only they and the 
statisticians had access to this information. The remaining trialists were blind l\) the 
treatment allocation until the final analysis had been completed. The trial rl?~ult~ will be 
presented in chapter 3. 
Chapter 3 - TRUST Results 
This chapter describes the main results and baseline characteristics of the patients 
randomised to TRUST. 
3. 1 Recruitment 
One hundred and fifteen UK general practices. with a mean list sile of 8218 patients, 
recruited 983 patients to TRUST, which was an average of 8.6 per practice. For a map 
of the location of the practices see Figure 3.1. Recruitment to TRUST was lower than 
for the pilot study when recruitment was 13 per 10 000 list size. In the main trial there 
were 10.5 patients per 10 000 list size. Figure 3.2 illustrates the number of patients 
randomised to TRUST over time and Figure 3.3 plots the number of patients 
randomised per practice list size. One possible explanation for the lower recruitment 
was the impact of the asthma management guidelines on asthma care in general practice. 
The pilot study was carried out between September 1993 and September 199-.+ and the 
first patient was not recruited to the main trial until July 1995. In the main trial 4-.+ % of 
patients not eligible at screening were excluded because their inhaled Pragonist 
requirement was less than twice per week compared to 19% in the pilot study. This 
reflected a greater use of inhaled steroids and less reliance on inhaled P2-agonists (153). 
The identification and flow of patients in TRUST is illustrated by the flow chart in 
Figure 3 A. 
3.2 Withdrawal rate 
The withdrawal rate was similar between the two groups. Patients were considered to 
have completed the trial if they attended the I-year \·isit or if they were withdrawn for 
protocol reasons: i.e. four treated exacerbations or one untreated exacerbation lasting 
longer than ~o days. Overall. 66° ° (320 / -'+86) of the placebo and 68% (3-.+0 / -'+97) of 
the active group completed the trial. In total ~3°~) (32~ /983) patients did not complete 
the trial and of those 2-.+ % (2-.+0 / 983) withdrew for non-protocol rC~ISl)I1S and so~ p'.' 
983) were lost to follow-up (Figure ~.4. 
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Figure 3.1. A map to show the location of TRUST practices 
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Figure 3.2 Actual and expected recruitment to TRUST 
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• expected recruitment 
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actual recruitment 
per practice 
• 
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486 placebo 
2801 potentially eligible 
patients screened 
1486 ineligible 
163 did not wish to take par 
1315 started run-in 
332 did not proceed 
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497 active 
320 
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the trial 
118 48 340 122 35 
lost to 
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follow-up 
completed dropped out 
the trial 
1 
257 attended 1 year visit 
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Figure 304 Flow of patients 
in TRUST 
t 
267 attended 1 year visit 
73 reached protocol endpoint 
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3.3 Baseline 
486 patients were randomised to receive placebo and 497 to receive active salbutamol. 
The two groups were similar with respect to gender. age, smoking, inhaled 
corticosteroids use and asthma severity (Table 3.1). 
Characteristics 
Number (%) male 
Number (%) in age groups 
<25 years 
25 - 34 years 
35 - 44 years 
45 - 54 years 
55 - 64 years 
65 - 74 years 
> 75 years 
Number (%) current smokers 
Number (0/0) using steroids 
No steroids 
800 mg or less 
More than 800 mg 
Number (%) on salbutamol 
Number (0/0) on terbutaline 
Mean (SO) PEF as % of 
predicted nonnal 
Placebo 
(n = 486) 
211 (43%) 
39 (8%) 
86 (18%) 
100 (21%) 
98 (20%) 
89 (18%) 
66 (14%) 
8 (2%) 
78 (16%) 
49 (10%) 
353 (73%) 
84 (170/0) 
442 (91 %) 
41 (80/0) 
85% (16) 
Active 
(n = 497) 
39 (SOo) 
106 (21 % ) 
101 (20° 0) 
101 (20°0) 
76 (15°0) 
64 (13~0) 
10 (2°~) 
88 (18%) 
53 (11 %) 
359 (72%) 
85(17~() 
435 (88%) 
56 (11 %) 
860/0 (15) 
Table 3.1 Characteristics at baseline in the two randomised groups. 
3.4 Exacerbations 
There was no differencc in annual exacerbation rate between the two randomised bTfOUP~ 
according to the definition of exacerbation den~loped during thc pilot study. There wa~ 
no difference hct\\'ccn thc two randomised groups when the data \\'crc anah ~l'd 
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according to baseline inhaled corticosteroids use (see section 2.3.6). There was no 
difference in the number of exacerbations experienced or duration of exacerbations. 
table 3.2. 
Exacerbation rates 
Annual exacerbation rate 
(95% confidence interval) 
(No exacerbations / patient years of 
follow-up) 
Exacerbation details 
No (0/0) patients with at least one 
exacerbation 
No (%) patients with at least two 
exacerbations 
No (0/0) of exacerbations according 
to duration of first exacerbation: 
< 1 week 
1 -2 weeks 
> 2 weeks 
No (%) of exacerbations according 
to duration of all exacerbation: 
< I week 
I -2 weeks 
> 2 weeks 
No (%) of exacerbations 
according to criteria at start of 
exacerbation: 
Corticosteroid use and at least 1 
diary card criterion 
Corticosteroid use but no diary card 
criteria 
Placebo 
(n = 486) 
1.30 
(1.18to 1.43) 
(438/337) 
223 (46~ 0) 
56 (25%) 
64 (29%) 
103 (4hOo) 
146 (33%) 
121 (28%) 
171 (39%) 
54 (12%) 
166 (38%) 
Diary card criteria but no 218 (50%) 
corticosteroid use 
Table 3.2 Exacerbations in the two randomised groups. 
3.5 Secondary outcomes 
The secondary outcome measures for TRl'ST \\'Cfe: 
1. Use of rescue inhaled Pragoni~t. 
2. Diurnal variation in PEF. 
Active 
(n = 497) 
1.25 
(1.14 to 1.38) 
(425 / 339) 
214 (43~0) 
99 (20%) 
57 (27%) 
67 (31%) 
90 (420/0) 
134 (32%) 
127 (30%) 
164 (39%) 
58 (l4~o) 
181 (430/0) 
3. Symptom score. 
4. Days lost from work / nonnal activities. 
5. Use ofNHS services - including GP and hospital consultations. 
6. Changes in overall score on the quality of life questionnaire. 
3.5.1 Use of rescue inhaled ~ragonist 
Daytime rescue ~2-agonist use was significantly less in the active group compared to the 
placebo group (p < 0.01) and those on active treatment required less night time reliever 
use than those on placebo treatment, see table 3.3. 
3.5.2 Diurnal variation in PEF 
Mean diurnal variation in PEF was significantly higher with active treatment compared 
to placebo (p < 0.001). There was no difference in mean morning PEF between placebo 
and active but evening PEF was significantly higher with acti\'c treatment (p < 0.01), see 
table 3.3. 
3.5.3 Symptom score. 
There was no difference in the proportions of symptom free nights between the two 
treatment groups but those on active treatment had a small increase in the proportion of 
symptom free days, see table 3.3. 
3.5.4 Days lost from work I normal activities 
There was no difference in the number of days off work between the two treatment 
groups. 
3.5.5 Use of NHS services - including GP and hospital consultations 
\' ery few patients required hospital treatment for their asthma during the course nf thl' 
trial, six in placebo group and seven in the active group, 
3.5.6 Changes in overall score on the quality of life questionnaire 
There was no difference in any of the dimensions of the mean Short Form 36 (SF-':~()) 
scores between the two treatment groups. 
Placebo Active Active - placebo* 
(n = 486) {n = 497) (95% el) 
Morning PEF (l/min) 
Run-in 404 (4.7) 402 (4.7) 
Follow-uQ 408 (4.8) 406 (4.9) 0.2 (-3.8 to 4.2) 
Evening PEF (l/min) 
Run-in 417 (4.7) 419 (4.6) 
Follow-uQ 419 (4.7) 432 (4.7) 10.3 (6.7 to 14.0)+ 
Diurnal variation (%) 
Run-in 4.2 (0.4) 5.4 (0.4) 
Follow-uQ 3.4 (0.3) 7.7 (0.5) 3.3 (2.5 to 4.1)t 
Symptom free nights (0/0) 
Run-in 59.0 (1.7) 56.8 
Follow-u2 62.1 (1.7) 61.0 (1.7) 1.2 (-1.9 to 4.4) 
Symptom free days (%) 
Run-in 37.7 (1.6) 37.9(1.6) 
Follow-uQ 46.0 (1.7) 52.4 (1.7) 5.7 (2.0 to 9.3)± 
Night time rescue use (puffs) 
Run-in 0.83 (0.05) 0.78 (0.04) 
Follow-uQ 0.56 (0.03) 0.48 (0.03) -0.1 O( -0.18 to -0.03)± 
Daytime rescue use (puffs) 
Run-in 2.40 (0.10) 2.20 (0.09) 
Follow-u2 1.60 (0.08) 1.26 (0.08) -0.30( -0.4 7 to -O.13)t 
Days of work 
Run-in 0.6 (0.3) 0.9 (0.3) 
Follow-uQ 0.8 (0.2) 0.6 (0.2) -0.2 (-0.7 to 0.3) 
Baseline measurements were made during 3-week run-in period and follow-up measurements after 
randomisation. Values based on calculating mean value over time for each patient and then calculating 
the mean (SE) of these patient-specific averages for each group. 
• Adjusted for baseline using analysis of covariance, tp<O.O 1, tp<O.OO 1. 
Table 3.3 Secondary outcome measures. 
3.6 Discussion 
The results of TRUST suggest that regular use of salbutamol for 52 weeks wa5 not 
associated with more exacerbations in patients with mild to moderate asthma. The5c 
results complement those of Drazen et al (95) who reported similar results for th05c 
patients taking inhaled P2-agonists alone to control their asthma. Thc5c results 
contradict those of Sears et al (51;121) who reported worse asthma control with thc 
regular use of fenoterol, probably because of the choice of primary outcome measure 
used in the Sears trial. The results of TRUST support those from trials of long acting 
P2-agonists (52;72-77;79-82;84;86;89-91 ;96;97;99; 101; 1 03-1 06; 1 08-112). 
The results of TRUST are particularly relevant to asthmatics in the United Kingdom. 
over 70%) of whom are treated with inhaled corticosteroids up to and including 2mg per 
day. The sample size was large enough to detect a clinically significant difference in 
exacerbation rate between the two groups and the exacerbation rate in the placebo group 
was close to the 1.5 exacerbations per patient per year expected. A retrospective power 
calculation determined that with 983 patients TRUST had 860/0 power to detect a change 
of 200/0 in the exacerbation rate, and 550/0 power to detect a change of 15% in the 
cxacerbation rate if the average annual rate of exacerbation in patients in the placebo 
group was 1.3. The power was lower when calculated retrospecti\'cly because the 
calculation was adjusted to take into account the over dispersion of exacerbations in 
some patients. The significant increase in evening PEF with regular salbutamol \\'as as a 
result of the pharmacological effect of regular bronchodilator use but was too small to 
be clinically relevant. . 
The results of TRUST, along with the results of similar trials of long and short acting 
p::-agonists. provide strong evidence that inhaled Pragonists do not cause a \\'(xsening 
of asthma. Howc\'cr, short acting P2-agonits should be used with caution to prevent 
patients relying too hcavilv on them and failing to seek additional treatment when 
control worsens. 
Chapter 4 - Systematic Review 
This chapter describes a systematic review that was undertaken to identify all 
randomised controlled trials of Pragonists in mild to moderate asthma. 
4. 1 Introduction 
The aim of this systematic review was to identify all randomised controlled trials of 
inhaled P2-agonist therapy in mild to moderate asthmatics. The primary outcome 
measures from those trials fulfilling the systematic revie\\' inclusion criteria \n~rc 
extracted. A systematic review was carried out rather than a simpler search of the 
literature to ensure that as many trials and their different primary outcome measures 
were identified as possible. 
The systematic reVIew was undertaken in response to a NHS Executive Asthma 
Management National Research and Development Programme call for proposals in 
November 1996 (see Appendix 4.1) although not funded. Thorough checks of the 
Cochrane Database of Systematic Reviews (CDSR), the NHS Centre for Revicws and 
Dissemination (CRD) Database of Abstracts of Reviews and Effectiveness (DARE) 
wcre carried out using the Cochrane Library (Issue 3, 2001) and the Internet. There 
were no relevant systematic reviews listed on either of the two databases searched. The 
NHS Executive Asthma Management National Research and Dc\'elopment Programme 
commissioned one relevant systematic review from the call for proposals in 1\ ovember 
1996. The aim of the commissioned review was to fonnally evaluate the properties of 
the outcome measures used routinely in clinical trials in asthma for each type of anti-
asthma medication. 
4.2 Methods 
The method for undertaking this systematic re\'iew was taken from the :'\ HS Centre for 
Rcvic\\'s and Dissemination (CRD) Guidelines for Those Carrying Out or 
('ommissioning Re\'iews, CRD Report ;\umber -+ January 1996 ( 1)-+). 
Knipschild argued that a systematic review should be an exhaustive process and should 
include papers from many sources including non-English language sources (155). 
Dickerson, in a study to examine the sensitivity and p~ecision for Medline searches for 
randomised controlled trials found that the 18%) of the articles identified were not in 
English and 20% of Medline listed articles overall were not in English (156). This was 
taken into account when conducting the search for this project, however because there 
was no funding available for translation, this search was restricted to papers in the 
English language with an abstract on Medline. Trials were excluded if they did not 
meet the inclusion criteria without incurring unnecessary expense. According to the 
information on Ovid Medline, over 60% of Medline records after 1975 contain 
abstracts. 
The initial literature search was undertaken usmg Ovid Medline and the Cochrane 
Controlled Trials Register (CCTR) (Issue 3,2001) with a further search of the reference 
lists of all papers fulfilling the inclusion criteria. The search was conducted through 
Ovid Medline and CCTR with a second search of the reference lists of all papers 
identified and included from the two searches. The modified Medline search method of 
Dickerson, from the CRD Guidelines for Those Carrying Out or Commissioning 
Rn 'ielt's (154) was used to identify the initial trials. The search strategy for Medline is 
included at Appendix 4.2. 
The inclusion criteria for trials were set as: 
1. Randomised controlled trials. 
J Double blind allocation. 
3. Four or more week's treatment period. 
4. "Clinical" primary outcome measures. 
5. Inhaled Pragonist therapy. 
6. Mild to moderate asthma. 
7. Adults 16 ycars and O\'Cr. 
8. English language. 
9. Ahstract on Medline. 
10. Medlinc database from 1966 to 200 I. 
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It was important to limit the search to trials with a "clinical" primary endpoint as 
opposed to an endpoint such as bronchial hyper-reactivity. The aim of this review wa:, 
to identify a standard outcome measure or combination of outcome measures for use in 
clinical trials of inhaled bronchodilator therapy. which would be relevant in a primary 
care setting. This environment was chosen because most mild to moderate asthmatics 
are managed by their general practitioner and because the results of this project may be 
of use to health care professionals to assess asthma control in their patients. 
"Clinical" outcomes included PEF, symptoms. rescue inhaled P2-agonist use. 
exacerbations, hospital or primary care visits. Trials were excluded if the primary 
outcomes were methacholine or histamine challenges. dose-response studies. dose-
reduction studies, serial FEY) measurements, biochemical or histological measurements 
or cardiovascular outcomes because these measurements are difficult to make in general 
practice where the majority of asthmatics are managed. Trials were also excluded where 
the primary endpoint was FEV I because measurements of FEV I were not made during 
TRUST and the data from TRUST were used for the analysis to compare the primary 
outcome measures. 
The information was collected from the all the papers using the data collection sheet at 
Appendix 4.3 and the information stored using Lotus 123 and Reference Manager® for 
\Vindows. The purpose of this data collection sheet was to ensure that all the papers 
were read objectively and the relevant information retrieved. It allowed a further. non-
biased. decision to be made about whether a paper was included in the final selection. 
The checklist included the recommended inclusions for randomised controlled trials. 
The results of the trial did not influence the decision as to whether to include the article 
in the review. The aim of the data retrieval process was to confirm that the trial met the 
inclusion criteria for the review and to document the primary and secondary outcome 
measures used. 
.58 
4.3 Results 
Using the Medline search strategy at Appendix 4.2. 641 papers were identified and a 
search of CCTR yielded 407 papers. A total of 591 papers were excluded from the 
Medline search and 369 from the CCTR search after reading the abstract. Eighty-fi\"e 
papers from the two searches appeared to fulfil the inclusion criteria of which 2.+ were 
selected after reading the papers. The reference lists of the 2.+ papers were searched and 
a further two papers identified and included. Figure 4.1 details the search for papers by 
flow chart and the reasons for exclusion from the reyie\\' are listed in the tables at 
Appendix 4.4. 
In total the searching procedure identified 26 papers fulfilling the inclusion criteria. The 
papers are listed at Appendix 4.5 and the primary outcome measures used in these trials 
are listed below. 
1. Mean PEF (morning, evemng or both) (69;71;86:91;95-98:106:108-
110;112;157;158). 
2. Diurnal variation (77). 
3. Symptoms (94;103). 
4. Asthma control (51 ;83). 
5. Exacerbation (l 0 1; 1 04;1 05: 107: Ill: 123). 
The specific details of the individual primary outcome measures will be detailed in 
Chapter 5 when the analysis using these measures will be described. 
Figure 4.1. A flow chart detailing the search for papers to be included. 
Medline 
(1966 to date) 
641 papers 
identified 
594 papers excl uded 
(see Appendix 4.4) 
47 papers 
25 papers excluded 
(See Appendix 4.4) 
7 13 
CCTR 
(Issue 3,2001) 
407 papers 
identified 
369 paper excluded 
(see Appendix 4.4) 
38 papers 
4 12 papers excluded 
(See Appendix 4.4) 
Reference lists searched 
2 papers added 
26 papers 
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4.4 Discussion 
The systematic review identified 26 trials and five different choices of primary outcome 
measure to assess the effect of the interventions tested. Fifteen of the trials identified 
used PEF as the primary outcome measure, one used diurnal variation, two used 
symptom score and the remaining trials developed composite measures of asthma 
control or exacerbation that varied in the emphasis on different diary card variables. 
Three papers reported the use of more complex modelling techniques to analyse mean 
PEF using a mixed effects linear model (95~96; 112). Th;s more complex modelling was 
not used for further analysis in this project because it was difficult to make comparisons 
with TRUST exacerbation. The variety of primary outcome measures used in these 26 
papers highlighted the dilemma researchers faced when trying to decide which measures 
to use for their particular trial. 
Whilst FEV I provides the most reliable measure of airflow limitation because it is 
highly reproducible and depends less on patient co-operation than PEF it only provides a 
snapshot of the asthma because the measurements can usually only be made during 
clinic visits. When planning TRUST we decided not to carry out FEV I measurements 
because of the huge expense involved in equipping each of the 116 practices with hand 
held spirometers. Whilst single PEF readings are associated with more noise than FEV I 
readings when many PEF readings are averaged over a period of time they may provide 
a more accurate picture of the fluctuating nature of the condition. However. daily PEF 
recordings are associated with reduced compliance. In the primary care setting many 
patients do not have their FEV I assessed because practices may not have access to 
spirometers and it is unlikely that many patients would have their own hand held 
spirometer for daily use. 
Several groups developed a primary outcome measure using a combination of factors 
(51 ;83; 101; 1 04;1 05; 1 07: Ill: 123). \Vhilst there were some similarities between the 
combination of measures chosen the emphasis or priority given to certain Cl)mpOnents 
may have been di tTerent. 
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In order to determine the measurement properties and characteristics of the different 
primary outcome measures identified by this systematic reyiew they were be (~lmpared 
using the TRUST data. 
4.5 Summary 
The systematic review identified 26 trials for inclusion in the next stage of the analysis 
to compare the primary outcome measures with the TReST definition of exacerbation. 
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Chapter 5 - Analysis of TRUST Dataset 
Chapter 5 describes the results when TRUST was analysed using the primary outcome 
measures identified in the systematic review. 
5. 1 Introduction 
When taking part in randomised controlled trials to assess anti-asthma therapies. 
patients were frequently asked to complete daily asthma diary cards. Thcv \,·crc 
typically asked to record PEF and symptoms in the morning and evening before 
medication, additional doses of inhaled Pragonists, changes in inhaled corticosteroid 
medication or courses of oral corticosteroids and days off work with asthma or visits to 
the hospital or GP for their asthma. Each patient generated a huge amount of diary card 
data for the period they were in the trial. Analysing these data was n~ry difficult 
because of the enormous volume of data involved and because asthma is characterised 
by frequent fluctuations in PEF or symptoms. 
It was clear from the systematic review that several different methods for analysing 
diary card data from randomised controlled trials had been tried. Some of the earlier 
trials were analysed using a single variable such as mean morning PEF (69;71 ;86;91 :95-
98; 1 06; 1 08-11 0; 112; 157; 158) or diurnal variation (77). More recently the emphasis 
seems to have been on the development of composite measures of asthma control such 
as the Sears measure of asthma control (51 ;83). various definitions of exacerbation 
(101:104:105:107;111:123) or complex modelling of PEF data (95:96;112). Because 
asthma is a fluctuating disease simply averaging variables, such as morning PEF. over 
the follow-up period may result in the loss of information about daily fluctuations in 
PEF or symptoms. For example, a patient may havc experienced scvcral sc\crc 
fluctuations in PEF during the course of the follow-up but ovcrall their mean follow-up 
PEF had changed little from baseline PEF. The possible advantage of the definitions of 
asthma exacerbations was that they attempt to overcome this loss of infomlation and 
identify days of change whilst enabling the rcscarchers to deal with the vast amount of 
data collected. The definitions of c:\3cl'fbation were developed independently uf t)I1C 
another with subtle variations in the emphasis on thc diary card variabk~. Thcrl' is no 
infonnation as to how they compare in their ability to detect change or whether the\' 
confer any advantage over the use of single variables alone. 
The primary outcome measures identified by the systematic review were used to analy~t? 
the TRUST data. A total of 26 randomised controlled trials were identified bv the 
systematic review (51;69;71;77;83;86;91:94-98;101;103-112:123;157;158) with a total 
of five different primary outcome measures. 
1. Mean PEF (morning, evemng or both) (69:71;86;91;95-98:106;108-
110;112;157;158). 
2. Diurnal variation (77). 
3. Symptoms (94; 1 03). 
4. Asthma control (51 ;83). 
5. Exacerbation (101;104:105:107:111;123). 
The aim of the first part of the analysis was to determine what the overall result of 
TRUST would have been if an outcome measure other than the TRUST definition of 
exacerbation had been used to analyse the trial. Not all the statistical methods were 
appropriate for use on the TRUST data. In these cases the important consideration was 
the behaviour of the outcome measure chosen, for example morning PEF, which was 
compared with the TRUST definition of exacerbation in the next stage of the analysis. 
The complete TRUST trial data were used for all the analyses. For all primary outcome 
measures the data were analysed on an intention to treat basis and when necessary the 
data were censored at the point of withdrawal from the trial. All data were analysed 
using the STAT A 6 statistical package. 
5.2 Mean PEF (including diurnal variation) 
The primary outcome measure used in 15 papers identified was mean PEF. usually mean 
morning pre-bronchodilator PEF (69;71:86:91;95-98;106;108-110:l12:157:15~). Three 
trials compared the ditTerence between the baseline and treatment period u"ing Studcnt'~ 
t-test (69: 71: 157). \ tore recently, mean morning PEF was compared between treatment 
groups using A 1'\CO\':\ (analysis of Cl)\'ariance) that enabled cPITections to be made for 
baseline values (69;71;86;91;97;98;106;108-110:158). The latter method was an 
extension of the t-test that was made possible with improved statistical programs. The 
remaining trials reported a more complex modelling of mean PEF to analyse the data 
(95;96; 112). 
5.2.1 Method for mean PEF (including diurnal variation) 
The systematic review identified two papers that reported the analysis of mean PEF 
using t-test. Beswick et al (71) compared mean morning and e\"ening PEF bet\veen 
baseline and the treatment period and the significant differences of mean PEF were 
determined both within and between treatments using Student's t-test. The mean 
morning and evening PEF were calculated for the run-in and four three-month periods 
(months 1 to 3, 4 to 6, 7 to 9 and 10 to 12). Greening et a1 (157) performed a similar 
analysis with a mean PEF value for each week of the follow - up. The mean morning 
and evening PEF from the run-in and follow-up periods were compared using a 
Student's t-test. Trembath et al (69) compared the mean daily PEF between baseline 
and the treatment period and the significant differences of mean PEF were determined 
both within and between treatments using Student's t-test. Patients were regarded as 
treatment failures if they required additional corticosteroids during follow-up and were 
withdrawn from the trial. 
The systematic review identified seven papers (69;71;86;91;97;98;106:108-110;158) in 
which the authors have analysed the trial data using mean PEF (either morning, e\"ening 
or both) or diurnal variation with ANCOV A (analysis of covariance) (77). The mean 
difference between the treatment groups was calculated and an ANCOV A carried out 
using the mean PEF values from the second period of the run-in. 
Diurnal variation was calculated using the formula below where evening PEF was used 
for PEFmax and morning PEF was used for PEFmin. 
PEFma\-PEFmin \"100 -d' I . t' 
-- --- - - J - lUma vana IOn 
P/~'Fmax+ PEFmin 2 
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The more complex models for analysing PEF will not be repeated in this analy~is 
because of the difficulty in making the later comparisons \\'ith the TReST exacerbation. 
5.2.2 Results for mean PEF (including diurnal variation) 
Comparing the mean morning and evening PEF with t-test there was a signitIcant 
improvement in evening PEF with regular salbutamol when all periods of follow-up 
were compared in tum with the run-in period (p<0.00 1). table 5.1. There was no 
difference in morning PEF between the two groups for any of the periods of follow-up. 
Mean PEF (llmin) 
Months after Run-in 1 to 3 4 to 6 7 to 9 10 to 12 
trial entry l\lonths :\Ionths :\Ionths :\Ionths 
Placebo (n = 451) (n = 459) (n = 372) (n = 304) (n = 270) 
Morning PEF 403 (100) 403 (100) 410 (101) 415 (100) 419(102) 
Evening PEF 416 (100) 416(100) 420 (101) 425 (100) 428 (102) 
Active (n = 472) (n = 468) (n = 379) (n = 320) (n = 279) 
Morning PEF 403 (103) 402 (102) 407 (105) 416 (108) 421 (109) 
Evening PEF 420(101) 428 (99) 432 (101) 439 (105) 445 (105) 
Table 5.1 l\1ean morning and evening PEF (SD) for run-in and follow-up 
divided into run-in and four three-month periods. 
Trembath (69) regarded patients who required a course of additional corticosteroid~ as 
treatment failures. Including or excluding patients regarded as treatment failures did not 
alter the result, table 5.2. The mean difference in mean PEF between baseline and 
follow-up was 4.23 lImin (95% CI 1.08 to 7.39) with placebo and 9.04 I min (950/0 CI 
5.77 to 12.32) with active treatment, p = 0.04 \\'hen those patients requiring an 
additional course of corticosteroids were excluded. \\"hen those patients requiring 
additional corticosteroids were included the mean differences in mean PEF were 2.1-
I min (95°~) CI -0.31 to 4.65) and 7.64 l,'min (95%, CI 5.09 to 10.1 S) rc~pc~:ti\"ely. p == 
0.003 
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Placebo 
Excluding patients requiring 1 or more courses of additional corticosteroids 
(n = 280) (n = 296) 
Run-in 418 (101) 421 (100) 
Follow-up 424 (101) 431 (100) 
Including patients requiring 1 or more courses of additional 
corticosteroids 
Run-in 
Follow-up 
Table 5.2 
(n=458) (n=472) 
410 (99) 411 (101) 
413 (100) 418(101) 
l\1ean daily PEF (SD) during run-in and follow-up by treatment 
group. 
As expected there was no significant difference in morning PEF between the run-in and 
follow-up, see table 5.3, when the data were adjusted for baseline levels using 
ANCOV A. There was a significant improvement in evening PEF with active treatment 
compared with placebo. When daily PEF was compared (i.e. the average of the daily 
readings for morning and evening PEF) there was a significant improvement with 
regular salbutamol and ,this was likely to be as a result of the significant improvement in 
evening PEF demonstrated on active treatment. The significant improvement in the 
group on active treatment seen with diurnal variation was because of the signiticant 
improvement in evening PEF in those patients. 
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Placebo Active Active-placebo (95% CI) P 
Mean (SE) morning PEF 
(n = 472) (n = 460) 
Run-in 403 (4.71) 403 (4.71) 
Follow-up 406 (4.69) 406 (4.75) 0.89 (-2.98 to 4.76) 0.653 
Mean (SE) evening PEF 
(n = 458) (n = 471) 
Run-in 416 (4.67) 419(4.64) 
Follow-up 418(4.67) 430 (4.63) 10.35 (6.75 to 13.96) < 0.001 
Mean (SE) daily PEF 
(n = 458) (n = 471) 
Run-in 410(4.66) 411 (4.64) 
Follow-up 413(4.65) 418 (4.66) 5.55 (2.01 to 9.08) 0.002 
Mean (SE) diurnal variation 
(n = 458) (n = 467) 
Run-in 2.15 (0.20) 2.85 (0.21) 
Follow-up 1.84 (0.16) 4.21 (0.23) 1.83 (1.41 to 2.25) < 0.001 
Table 5.3 1\1ean morning, evening and daily PEF and diurnal variation by 
treatment group adjusted for baseline levels using A:\COVA. 
5.2.3 Discussion for mean PEF (including diurnal variation) 
The results for the analysis of the TRUST dataset using mean morning, evening and 
daily PEF supported the results reported in the TRUST paper (123). There was no 
difference between the two treatment groups when mean morning PEF was used and 
there was a statistically significant improvement when evening PEF was used though in 
clinical tem1S the increase was quite small. Trialists frequently set the sample size in 
order to detect a change of 15 to 20 IImin in PEF. Using the mean baseline morning 
PEF of 403, to haye 980/0 power at the 5° ° level to detect a ditTerence of 15 IImin 
bctween treatment groups O\'cr twelyc months follow-up only 66 patient:-; would be 
required so TRUST had more than enough power t() dekct a diffcrcncc of 15 I min 
between treatment groups. 
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Mean morning PEF is often used as an indicator of asthma control and is used to 
provide an estimate of baseline lung function in the absence of FEV I measurement 
(142). Assuming that morning PEF and exacerbation. according to the TRL'ST 
definition, were measuring the same underlying process then we would ha\'e expected 
the result of TRUST to be the same whether morning PEF or exacerbation were used as 
the primary endpoint. The improvement in e\'ening PEF with regular treatment was as a 
result of the cumulative effect of regularly scheduled salbutamol during the course of a 
day and may not represent an actual improvement in the underlying asthma. If regular 
salbutamol were making asthma worse it would be expected that the increase in evening 
PEF would have been less and there may have been a decrease in morning PEF. 
5.3 Symptoms 
Change in day or night time symptoms or a composite daily symptom score were the 
primary outcome measures used in two of the papers identified in the systematic re\'icw 
(94;103). 
5.3.1 Method for symptoms 
Apter et al (94) simply generated mean daytime and night time symptom scores for run-
in and follow-up. Van der Molen et al (l03) generated a combined daily symptom score 
comprising daytime and night time symptoms and calculated the mean score for run-in 
and follow-up. Both groups used a t-test to make the comparison between treatment 
groups. 
The symptoms recorded on the TRUST diary card were as follows: 
Daytime symptoms 
These were assessed each evening, just before going to bed. Sylnptoms wcre chest 
tightness, wheezing. breathlessness and cough. 
o Nn symptoms during the day. 
Sylnptoms for one short period during the day. 
2 S)lnptoms for two or more short periods during the day. 
3 Symptoms for most of the day. which did not interfere with usual da)1ime 
activities. 
4 Symptoms for most of the day, which did interfere with usual day1ime 
activities. 
5 Symptoms so severe that you could not perform your usual daytime 
activities. 
Night time symptoms 
These were assessed each morning immediately after awakening. :-.'ight time S)ll1ptoms 
were chest tightness, wheezing, breathlessness and cough. 
o No symptoms during the night. 
1 Symptoms on waking but not causing you to wake early. 
2 Symptoms causing you to wake once or wake early. 
3 Symptoms causing you to wake twice or more (including \\'aking early), 
4 Symptoms causing you to be awake most of the night. 
5 Symptoms so severe that you did not sleep at all. 
5.3.2 Results for symptoms 
There was a significant improvement In mean daytime symptoms \\'ith regular 
salbutamol compared to placebo (p = 0.007) but no difference in mean night time 
symptoms (p = 0,21). When daytime and night time symptom scores were combined to 
give a total daily symptom score there was a significant improvement with regular 
salbutamol (p = 0.003). Table 5.4 details the results for mean daytime. night time and 
total daily symptoms. 
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Placebo Active Active-placebo p p 
(n = 458) (n = 471) (95% en (A~COYA)* T test 
1\ lean (SE) daytime symptom score 
Run-in 1.04 (0.04) 1.05 (0.04) 
Follow-up 0.92 (0.04) 0.82 (0.04) -0.10 0.009 0.007 
(-0.17 to -0.02) 
'lean (SE) night time symptom score 
Run-in 0.60 (0.03) 0.62 (0.03) 
Follow-up 0.55 (0.03) 0.55 (0.03) -0.03 0.3 0.21 
(-0.17 to -0.03) 
Mean (SE) total daily symptom score 
Run-in 1.64 (0.06) 1.67 (0.06) 
Follow-up 1.46 (0.06) 1.37 (0.06) -0.12 0.003 0.02 
(-0.22 to -0.01) 
* Adjusted for run-in levels using ANCOV A. 
Table 5.4 l\1ean symptom scores (min 0 to max 5) by treatment group. 
5.3.3 Discussion for symptoms 
The results from the comparison of daytime and night time symptoms are consistent 
with the results reported in the TRUST paper, which used symptom free days and nights 
(123). There was a significant improvement in the number of symptom free days (p < 
0.001) but not symptom free nights. The improvement in daytime symptoms could ha\'e 
been because of the cumulative effect of regular salbutamoL which also resulted in 
significantly higher evening PEF readings. 
5.4 Asthma control 
Composite measures for use in clinical trials were developed in an attempt to include 
more of the asthma diary card variables to determine whether a patient \\'as better or 
\\'orse with a particular treatment. :\ definition of asthma control was de\'dopcd hy 
Scars et al for use in their Crt)SSl)\Cr trial tl) assess thL' ~ftL'~:t of rcgular usc of fcnotcftll 
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on asthma control (51). A subsequent trial by Chapman et al (83) used the same 
outcome measure in a trial of regular salbutamol. Chapman repeated the analysis six 
times changing the order of the components and also the emphasis of the componenb. 
5.4.1 Method for asthma control 
The trial by Sears et al (51) was a crossover trial and the comparisons were made 
between the placebo period and active treatment period. The period of better or worse 
asthma control was determined by the direction of change of the components of asthma 
control detailed below. If the changes in the components of asthma control were not all 
in the same direction the following order was used: 
1. Short course of oral prednisolone. 
2. Morning PEF. 
3. Nocturnal P2-agonist use. 
4. Nocturnal symptoms. 
5. Daytime symptoms. 
6. Evening PEF. 
7. Rescue daytime inhaled P2-agonist use. 
Applying this to a re-analysis of TRUST, baseline and follow-up data were compared 
using an unpaired t-test to determine whether there was better or worse asthma control 
during follow-up compared to run-in. Each of the components of asthma control above 
were classified as better, worse or no change. Overall asthma control was assigned 
according to the order of the components. For example, if a patient had a course of 
corticosteroids they were classed as experiencing worse asthma control regardless of the 
direction of change lower down the order. If a patient did not use corticosteroids the 
next component in the order, morning PEF, would be used to classit}, asthma control, 
and so on. An unpaired t-test was used rather than the paired t-test reported because 
TRUST \\·as not a crossover trial and a paired t-test would not han:: been pl)ssible. Once 
the periods of asthma control had been determined the comparison between treatment 
groups was made using Chi square. 
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Chapman extended the definitions of asthma control by changing the order of the 
components to develop six criteria for asthma control (83). Criteria A were the same as 
asthma control in the Sears' analysis (51) and criteria B \\'ere: 
1. Short course of oral prednisolone. 
2. Morning PEF. 
3. Night time rescue P2-agonist use. 
4. Night time symptom score. 
5. Daytime symptom score. 
6. Evening PEF. 
7. Daytime rescue P2-agonist use. 
Rescue bronchodilator use alone was ignored and such patients were regarded as 
showing indeterminate di fferences between treatment periods. 
Criteria C: 
1. Short course of oral prednisolone. 
2. Night time rescue P2-agonist use. 
3. Morning PEF. 
4. Night time symptom score. 
S. Daytime rescue ~2-agonist use. 
6. Evening PEF. 
7. Daytime symptom score. 
Criteria D: 
1. Short course of oral prednisolone . 
.., ~ight time rcs\..'ue Pragonist usc, 
3. Morning PEF. 
4. ;-...right time symptom score. 
5. Daytime rescue ~2-agonist use. 
6. Evening PEF. 
7. Daytime symptom score. 
Rescue bronchodilator use alone was ignored and such patients were regarded as 
showing indeterminate differences between treatment periods. 
Criteria E: 
Assigned control only if one or more significant differences were non-discrepant 
between the treatment periods. 
Criterion F: 
As for E but excluded differences in daytime bronchodilator use only. 
Each patient's individual mean values were compared and t-tests performed. If the 
difference between the run-in and follow-up values was significant the variable was 
classified as better or worse and overall control was assigned according to the order of 
the components in the criteria. Any variable with a non-significant change was 
classified as no change. The overall comparison between the two treatment groups was 
with Chi Square. 
5.4.2 Results for asthma control 
There was no significant difference in asthma control between the two treatment groups. 
Significant improvements with regular salbutamol were seen with three of the individual 
components of asthma control: daY1ime symptoms (p = 0.()()4). daytime inhaled 1~2 -
agonist use (p = 0.03) and evening PEF (p = 0.03). 
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Placebo Active Total ~* 
Asthma control (n = 461) (n = 469) O.l 
Better 123 150 273 
No change 183 162 345 
Worse 155 157 3P 
Corticosteroid use (n = 461) (n = 469) 0.4 
No oral steroids 397 412 809 
Oral steroids 64 57 121 
;\Iorning PEF (n = 427) (n = 445) 0.2 
Better 140 166 306 
No change 180 161 341 
Worse 107 118 225 
Nocturnal ~2-agonist use (n = 419) (n = 430) 0.3 
Better 133 155 288 
No change 240 225 430 
Worse 46 50 96 
Nocturnal symptoms (n = 425) (n = 440) 0.4 
Better 108 130 238 
No change 258 252 510 
Worse 59 58 117 
Daytime symptoms (n = 425) (n = 440) 0.004 
Better 140 194 334 
No change 215 188 403 
Worse 69 58 127 
Evening PEF (n = 427) (n = 443) < 0.001 
Better 127 203 330 
No change 177 162 339 
\Vorse 123 78 201 
Inhaled ~2-agonist use (n = 421) (n = 435) 0.03 
Better 214 258 472 
No change 151 135 286 
\Vorse 56 42 98 
*Comparisons made using Chi square. 
Table 5.5 Number of patients according to each category of change for asthma 
control and the components of asthma control, by treatment group. 
The result for the TRUST analysis using the Chapman criteria A and B was the same as 
for the Sears asthma control. Ignoring the bronchodilator use did not result in a change 
in outcome for any patient. Changing the order of the components as in criteria C and D 
tended to result in patients changing category from "worse" control tp "no changc" but 
there was no significant difference between placebo and actiYe treatment grllUps. \\'hen 
pJticnts \\'cre required to ha\'c one or more non-discrepant signiticant differences in any 
..., -
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of the criteria (criteria E and F) there was a significant difference between placebo and 
active treatment groups in favour of regular salbutamol (p = 0.002 criteria E and p = 
0.001 for criteria F), see table 5.6. 
Placebo Active Total P* 
(0 = 486) (n = 497) 
Chapman criteria E 0.002 
Better 228 286 514 
No change 97 73 170 
Worse 136 110 246 
Chapman criteria F 0.001 
Better 222 282 504 
No change 108 79 187 
Worse 131 108 239 
*Comparisons made using Chi square. 
Table 5.6 Number of patients according to each category of change of the 
Chapman criteria E and F. by treatment group. 
5.4.3 Discussion for asthma control 
Detennining periods of asthma control using the methods of Sears (51) and Chapman 
(83) may not be an appropriate method of analysis for use in a trial of the design of 
TRUST. Firstly, TRUST was not a crossover trial. Secondly, asthma control was 
detennined by the direction of change of those yariables higher up the order irrespecti\'e 
of the direction of change in variables lower down the order. \\'hen asthma control was 
classified using Chapman criteria E and F many more patients were classified as 
experiencing better asthma control because classification was based on the direction of 
change of the majority of the components. 
Significant improvements with acti\'c treatment were seen with c\'ening PEF. daytlmc 
symptoms and daytime relic\'cr use. Howevl'r. when combined to detcnninc o\l'rall 
asthma control (Chapman criteria A and B) there was no differcnce betwl'cn the t\\l) 
treatment groups. On examination of the ST:\ TA log tik asthma control was 
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detennined by the use of additional corticosteroids and morning PEF, and those item5 
lower down the hierarchy had little or no effect on whether the patient had better or 
worse asthma control. 
The Sears trial used direct comparisons between the treatment and control period~ of the 
crossover trial. Using a paired t-test to compare the two treatment periods, day 1 of 
period 1 was compared directly with day 1 of period 2 which assumed that there were no 
time trends and that the daily data were not connected. In the case of daily asthma diary 
cards this is probably not true and values for one day are dependent to an extent on the 
value from the previous day. 
5.5 Exacerbations 
Four definitions of exacerbation were identified by the systematic rcv\c\\' 
(101;104;105;107;111;123). All the definitions made use of the diary card data to 
detennine periods of exacerbation but the different definitions put the emphasis on 
different components of the diary card data. Not only do the definitions use different 
combinations of diary card variables to determine the start of an exacerbation but they 
also define the end of an exacerbation differently. The four definitions of exacerbation 
are listed below. 
5.5.1. TRUST exacerbation 
1. Use of oral or increased inhaled corticosteroids. 
Or at least two or more of the following: 
2. Fall in PEF to less than 80% of median baseline level. 
3. Bronchodilator per 24 hours increased by three or more over baseline. 
4. Symptom score increased during the day or at night by two or more over 
median baseline level. 
The end of an exacerbation was defined as the ccssation of oral cortic(lsteroids or return 
to original dose of increased inhaled corticosteroids and all the followi ng criteria on tw() 
cons~:L'uti\'c days: 
I. PEF'-. SOllO median baselinc k\cl. 
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2. Bronchodilator inhalations per 24 hours increased by no more than 2 oyer 
median baseline level. 
3. Symptom scores increased day and night by no more than one over median 
baseline level. 
5.5.2 FACET severe exacerbation 
There were two types of FACET (Formoterol and Corticosteroids Establishing Therapy) 
exacerbation, mild and severe, but only the severe exacerbation will be considercd in 
this analysis. The severe exacerbation was the primary outcome measure in the FACET 
trial (101) and also in a more recent trial comparing formoterol and terbutal ine bv 
Tattersfield et al (111). 
A severe FACET exacerbation started on a particular day if the following occurred: 
1. Use of oral corticosteroids. 
2. Or a fall in PEF to less than 70% of mean baseline lc\'cl on two consecutive 
days. (Only day two and subsequent exacerbating days were categorised as an 
exacerbation). 
A patient could be classified as experiencing a subsequent exacerbation on day eleven, 
ten days after the first day of the previous exacerbation. on the condition that they were 
not still taking oral corticosteroids. For those still taking oral corticosteroids, the tirst 
day for checking for subsequent exacerbations was the first day without oral 
corticosteroids. 
Patients taking part in the FACET trial were not permitted to increase the dose of 
inhaled corticosteroids to treat an exacerbation and this was not included as part of their 
definition of cxacerbation. Writing the programs to identify the FACET sevcrc 
cxacerbations was complicated because of the \\'ay in which corticosteroid use \\'as 
coded in the TRUST diary card. The TRUST diary card simply stated whcther 
additional corticosteroids were used on a particular day and did not specify whether they 
wcrc oral or inhaled. Those exacerbations known to havc becn dctined by u~e of 
inhaled cortico~tcroids were not classified as FACET exacerbatinns The analvsis was 
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perfonned twice, once including only those patients treated with known oral 
corticosteroids and again including those patients treated with unknown corticosteroids. 
5.5.3 Exacerbation from the paper by Wilding et al (104) 
As with the FACET definition of exacerbation, this definition does not use an increase 
in inhaled corticosteroids and the data were prepared in the same way as for the FACET 
exacerbation. An exacerbation was defined as any two of the following: 
1. 300/0 fall in morning PEF. 
2. A fall in FEY I of either 0.7 litres or 300/0 from baseline. 
3. Increased use of P2-agonist (by more than four puffs per day). 
4. The need for oral prednisolone. 
5. More bronchodilator treatment on two or more consecutive nights. 
6. Increased symptom scores of one or more over baseline on t\\'() successive days. 
5.5.4 Definition of exacerbation defined by Taylor et al (105) 
Taylor et al described a complicated definition of exacerbation that involves generating 
asthma scores and then exacerbations from these scores. Hancox et al (107) used 
similar asthma scores but did not generate exacerbations from the asthma score. 
Asthma scores were determined as follows: 
Score 0: Stable asthma 
Either: 
Or: 
• Morning PEF > 900/0 of baseline best value and bronchodilator puffs < 7 per 24 
hours. 
• Morning PEF 76 - 90% of baseline best \'alue with no deterioration in any of the 
symptom scores listed below in mildly unstable. 
Score 1: .Uild(r ullstable asthma 
Either two or more of the following: 
• Morning PEF 76 - 90~~ of baseline best value. 
• 
• 
Bronchodilator puffs = 7 on baseline rounded ml'an per 24 hours. 
Deterioration in day or night S)lllptom score l)f one or more compared to 
rounded baseline mean. 
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Or: 
• Appearance or worsening of nocturnal wakening. 
• Morning PEF 61 - 75% of run-in best value but without deterioration in and 
symptom score listed above. 
Score 2: Minor deterioration 
Either: 
Or: 
• Morning PEF 61 - 75% of run-in best value and two or more of the criteria listed 
for asthma score 1. 
• Morning PEF 40 - 60% of run-in best value but without a deterioration in any 
symptom scores listed for asthma score 1. 
Score 3: Major deterioration 
• Morning PEF 40 - 60% of run-in best and two or more of the criteria listed for 
asthma score 1. 
Score 4: Major exacerbation / medical emergency 
Either: 
• Morning PEF <40% of run-in best value irrespective of symptoms. 
Or: 
• Attendance at GP or hospital emergency department with severe asthma. 
The criteria for determining minor and major exacerbations were as follows. 
• Minor exacerbation - asthma score 2 for two or more days. 
• Major exacerbation - asthma score 3 for two or more days or one day \\'ithin a 
minor exacerbation. 
• Medical emergency - asthma score -+ for one or more days. 
An exacerbation ended when the asthma score returned to 0 or 1 for three or more days 
othen\'ise the exacerbation was considered to be continuing. 
For all four definitions of exacerbation the total number of exacerbations were divided 
hv the total person years follow-up to determine the overall exacerbation rate, The 
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distributions of these annual rates in the two randomised groups were compared using 
non-parametric Wilcoxon rank sum test. 
5.5.5 Results for exacerbation 
The results for TRUST analysed using the TRUST definition of exacerbation ha\'e been 
reported in chapter 4. There was no significant difference in exacerbation rate between 
the placebo and active group when the TRUST data were analysed using the FACET 
definition of severe exacerbation. The proportion of patients having at least one 
exacerbation, and the total number of exacerbations, were similar in the two groups. 
Table 5.7 details the results for all definitions of exacerbation. There was no significant 
difference between the placebo and active treatment groups when using the FACET 
definition of exacerbation. The number of severe FACET exacerbations, including 
those with unknown corticosteroids, was much lower than the number of TRUST 
exacerbations reported but the result still reflected the TRUST results reported. 
Including those patients with unknown corticosteroids did not affect the comparison 
between placebo and active treatments. The FACET exacerbations could not be 
examined in tenns of the length of exacerbations because of the way in which the end of 
en exacerbation was defined. There was no significant difference in the rate of 
exacerbation between the two groups when the patients were analysed according to their 
baseline inhaled corticosteroid use. 
Using the Wilding definition of exacerbation (l04) there was a slight but non-significant 
di tTcrence in the exacerbation rate between the treatment groups in favour of those 
patients taking regular salbutamol when the data included those exacerbations treated by 
oral corticosteroids alone and also including unknown corticosteroids. 
There was no significant difference in the exacerbation rate between the two treatment 
groups using the definition of exacerbation described by Taylor et al (105: 107). Once 
again the total number of exacerbations was fewer that with the TRL1ST Jdinition of 
.... 
exacerbation. 
S 1 
TRUST FACET' 
(oral steroids) 
Placebo Active Placebo Active 
Exacorbation rates 
Annual exacerbation rill~ 1.3 1.25 0.25 0.41 
(<J<J%CI) (1.18101.43) (1.14101.38) (0.20100.31) (0.34100.48) 
(n\Jml~r of exacerbations 1 palient yea~ of follow up) (438/337) (425/339) (791319) (135/331) 
Exacorbation dotails 
NIJml~r of pilllenl<; with ill Ir,;]<;1 1 exacerbation 223 (46%) 214 (43%) 61 (13%) 62 (13%) 
N'Jmt,.,r ()f palwfll<; \NIth allr>;]<;1 2 exacerbalions 114 (23%) 99(20%) 17(3%) 24 (5%) 
Includes r>x;1u,rbililon<; \NIltI ii change in PEF and those Ireated wilh known oral sleroids 
~ Includes r>Xilcerballons Wlttl a change in PEF and lhose Irealed wilh oral and unknown sleroids 
t p = 0.06 
tp=O.f)/ 
FACET2 
(inc. unknown steroids) 
Placebo Active 
0.66 0.78 
(0.58 to 0.76) (0.69100.78) 
(212/320) (258/331 ) 
138 (28%) 135 (27%) 
51 (11%) 24 (10%) 
Tablo 5.7 The rosults of TRUST according to the defintions of exacerbation identified by tho systematic review. 
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Wilding' Wilding 2 Taylor 
(oral steroids) 
-
(inc. unknown steroids) 
Placebo Active Placebo Active Placebo Activo 
3.8 3.3t 4.12 3.6:t: 0.73 0.91 
(3.61 104.04) (3.10103.50) (3.90 to 4.35) (3.37 to 3.78) (0.64 to 0.83) (0.81 to 1.03) 
(1221/320) (1091/331) (1318/320) (1181/331) (233/3?0) (30?/331) 
302 (62%) 284 (57%) 319(66%) 307 (62%) 135 (28%) 133 (27%) 
207 (43%) 200 (40%) 230 (47%) 216 (43%) 56 (12%) ~3 (11"1n) 
5.5.6 Discussion for exacerbation 
Analysing the TRUST data using the FACET definition of exacerbation reinforced the 
reported TRUST result (123) that there was no difference in exacerbation rate when 
salbutamol was taken on demand compared to regular use. The number of F.-\CET 
severe exacerbations reported was fewer than the number of TRUST exacerbations and 
the exacerbation rate of 0.96 per patient per year was much less than the predicted 
exacerbation rate with placebo of 1.5 per patient per year used for the TRl'ST sample 
size calculations. Using the FACET definition of exacerbation TReST trial had 400 '0 
power to detect a change of 20% in exacerbation rate between treatment groups if only 
courses of oral corticosteroids are included. To increase the power to 98 0 0 to detect a 
20% difference in exacerbation rate nearly 4000 patients would need to be followed up 
for one year. The reason for the reduced number of exacerbations was the emphasis on 
a fall of30% in morning PEF on two or more consecutive days. For patients in TRUST, 
morning PEF fell to 70% or less of baseline morning PEF on less than 1 % of the total 
days, 1425 days out of 206073. 
In contrast to the FACET definition of exacerbation, the definition used by \Vilding et al 
(l04) resulted in many more exacerbations than with the TRUST definition because the 
criteria for change in symptom scores and additional bronchodilator use were set quite 
low. The TRUST definition of exacerbation stipulated a change in t\\/O or more over 
baseline symptom score for two consecutiye days whereas the Wilding definition 
required only an increase in one oyer baseline. The Wilding definition placed less 
emphasis on the use of oral corticosteroids because they had to have two or more of the 
components for an exacerbation. 
The definition of exacerbation described by Taylor (105) was \'ery complex to code and 
again the emphasis on changes in PEF meant that there were fewer exacerbations than 
with the TRUST definition. Using the Taylor definition of exacerbation nearly twice as 
many patients would need to be followed for a year to ha\ e 98% power to detect a ::wo,o 
di fference in exacerbation rate between the two treatment groups. 
S ... 
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5.6 Discussion 
The results of this analysis reinforced the main TRUST results (123). There was no 
difference in the exacerbation rates between the two groups using the different 
definitions of exacerbation but the total number of exacerbations in the 983 subjects 
varied from a total of 214 FACET exacerbations to 2312 \Vilding exacerbations with the 
TRUST definition of exacerbation in between. There were fewer exacerbations with 
those definitions that tended to rely on a fall in morning PEF compared to those 
definitions that also included changes in symptom scores. All definitions included a 
course of corticosteroid treatment as part of the definition. Additional corticosteroids 
alone could result in an exacerbation in all the definitions except the \\"ilding ddinition 
where it had to occur with at least one other change. 
There was no significant difference in mean morning PEF between the two treatment 
groups and TRUST had a more than adequate sample size to detect a change in mean 
mOIlling PEF of 20 lImin. PEF seemed to vary little in this group of patients as 
demonstrated by the very few days (0.7 % 1425 / 206073) when the morning PEF fell to 
70% or less of baseline. Both evening PEF and diurnal variation increased with regular 
salbutamol. It may be that these two measures were really measuring short-term change 
associated with cumulative doses of a bronchodilator rather than any long-term change 
in the underlying asthma. 
From the results of this analysis a composite outcome measure, which included 
symptoms as well as PEF, was the most useful measure of change in this group of mild 
to moderate asthmatics because so few patients demonstrated large changes (>=30° 0) in 
monling PEF. 
5.7 Summary 
This chapter detailed the results of the analysis of TRUST using the different primary 
outcome measures identified by the systematic review. The next stage of the analysis 
will compare the measurement characteristics of the primary outcome measures 
discussed here to detennine their sensiti\'ity and specificity and to try t~J identify \\'hich 
components were the most important in defining an exacerbation. 
By the end of the next stage of this analysis it will be clear how the TReST definition of 
exacerbation perfonned in comparison to the other primary outcome measures identi tIed 
and which measure was the most suitable measure for use in clinical trials of this nature. 
It will also be clear how the components of the TReST definition correlated and 
whether any were more important in tenns of the frequency with which they caused an 
exacerbation to be classified. 
Chapter 6 - Comparison of primary outcome measures 
Chapter 6 describes the comparison of the primary outcome measures identified bv the 
systematic review and the TRUST definition of exacerbation. 
6.1 Introduction 
The systematic review identified five different pnmary outcome measures used in 
clinical trials of long and short acting inhaled ~2-agonists. The aim of this analysis \\"as 
to compare the measurement characteristics of the primary outcomes identified \\"ith the 
TRUST definition of exacerbation. The four different definitions of exacerbation \\"ere 
also assessed to see whether one or more component played a greater role in 
determining an exacerbation and whether there was any correlation betwecn the diary 
card components. 
6.2 Mean PEF (including diurnal variation) 
6.2.1 Introduction for mean PEF (including diurnal variation) 
It might be expected that those patients who experienced one or more exacerbation 
according to the TRUST definition would also experience a decrease in mean morning 
PEF over the course of the trial. 
6.2.2 Method for mean PEF (including diurnal variation) 
In order to investigate the relationship between mean morning and evening PEF and the 
TRUST definition of exacerbation a series of regression models were used. Thc aim of 
this re!:,Tfession analysis was to identify whether change in a particular variable over the 
period of follow-up could predict whether a patient experienced an cxacerbation or not. 
Two basic models were used; the first model was a logistic regression modcl that 
assessed the degree to which change in a variable such as mean morning PEF betwc~n 
bascline and follow-up. adjusted for baseline morning PEF and length of follow-up. 
could predict whether a patient experienced a TRUST cxacerbation or not. The second 
model was a Poisson regression model that assessed the degree to which change in a 
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variable such as mean mornmg PEF between baseline and follow-up, adjusted fl1r 
baseline morning PEF, length of follow-up and clustering on patient number. could 
predict the number of TRUST exacerbations experienced during their follow-up period. 
It was expected that the results from the Poisson model might be more useful than the 
logistic regression model because the binary outcome might be too simplistic. 
A further Poisson analysis of morning PEF was undertaken using TReST exacerbations 
and monthly means for morning PEF. The dataset contained information on mean 
morning PEF and the presence or absence of an exacerbation for each month of follow-
up. Details of the regression analysis are at Appendix 6.1. 
6.2.3 Results for mean PEF (including diurnal variation) 
The regression model explored the relationship between the change in morning PEF 
between run-in and follow-up and the presence or absence of one of more TRUST 
exacerbations during the follow-up period. The logistic regression model suggested a 
significant but weak relationship between the mean difference in morning PEF between 
run-in and follow-up and the presence or absence of a TRUST exacerbation. A 1 1 min 
increase in mean morning PEF resulted in a 0.80/0 decrease (950/0 CI 0.35 to 1.3. P = 
0.001) in the odds of experiencing an exacerbation during the course of the follow-up. 
Therefore a 15 1 imin increase in mean morning PEF resulted in an 11.6%% decrease 
(95% CI 5.1 to 17.7. P = 0.001) in the odds of an exacerbation. Expressing the change 
in mean morning PEF as a categorical variable with 50 IImin divisions did not improve 
the logistic regression model for mean morning PEF. This suggested that the 
relationship between the change in mean morning PEF between run-in and follow-up 
and the presence of one or more TRUST exacerbation was linear. 
The Poisson regreSSIOn model for the change in mean mornmg PEF and the total 
number of TRUST exacerbations was more complicated and the relationship \\'as not 
linear. Table 6.1 details the results of the Poisson regression model with mean morning 
PEF expressed as a categorical variable. As the change in mean morning PFF betwel~n 
run-in and follow-up increased the TRUST exacerbation rate decreased but none of the 
results was signi ticant and there was no trend. There was an initial increase l)f ~:,O 0 in 
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TRUST exacerbation rate (OR 1.25 950/0 CI 0.67 to 2.36) when morning PEF increased 
from the reference category. This initial increase in exacerbation rate may ha\'e been 
because there were very few patients in the baseline group (n = 24) compared to the -.5() 
to 0 group (n = 374). From figure 6.1 it is clear that one patient experienced a TRl:ST 
exacerbation rate of 73 per year because he or she experienced one exacerbation in six 
days before withdrawing from the trial, see figure 6.1. Another patient experienced 11 
exacerbations. Excluding these patients from the analysis did not change the result. 
Change in am PEF from N TRUST exacerbation 95~/~ Confidence 
baseline (I/min) rate ratic. Interval 
Less than -50 
-50 to 0 
0 
50 to 100 
100 or more 
Table 6.1 
24 
374 1.25 0.67 to 2.:'7 
429 0.83 0.44 to 1.56 
37 0.76 0.34 to 1.69 
10 0.68 0.21t02.17 
The change in rate ratio of TRUST exacerbation according to the 
category of change in mean morning PEF. 
The relationship between a change in mean evening PEF between run-in and follow-up 
and the presence of one or more TRUST exacerbation \\'as weaker than with morning 
PEF. A 10 lImin increase in evening PEF resulted in a 6.5% reduction in the TRUST 
exacerbation rate and this relationship \\'as found to be linear. Figure 6.2 illustrates the 
relationship between evening PEF and TRUST exacerbation rate. 
Change in am PEF from TRt:ST exacerbation rate ratio 
baseline (n = 798) 
1 lImin 0.99t 
101/min 0.94t 
t p < 0.001 
95% Confidence 
Interyal 
0.99 to 1.0 
0.90 to 0.97 
Table 6.2 TRUST exacerbation rate ratio and change in eYening PEF. 
When monthly values for the mean change in morning PEF between run-in and fo11o\\·-
up were used the relationship between TRUST exacerbation and mean morning PEF 
was stronger. The general trend was for significant reductions in the exacerbation rate 
as the change in mean morning PEF increased, see table 6.3. 
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Figure 6.1 TRUST exacerbation rate against categories for mean 
difference in morning PEF between run-in and follow-up. 
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Change in monthly mean am ~ 
PEF from baseline (I/min) 
Less than -50 358 
-50 to 0 2838 
o 3250 
50to 100 438 
100 or more 252 
tp = 0.003, tp < 0.001 
TR(;ST exacerbation 
rate ratio 
1 
0.65+ 
0.32t 
0.32t 
0.18t 
95% Confidence 
Inten'al 
0.49 to 0.8-: 
0.23 to 0.43 
0.20 to 0.51 
0.09 to 0.36 
Table 6.3 Monthly TRUST exacerbation rate ratio and change in morning 
PEF. 
The relationship between change diurnal variation between run-in and follow-up and 
TRUST exacerbation was linear. A 10 llmin increase in diurnal variation between run-
in and follow-up resulted in a 33% (95% CI 1.01 to 1.75) increase in TRUST 
exacerbation rate, see table 6.4. 
Change in diurnal variation TRUST exacerbation rate 95% Confidence 
from baseline ratio (n = 798) Interval 
1 IImin 
10llmin 
t p = 0.04 
Table 6.4 
1.03t 
1.33t 
1.0 to 1.06 
1.01 to 1.75 
TRUST exacerbation rate ratio and change in diurnal variation 
from baseline 
6.2.4 Discussion for mean PEF (including diurnal variation) 
The relationship between TRUST exacerbation and morning and evening PEF averaged 
ovcr the whole period of follow-up was weak but the relationship \\'ith diurnal variation 
was stronger. Simply averaging thc PEF over the entire follow-up period seemcd to 
oversimplify the relationship \\'ith TRUST exacerbations because thc rapid fluctuations 
were not reflected in the overall mean value. Intuiti\cly one might CXPL'ct a linear 
relationship betwccn PEF and TRUST cxacerbation rate. The relationship with evcning 
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PEF was linear but the relationship with mean morning PEF was more complicated. 
perhaps because of the distribution of the patients between the categories of PEF 
change. A large proportion, 92% (803/874), of patients experienced a change in mean 
morning PEF of between -50 and 50 lImin and this may ha\"e accounted for the non-
linear and weak relationship with TRUST exacerbation. 
There was a stronger relationship between change in diurnal variation and TRLST 
exacerbation. As diurnal variation between run-in and follow-up increased there \\"as a 
linear increase in the rate of TRUST exacerbations. The stronger relationship could be 
because a 10 lImin change in diurnal variation represented a larger relati\'e change 
between run-in and follow-up than a 10 lImin change in morning or e\'Cning PEF. An 
increase in diurnal variation is usually associated with worse asthma control. In 
TRUST, an increase in diurnal variation occurred because of an increase in evening PEF 
rather than a fall in morning PEF. Reddel et al (159) suggested that an increase in 
diurnal variation was associated with poor asthma control and not exacerbation. The 
difference between their patients and TRUST patients was that TRUST did not use the 
run-in period to modify treatment to achieve stable asthma. An increase in diurnal 
variation in a TRUST patient was unlikely to reflect worsening asthma control because 
of the significant improvement in evening PEF. 
There are several reasons why the relationship between mean morning PEF and TRUST 
exacerbations may not have been as strong as expected. The mean follow-up PEF 
(morning and evening) was the mean PEF for the whole of the follow-up period for a 
particular patient. Simply averaging the PEF over such a period meant that there was no 
information about the daily fluctuations used to identify exacerbations. A patient may 
have experienced several sharp fluctuations in morning PEF resulting in exacerbations 
but their o\"erall mean PEF remained unchanged. Most patients experienced a change in 
mean morning PEF of between -50 and 50 lImin, concentrating most exacerbations in 
this group. 51 % of the TRUST exacerbations were because of courses of oral or 
increased inhaled corticosteroids alone (123) and there may not have been an associated 
decrease in PEF. either morning or evening. 
Repeating the analysis to include monthly values for mean morning PEF impro\'ed the 
relationship with TRUST exacerbation, Generating monthly mean values increased the 
likelihood of sharp fluctuations in PEF having an effect on the overall monthly mean 
value that was more closely related to TRUST exacerbation, 
In conclusion, if using mean morning PEF as a primary outcome measure, it may be 
more useful to look at monthly mean changes because fluctuations in asthma \\'ould be 
more likely to have an effect on the monthly mean value. The overall length of the trial 
would depend on the exact question it was designed to answer. 
6.3 Symptoms 
6.3.1 Introduction for symptoms 
It might be expected that those patients who experienced one or more exacerbation 
according to the TRUST definition would also experience an increase in daytime or 
night time symptoms over the course of the trial. 
6.3.2 Method for symptoms 
The method of analysis to determine the extent to which the mean values for daytime 
and night time symptoms predicted whether a patient experienced one or more TRUST 
exacerbations was the same as that to assess the effect of mean morning PEF. details at 
Appendix 6.2. 
6.3.3 Results for symptoms 
The odds of experiencing one or more TRUST exacerbations increased by 73% (OR 
1.73 95% CI 1.34 to 2.24) when the mean difference in daytime symptoms score 
between run-in and follow-up increased by one and this relationship appeared to be 
linear. When Poisson regression was used the TRLST exaccrbation rate increased by 
660~) (OR 1.66 95%) CI 1.40 to 1.97) as the mean ditTerence in daytime symptoms 
bet\\"l~en run-in and follow-up score increased by one and again this relationship \\'as 
linear. Combining the daytime and night time scores to form a total daily S}111ptoms 
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score did not improve the model for either the logistic or Poisson regression models. 
odds ratios being 1.51 (95% C1 1.27 to 1.80) and 1.49 (95°~ C1 1.33 to 1.6~) 
respectively. 
6.3.4 Discussion for symptoms 
An increase in the mean daytime symptom score of one over baseline was associated 
with a 73% increase in the odds of one or more TRUST exacerbations and a 66%, 
increase in the annual TRUST exacerbation rate. Even though the symptom scores were 
mean scores for the entire follow-up period, they still reflected the underlying 
fluctuations in symptoms that lead to TRUST exacerbation An increase in the mean 
daytime symptom score did predict whether patients were more likely to have 
experienced one or more TRUST exacerbations. Generating a total symptom score by 
combining day and night time symptom scores was no stronger a predictor of TRUST 
exacerbation than daytime symptoms alone. This was surprising because if asthma was 
worse it might be expected that there would be an increase in both day and night time 
symptoms. A possible explanation may be that an increase in daytime symptoms did 
not occur with a corresponding increase in night time symptoms of the same magnitude. 
In conclusion, an increase in the mean daytime symptom score over baseline did seem to 
be a useful measure in tenns of its ability to predict TRUST exacerbations. 
6.4 Asthma Control 
6.4.1 Introduction for asthma control 
There was no significant difference in asthma control between the two treatment groups 
although significant impro\'ements were seen with acti\'e treatment with daytime 
symptoms. daytime inhaled P2-agonist use and evening PEF. \\'hen patients wcre 
required to havc one or more non-discrepant significant differences in any of the criteria 
there was a significant improvement in favour of active treatment. 
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6.4.2 Method for asthma control 
Because of the limited applicability of the Sears measure of asthma control to future 
trials the comparisons with TRUST exacerbation were simple comparisons. :\ 
regression model was used to determine whether poor asthma control predicted an 
increase in the TRUST exacerbation rate. 
6.4.3 Results for asthma control 
Patients who were classified as having worse asthma control were more likely to 
experience TRUST exacerbations and those patients with better asthma control were 
more likely to experience no exacerbations, see table 6.5. 
Asthma control 
TRUST Better )\:0 change "'orse Total 
exacerbation 
No 173 199 121 493 
(63%) (58(%) (3900) 
Yes 100 146 191 437 
(37%) (42%» (61 %) 
Total 273 345 312 930 
Table 6.5 The number (%) of patients according to Sears asthma control who 
experienced TRUST exacerbation. 
Using the modified asthma control proposed by Chapman (see section 5.4.1 for details) 
there was little change when the order of e\'ents was changed except for criteria E and F 
when the proportion of patients with better asthma control who also suffered a TRL.:ST 
exacerbation increased, -+30/0 (219/514) for criterion E and 42% (224/504) for criterion 
F. 
Using a simpk Poisson regression model, \\'orse asthma control was associated \\'ith an 
increase in the TRL.:ST exacerbation rate ratio of between 5~,h{l() {OR l.54 95°~ CI 1,3 
to 1.9) to more than 2 fold increase (OR 2,15 95° 0 CI l.S to 2.6), sec table 6.6, 
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t p < 0.001 
Table 6.6 
Asthma Control 
Criteria A 
Criteria B 
Criteria C 
Criteria D 
Criteria E 
Criteria F 
Rate Ratio 
1.54+ 
(1.27 to 1.86) 
1.54t 
(1.27 to 1.86) 
1.83t 
(1.50 to 2.23) 
1.83t 
(1.50 to 2.23) 
, 1 ~..l. 
_. ::"I I 
(1. 77 to 2.62) 
2.12t 
(1.74 to 2.59) 
The change in rate ratio of TRUST exacerbation according to the 
Chapman criteria of asthma control. 
6.4.3 Discussion for asthma control 
The relationship between TRUST exacerbation and asthma control suggested that those 
patients with worse asthma control tended to experience more TRUST exacerbations. 
The relationship between TRUST exacerbation and asthma control was not investigated 
in more detail because of the limited applicability of asthma control in future 
randomised controlled trials. This method was used in a crossover trial where the 
period of active treatment was compared directly with the period of placebo treatment 
within the same patient. It was not an appropriate method for use in a parallel group 
design trial because the whole of the follow-up was compared with a relatively short 
run-in period within the same patient. 
96 
6.5 Asthma exacerbations 
6.5.1 Introduction for exacerbations 
There was no difference between placebo and active treatment when TReST was 
analysed using the definitions of exacerbation identified by the systematic review 
(101 ;104;105;107;111) but the total number of exacerbations according to the different 
definitions varied enormously. The aim of this analysis was to determine how the 
TRUST definition of exacerbation performed in comparison to the other three 
definitions of exacerbation (101; 1 04; 105; 1 07: Ill). Their measurement characteristics 
were compared, as were the relationships between th\! diary card variables and the 
definitions. 
6.5.2 Method for exacerbations 
The three definitions of exacerbation (101:104:105:107;111) were compared with the 
TRUST definition of exacerbation in two ways. Firstly, periods of exacerbation (linked 
days of exacerbation), using end rules to determine the end of an exacerbation, were 
compared with TRUST (see section 5.5 for specific details of exacerbation end rule). 
Secondly, exacerbation days according to the three definitions were compared with 
TRUST. The exacerbations were compared in two ways because of the difficulty in 
matching the start dates exactly for periods of exacerbation. Using the daily 
exacerbations solved this problem and allowed for more comparisons to be made. 
The periods of exacerbation were consecutive days of exacerbation all considered to be 
, 
part of the same episode. Day one of the exacerbation was identified using the speci fic 
exacerbation criteria and the exacerbation was considered to ha\'e continued until the 
criteria for the end of an exacerbation were met. For example, the end of a TRLST 
exacerbation was defined as the cessation of the use of oral corticosteroids together with 
all the following criteria on two or more consecutive days: 
I. PEF greater than SOS 0 of median baseline level. 
") Rescue P2-agonist inhalations per 24 hours increased hy no more than two over 
baseline median levels. 
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3. Daytime and night time symptom scores increased by no more than one o\"er 
median baseline level. 
Periods of exacerbation were identified for all three definitions of exacerbation and the 
resulting dataset contained a start date and end date for every exacerbation and the 
qualifying criteria the patient fulfilled. The datasets for the periods of exacerbation for 
each definition were combined with the TRUST exacerbation dataset. matching 
exacerbation start dates. This process was complicated because the different definitions 
of exacerbations identified periods of exacerbation on slightly different days. The 
exacerbation start dates were matched with TRUST exacerbation start dates up to ten 
days either side to try to ensure that as many of the different exacerbations were 
matched as possible. Ten days either side of the start date was chosen because FACET 
exacerbations used a ten-day rule to detennine the end of an exacerbation. It was felt 
that exacerbation start dates more than ten days apart might not be part of the same 
episode. Not all the periods of exacerbation from one of the definitions of exacerbation 
could be matched with periods of TRUST exacerbation because of the difference in 
numbers of exacerbations between definitions. The comparison of daily exacerbations 
was much simpler. Days when the patient fulfilled the various definitions of 
exacerbation were identified and no attempt was made to try and link these days into 
periods of exacerbation. 
For both periods and days of exacerbation, logistic regression models were used to 
identify the extent to which the variables predicted an exacerbation, details at Appendix 
6.3. Two by two tables were constructed for the exacerbation days to compare days of 
TRUST exacerbations with other days of the three other exacerbations. Similar tables 
were constructed for the variables and combination of variables to test sensitivity and 
specificity. 
The use of additional corticosteroids was a criterion m all four definitions of 
exacerbation with or without accompanying criteria. In order to identi fy which variables 
predicted whether patients increased inhaled corticosteroids or embarked on a course of 
oral treatment two regression models \\"ere used. The first model \\as a logistic 
rC!:-,Tfl'SSlOn model usmg days of exacerbation and the diary card \"ariables as the 
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explanatory variables. The second model used day one of the TRUST exacerbation and 
included those exacerbations with and without corticosteroids. The regression analysis 
was repeated for the diary card variables on day one and the preceding days. details of 
the models used are at Appendix 6.4. 
6.5.3 Results for exacerbation 
6.5.3.1 TR UST 
There were 860 TRUST exacerbations and 7184 days of TReST exacerbation. 53° ° 
(455/860) of the TRUST exacerbations were classified according to corticosteroid use 
alone or with at least one of the other diary card criteria. Table 6.7 details the 
proportion of TRUST exacerbations according to the components of the definition. 
TRUST exacerbations TRUST exacerbations days 
(n = 860) (n = 7184) 
Corticosteroid use 455 (52%» 5678 (790/0) 
20% fall in morning PEF 114 (13%) 632 (9%) 
Increase in rescue P2 - agonist 374 (44%) 1912 (27%) 
Daytime symptoms 343 (40%) 2055 (29%) 
Night time symptoms 235 (27%) 1217(17%) 
Table 6.7 Number (%) of TRUST exacerbations (periods and days) according 
to the criteria fulfilled. 
A logistic regression analysis was carried out to determine which of the diary card 
variables were the strongest predictors of a TRUST exacerbation. Table 6.8 lists the 
crude and adjusted odds ratios for TRUST exacerbations and exacerbation days as well 
as exacerbations with and without corticosteroid use. Use of additional corticosteroids 
could not be included in the model because by definition it predicted TRUST 
exacerbation on its own and was dropped from the computer model. 
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An increase in daytime symptoms was the strongest predictor of exacerbation with close 
to an eight fold increase in the odds ratio for an exacerbation with an increase in 
symptom score of 2 (OR 8.31 950/0 CI 6.14 to 11.24) for exacerbation and a six-fold 
increase for exacerbation days (OR 5.96 95% CI 4.67 to 5.57). A fall in morning PEF 
of 200/0 or more resulted in a more than two-fold increase in the odds ratio for an 
exacerbation (OR 2.61 95%) CI 1.71 to 3.97) and a four-fold increase in the odds ratio 
for an exacerbation day (OR 4.13 95% CI 3.0 to 5.7). \\ben the TRUST exacerbations 
were split according to those treated with corticosteroids and those without 
corticosteroids the effect of the variables on the odds ratio for an exacerbation changed. 
the relationship between the variables and those exacerbations treated \\'ith 
corticosteroids were linear. An increase in daytime symptoms had an e\'en greater effect 
on TRUST exacerbations without corticosteroids, with an odds ratio of 12.36 (95 0 0 CI 
7.1 1 to 21.47) increase of two over baseline. Use of rescue Pragonists and an increase 
night time symptom score of two or more over baseline had a greater effect on the 
likelihood of a TRUST exacerbation without corticosteroids than all TRUST 
exacerbations. The effect of all diary card variables on TRUST exacerbations treated 
with corticosteroids was much less than on all exacerbations or those without 
corticosteroids and the relationships were linear. This suggested that those 
exacerbations treated with corticosteroids were associated with fewer symptoms and 
changes in PEF than those exacerbations not treated with corticosteroids. 
6.5.3.2 FACET 
Using TRUST data there were 214 FACET (known oral corticosteroids only) and 470 
FACFT (including oral and uncertain corticosteroids) exacerbations. Table 6.9 details 
the numbers of FACET exacerbations according to the definition of exacerbation. 
\Vhen days of FACET exacerbation were considered 800/0 (2466/3095) of FACET 
exacerbations \\'Cre as a result of additional corticosteroid use and this fell to 60% 
(937/1566) when only those known to have used oral corticosteroids were included. 
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FACET Exacerbation 
Corticosteroid use 
Morning PEF <70% run-in 
Both 
Including oral 
corticosteroids only 
(n = 214) 
90 (420/0) 
121 (57%) 
3 (1%) 
Including unknown and 
oral corticosteroids 
(n = 470) 
346 (77~ 0) 
121 (2600) 
3 (1 ~/o) 
Table 6.9 Number (%) FACET exacerbations according to the components of 
the definition of exacerbation. 
All the comparisons of the measurement characteristics of the TRUST and FACET 
definitions of exacerbation were carried out on the daily exacerbations because it did not 
rely on date matching. The analysis was repeated for FACET exacerbations including 
those treated with known and unknown corticosteroids and those treated with known 
oral corticosteroids separately. Using the TRUST definition of exacerbation as a gold 
standard, the FACET definition had 37% sensitivity (95% CI 35.6 to 37.8) and 99.80/0 
specificity (95% CI 99.7 to 99.8) when those exacerbations with unknown 
corticosteroids were included. The sensitivity fell to 16% (950/0 CI 14.6 to 16.3) when 
known oral corticosteroids only were included, table 6.10. Using the FACET 
exacerbation as the gold standard, TRUST exacerbation had a sensitivity of 850/0 (95 0 0 
CI 84 to 87%) and specificity of 98% (95% CI 97.9 to 980/0). 
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FACET 
(including oral and 
unknown corticosteroids) 
TRLST exacerbation 
No Yes 
TRUST exacerbation No 219036 4545 
Table 6.10 
(99.8%) (63%) 
Yes 456 2639 
(0.2%) (37°'0) 
Total 219492 7184 
Days of exacerbation according to 
definitions. 
I 
I 
: 
the 
FACET 
(including oral 
corticosteroids only) 
TRl'ST exacerbation 
\"0 Yes 
~19036 6074 
(99.80/0) (84 . .5°, n) 
456 1110 
(0.2° 0) (15.6%») 
219492 7184 
----
TRl'ST and FACET 
Using a logistic regressIOn model, the odds ratio for those patients expenencmg a 
FACET exacerbation also experiencing a TRUST exacerbation \\'as 279 (95~ <> CI 251 to 
309) if patients with unknown corticosteroid use were included. This decreased to 89 
(95% CI 79 to 98) for those patients with known oral corticosteroids only. 
The extent to which the diary card variables predicted whether a patient experienced a 
FACET exacerbation (definition in section 5.5.2) or not was examined using a logistic 
regression model, table 6.11. The strongest predictors of exacerbation using the FACET 
definition were a fall in morning PEF of 200/0 or more and increase in daytime 
symptoms. The effect of an increase in night time symptoms was less than expected and 
the likelihood of exacerbation did not increase with increasing night time symptoms. 
The use of corticosteroids was excluded from the model because their use was logically 
linked to a FACET exacerbation and dramatically reduced the predictive effect of all the 
other diary card variables. The odds ratio for a fall in mean morning PEF \\'as greater 
when onl\' those exacerbation requiring treatment with oral cortil'ostewids were 
included compared to those including unkno\\'n corticosteroids, but was still a \ery 
strong predictor in both cases, This suggested that the exacerbations resulting In 
treatment with OLII corticosteroids were ml)re se\ere. 
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(28910589) (11110484) (48210102) (1.0510 6.73) 
5 IftI n:,.,ne in Ngt'll1Ime ~ .... 157t 155 316t 108 
(61.010406) (0110255) (12210818) (041032.2) 
210 " ..... "reese in !ftC"" ~egoriSt \Se 434t 11 386t 130 527t 1.13 463t 115 
(325 10 5.81) (07410163) (341104.36) (087 10 1.95) (34710799) (06810 1 89) (39110549) (068101.95) 
"10 10...". rc_ in teK"" I\raoo-t \Se 10 It 105 694t 107 160t I" 11 It 092 
(59310 17.1) (051102.17) (535109.01) (06010193) (8251030.8) (04710263) (81210 IS 1) (03910219) 
~ 10 poll. rc_ in !'He"" IL·eoorr.;t I&e 149t 094 11 6t 153 249t 112 238t 241 
(6 92 10 32.0) (035102.57) (79810169) (03310716) (10010621) (032103.94) (16110 35 3) (02110276) 
5 lEI 10'lft dec ... se on pm PEF 2.21t 1 14 201t 117 293t 101 233t 108 
(l69t0287) (08310 1 57) (1 8210 2.22) (09310148) (19110450) (06310 163) (202 10 270) (077101.54) 
'010 2O'!Iodacreaw on pm PEF 744t 138 567t 1.37 128t 1 16 852t 131 
(554 109 98) (094 10 2.03) (502106.40) (0.91 10 2 08) (82410 198) (07210 1 87) (72710999) (0.80 10 2 16) 
'2O'\fo dec_ in pm f'f f 295t 138 199t 1.36 757t 148 397t 144 
121510 40 51 1082102331 1171102321 1077102411 {47 7 10 1151 108410 2 601 1333104721 1080102591 
T p ~ 000,. t p < 0 OS. ~ P < 001 
• The br1Ioeen ... ,. •• nd eucertJabon ""'.r. ~ nlllo lor 1 lftI ct.,. shawl 
.~ lor buetne ....... age. se •• nd cu;~ on ,.~ .. stu:ty.....-r 
T ...... " The effect of dlery cant varlebl .. on the odda 111110. crt ..... rlenclng a FACET ••• cerballon or FACET exacerballon day. 
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6.5.3.3 Wilding definition of exacerbation 
Using TRUST data there were 2499 exacerbations. including oral and unknown 
corticosteroids, according to the definition by \Vilding (definition in section 5.5.3) and 
2312 exacerbations including known oral corticosteroids only. Corticosteroid use plus 
one other criterion accounted for only 4% (90 / 2312) of Wilding exacerbations. The 
most common reason for exacerbation was increase in daytime symptoms and night 
time reliever use, 75% (1737 / 2312) of all Wilding exacerbations when known oral 
corticosteroids only were included. Including those exacerbations with oral and 
unknown corticosteroids resulted in 11 % (277 / 2499) exacerbation including 
corticosteroids and 70% (1737 / 2499) of exacerbations were as a resul t of daytime and 
night time symptoms. 
As with FACET, comparing days of exacerbation according to the TRUST and \\'ilding 
definitions was more useful because it did not rely on matching dates. Using TRUST as 
the gold standard, the Wilding exacerbation definition had 34.8% sensitiyity (95~<> CI 
33.74 to 35.96) and 95.23% specificity (950/0 CI 95.14 to 95.32) when only patients with 
known oral corticosteroid use were included, increasing to 51 % sensitivity (95 0 <> CI 
50.02 to 52.35) when patients with unknown corticosteroids were included, table 6.5.6. 
When the Wilding definition of exacerbation (known oral corticosteroids only) was the 
gold standard TRUST exacerbation had 19.3% sensitiyity (95% CI 18.37 to 19.720/0) 
and specificity of 97.81 % (95% CI 97.75 to 97.87). For those patients experiencing an 
exacerbation by the Wilding definition there was a 21 fold increase in the odds of 
experiencing a TRUST exacerbation (OR 21 95% CI 17 to 26) including patients with 
, 
unknown corticosteroid use. This was reduced to an 11 fold increase (OR 11 95~o CI 9 
to 13) when those patients with unknown corticosteroids were excluded. 
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\\'ilding exacerbation \\'ilding exacerbation 
(including oral and (including oral 
unknown corticosteroids) corticosteroids only) 
TRUST exacerbation TReST exacerbation 
No Yes :\0 Yes 
TRUST exacerbation No 209028 3507 209028 4681 
Table 6.12 
(95%) (49%) (950/0) (65 00) 
Yes 10464 3677 10464 2503 
(5%) (510/0) (5%) (35%) 
Total 219492 7184 219492 7184 
Days of exacerbation according to the TRl"ST and \Yilding 
definitions. 
A logistic regression model was used to determine the extent to which the diary card 
variables predicted whether a patient experienced a Wilding exacerbation or not, table 
6.13. 
The strongest predictors of Wilding exacerbation days were corticosteroid use (OR 
14.43 95% CI 10.41 to 19.99) followed by daytime and night time symptoms (OR 2.54 
95 0 ;) CI 2.25 to 2.87 and OR 2.12 95% CI 1.79 to 2.52 respectively) when patients were 
included with exacerbations treated with oral and unknown corticosteroids. The effect 
of corticosteroid use was reduced when only those courses of known oral corticosteroid 
were included (OR 1.66 95% CI 1.14 to 2.42). Corticosteroid use could be included in 
the multivariate model because it was not logically linked to exacerbation in this 
definition since it had to occur in combination with one other criterion. When periods 
of exacerbation were analysed the effect of day and night time s:mptoms was reduced 
but they were still the most important predictors of exacerbation. 
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hi- (Jndudfng patients with exacerbations treated with oral and unknown steroids) (Including patients with exacerbations treated with oral steroids only) 
-, card variabfe WIldIng Exacerbations Wilding Exacerbation Days Wilding exacerbations W1Idlng Exacerbation Days 
Crude Odds Ratio Adjusted Odds Ratio- Crude Odds Ratio Adjusted Odds Ratio- Crude Odds Ratio Adjusted Odds Ratio- Crude Odds Ratio AdJust.d Odds Ratto-
. . (95% C9 (95% C9 (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) 
Oracotico&terOds 5.05 13.54t 14.43t 1.59 5.17t 1.66§ 
(4.44 to 5.74) (12.81 to 14.32) (10.41 to 19.99) (1.28to 1.96) (4.84 to 5.51) (1.14102.42) 
1 Vmin increase in am PEF 0.99t 1.ot 0.99t 1.00 0.99t O.995t 0.99t 1.00 
(0.99 to 0.99) (0.99 to 1.0) (0.99 to 0.99) (0.99 to 1.00) (0.99 to 0.99) (0.99 to 1.0) (0.99 to 0.99) (0.99 to 1.0) 
10 Vmin inc:reaIe in am PEF O.88t O.96t 0.87t 0.96 O.88t 0.96t 0.8n 0.96 
(0.87 to 0.88) (0.93 to 0.98) (0.86 to 0.87) (0.92 to 1.002) (0.87 to 0.88) (0.93 to 0.98) (0.87 to 0.88) (0.92 to 1.01) 
100 IImin inc:reaIe in am PEF 0.26t O.63t 0.24t 0.66 0.27t 0.63t 0.25t 0.66 
(0.24 to 0.29) (0.49 to 0.81) (0.23 to 0.25) (0.42 to 1.02) (0.24 to 0.29) (0.48 to 0.83) (0.24 to 0.26) (0.42 to 1.06) 
1 unit inaease daytime symptoms 3.05t 1.83t 4.85t 2.54t 3.09t 1.80t 4.83t 2.51t 
(2.94 to 3.17) (1.68 to 1.99) (4.74 to 4.97) (2.25 to 2.87) (2.97 to 3.21) (1.64 to 1.97) (4.72 to 4.96) (2.21 to 2.84) 
1 unit increase in night time symptoms 3.21t 1.63t 4.43t 2.12t 3.31t 1.68t 4.56t 2.15t 
(3.08 to 3.35) (1.47t01.81) (4.32 to 4.54) (1.79t02.52) (3.17 to 3.45) (1.50 to 1.88) (4.45 to 4.68) (1.80 to 2.58) 
1 puff ~e in reacue fJ7-agonist use 1.40t 1.17t 2.02t 1.62t 1.41t 1.18t 2.09t 1.65t 
(1.38 to 1.42) (1.11 to 1.24) (2.0 to 2.05) (1.50 to 1.75) (1.39 to 1.43) (1.12 to 1.25) (2.06t02.11) (1.52 to 1.79) 
1 IJlnin Increase in pm PEF 0.99t 1.00 0.99t 1.00 
{Qj)I:ltoO.99j (1.0t01.0) (0.99 to 0.99) (1.0 t01.Q1 
t p < 0.001, § p = 0.008 
"Adjusted lor baseline values, age, sex and dustering on patient study number. 
Table '.13 The effect of diary card variables on the odds ratios of experiencing a Wilding exacerbation or Wilding exacerbation day. 
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6.5.3.4 Taylor definition of exacerbation 
There were 535 exacerbations according to the Taylor definition of exacerbation. for 
definition see section 5.5.4. Using the days of exacerbation there was poor agreement 
between the Taylor and TRUST exacerbation with sensitivity of 7% (95~o CI 6.5 to 
7.8%) and specificity of 99.80/0 when TRUST exacerbation \\"as the gold standard. 
Using logistic regression the odds ratio of experiencing a TRUST exacerbation if a 
Taylor exacerbation occurred was 40 (95% CI 25.6 to 62.3). 
A logistic regression model was used to determine the extent to \\"hich the diary card 
variables predicted whether a patient experienced a Taylor exacerbation or not. The 
analysis was repeated for asthma scores from mildly unstable upwards. see table 6.14. 
An increase in night time symptoms was the strongest predictor of a Taylor e:xacerbation 
with an adjusted odds ratio of 1.64 (CI 1.38 to 1.95) followed by an increase in daytime 
symptoms with an adjusted odds ratio of 1.43 (CI 1.25 to 1.63). 
lOS 
Dary card v.lable Taylor exacerbations Taylor Exacerbation Days Taylor Scores 
Crude Odds Ratio Adjusted Odds Ratio· Crude Odds Ratio Adjusted Odds Ratio· Crude Odds Ratio Adjusted Odds Ratio· 
....,.--_____________ ...J(.::..:95~%~C=..LI)__ __(95% CI) (95% CI) (95% CI) (95% Cil (95% Cil 
Oral corticosteroids 21.58t 6.59t 21.58t 6.59t 4.21t 1.10 
(18.80 to 24.76) (4.77 to 9.12) (18.80 to 24.77) (4.77 to 9.12) (3.98 to 4.45) (0.9- to 1.35) 
1 Vmin increase in am PEF O.96t 0.97t 0.96t 0.97t O.96t 0.95t 
(0.96 to 0.96) (0.96 to 0.97) (0.96 to 0.97) (0.96 to 0.97) (0.96 to 0.96) (0.94 to 0.95) 
10 Vmin increase in am PEF 0.66t 0.72t 0.69t 0.72t 0.66t 0.58t 
(0.66 to 0.67) (0.68 to 0.76) (0.68 to 0.70) (0.68 to 0.76) (0.66 to 0.66) (0.54 to 0.61) 
100 Vmin increase in am PEF 0.02t 0.04t 0.03t 0.04t 0.02t 0.004t 
(0.01 to 0.02) (0.02 to 0.07) (0.02 to 0.03) (0.02 to 0.07) (0.02 to 0.02) (0.002 to 0.007) 
1 unit increase daytime symptoms 3.13t 1.43t 3.23t 1.43t 4.69t 5.85t 
(2.96 to 3.29) (1.25 to 1.63) (3.06 to 3.40) (1.25 to 1.63) (4.60 to 4.78) (4.60 to 7.44) 
1 unit increase in night time symptoms 3.86t 1.64t 3.86t 1.64t 4.98t 4.61t 
(3.65 to 4.09) (1.38 to 1.95) (3.65 to 4.09) (1.38 to 1.95) (4.89 to 5.09) (3.74 to 5.69) 
1 puff increase in rescue IlTagonist use 1.34t 1.06:1: 1.32t 1.06:1: 1.42t 1.11§ 
(1.32 to 1.36) (1.01 to 1.11) (1.30 to 1.35) (1.01 to 1.11) (1.41 to 1.42) (1.04 to 1.06) 
1 Vmin increase in pm PEF 0.97t 1.00 0.99t 1.00 0.98t 1.00 
(0.97 to 0.97) (0.99 to 1.0) (0.99 to ().~~) n _____ JO.99 to 1.0) (0.98 to 0.98) __ J9.99 to 1.0) 
t p < 0.001,:t p = 0.01, § P = 0.003 
·Adjusted for baseline values, age, sex and clustering on patient study number. 
Table 8.14 The effect of diary card variables on the odds ratios of experiencing a Taylor exacerbation,Taylor exacerbation day or Taylor score. 
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6.5.3.5 PEF diary cards 
Graphs were produced for each patient in tum, morning PEF was plotted against time 
and the start dates for the four definitions of exacerbation were marked on the graph. It 
provided a visual means of checking how the exacerbations related to changes in the 
patient's morning PEF. Figures 6.3 to 6.6 are a sample of patients' diary card data 
marking the exacerbations according to the different definitions. 
Figure 6.3 illustrates a patient who experienced seyeral exacerbations according to the 
Wilding definition before exacerbations according to the TRUST and Taylor definitions. 
The exacerbations according to the Wilding definition occurred with a much lower fall 
in morning PEF than exacerbations according to other definitions. The patient in figure 
6.4 experienced exacerbations according to all of the definitions. The FACET 
exacerbation may have been triggered first because the fall in PEF occurred in isolation 
and the other definitions required it to occur in combination with another variable. The 
patient in figure 6.5 experienced exacerbations according to all of the definitions. Again 
those exacerbations according to the Wilding definition tended to occur with higher 
morning PEF. Finally the patient in figure 6.6 experienced a severe fall in PEF that was 
not identified by any of the definitions of exacerbation. 
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6.5.3.6 Time to first exacerbation 
Finally the time to the first exacerbation according to all four definitions \\'as examined, 
Table 6.15 lists the mean time to first exacerbation for each definition and figure 6,7 
illustrates the time to first exacerbation using a Kaplan \ leier graph. 
Definition of exacerbation 
TRUST 
(n -= 432) 
FACET (including unknown corticosteroids) 
(n = 273) 
FACET (including oral corticosteroids only) 
(n = 123) 
Wilding (including unknown corticosteroids) 
(n = 626) 
Wilding (including oral corticosteroids) 
(n = 586) 
Taylor 
(n= 107) 
:\Iean (SD) 'Iedian days 
days to first to first 
exacerbation exacerbation 
108 
(93) 
103 
(92) 
121 
(99) 
62 
(76) 
61 
(76) 
115 
(92) 
82 
84 
92 
30 
30 
93 
Table 6.15 l\lean (SD) and median number of days to first exacerbation 
according to the four definitions of exacerbation. 
There were 60 days between the shortest mean time to first exacerbation and the longest 
mean time. Time to first exacerbation for three of the definitions was grouped around 
112 days and the time to first Wilding exacerbation was 61 days. This was because the 
Wilding definition of exacerbation included small increases in day and night time 
s)lnptoms and as a result many days were classified as being an exacerbation. 
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Time to first exacerbation according to the different 
definitions of exacerbation as a survival function. 
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6.5.3.5 Diary card variables 
From the tables of odds ratios for the four definitions of exacerbation the strongest 
predictors, other than corticosteroid use, for any definition of exacerbation were: 
1. Increase in daytime symptoms. 
2. Decrease in morning PEF by 100 l/min. 
3. Increase in night time symptoms. 
Use of additional corticosteroids was strongly associated with both TRUST and FACET 
definitions of exacerbation but could not be included in the regression models because it 
was logically linked to exacerbation and was automatically dropped by the STAT A 
program. The criterion for a fall in morning PEF of 100 IImin was chosen because it 
represented a fall in the mean PEF (402 l/min) of approximately 2S%. Whilst these 
factors seemed to be strong predictors of exacerbation it was important to test each 
alone and in combination to determine the sensitivity and specificity of their ability to 
detect exacerbations. 
For TRUST and FACET definitions of exacerbation the most sensitive single variable 
was additional corticosteroid use, with 79% (9S% CI 78.1 to 80) sensitivity and 100% 
specificity with the TRUST definition. With the FACET definition the sensitivity was 
82.8% (9S% CI 81.4 to 84.1) and specificity was 98.6% (9S% CI 98.6 to 98.7). The 
sensitivity decreased to 66% when only those exacerbations with oral corticosteroids 
were included in the analysis. The use of additional corticosteroids was much less 
sensitive with the exacerbations defined by Taylor and Wilding because they had to 
occur in combination with another change. 
Morning PEF (80% of baseline for two or more consecutive days) was very specific 
(>99%) for TRUST, FACET and Taylor definitions of exacerbations but the sensitivity 
was only 8.8% (9S% CI 8.2 to 9.S), 24.2% (9S% CI 22.7 to 2S.7) and 42.2% (9S% CI 
39.0 to 4S.5) respectively. When the FACET definition was used, excluding those 
patients with unknown corticosteroids, the sensitivity of morning PEF increased to 
4S.1% (95% CI 42.6 to 47.6). 
liS 
Daytime symptoms were also very specific for the definitions of exacerbation with over 
98% specificity for all four definitions of asthma. The sensitivity ranged from 32.9% 
(95% CI 29.9 to 36.0) with the Taylor definition to 15% (95% CI 13.7 to 16.3) with the 
FACET definition including unknown corticosteroid use. 
Daytime symptoms (increased by two or more on two consecutive days) and 
corticosteroid use had high sensitivity and specificity for TRUST and FACET 
definitions of exacerbation, see tables 6.16 and 6.17. There was high specificity (>96%) 
for the definitions of Taylor and Wilding but sensitivity was much lower, 50.5% (95% 
CI 47.2 to 53.7) and 28.2% (95% CI 27.5 to 29.0) respectively. 
Corticosteroids and 
daytime symptoms 
No 
Yes 
Total 
TRUST exacerbations 
No 
216539 
(98.7%) 
2953 
(1.3%) 
219492 
Yes 
315 
(4.4%) 
6869 
(95.60/0) 
7184 
Sensitivity 95.6% (95% CI 95.12 to 96.1), specificity 98.7% (950/0 CI 98.6 to 98.7). 
Table 6.16 Number (0/0) of days of TRUST exacerbation with or without 
corticosteroid use and or daytime symptoms. 
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Corticosteroids and 
daytime symptoms 
No 
Yes 
Total 
FACET exacerbations 
(including unknown 
corticosteroids) 
No Yes 
216364 490 
(96.8%) (15.8%) 
7217 2605 
(3.2%) (84.2%) 
223581 3095 
FACET exacerbations 
(including oral 
corticosteroids) 
No Yes 
216364 490 
(96.1 %) (31.30/0) 
8746 1076 
(3.9%) (68.7%) 
225110 1566 
Sensitivity 84.2% (95% CI 83.8 to 85.4), specificity 96.8% (95% CI 96.7 to 96.9) 
including unknown corticosteroids. 
Sensitivity 68.7% (95% CI 66.4 to 71.0), specificity 96.1 % (950/0 CI 96.0 to 96.2) 
including oral corticosteroids. 
Table 6.17 Number (%) of days of FACET exacerbation with or without 
corticosteroid use and or daytime symptoms. 
Corticosteroids and 
morning PEF ~o% 
No 
Yes 
Total 
TRUST exacerbations 
No 
217990 
(99.3%) 
1502 
(0.7%) 
219492 
Yes 
1172 
(16.3%) 
6012 
(83.7%) 
7184 
Sensitivity 83.7% (95% CI 82.8 to 84.5), specificity 99.3% (95% CI 99.3 to 99.4). 
Table 6.18 Number (%) of days of TRUST exacerbation with or without 
corticosteroid use with morning PEF ~o%. 
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Corticosteroids and 
morning PEF ~o% 
No 
Yes 
FACET exacerbations 
(including unknown 
corticosteroids) 
No Yes 
219162 
(98%) 
4419 
o 
3095 
FACET exacerbations 
(including oral 
corticosteroids) 
No Yes 
219162 
(97.4%) 
5948 
o 
1566 
(2%) (100%) (2.6%) (100%) 
Total 223581 3095 225110 1566 
Sensitivity 100%, specificity 98.0% (95% CI 98.0 to 98.1) including unknown 
corticosteroids. 
Sensitivity 100%, specificity 97.4% (95% CI 97.3 to 97.4) including oral 
corticosteroids. 
Table 6.19 Number (%) of days of FACET exacerbation with or without 
corticosteroid use and morning PEF < 80%. 
Adding morning PEF to daytime symptoms and corticosteroid use did not improve the 
sensitivity and specificity for TRUST exacerbation. Adding daytime symptoms to 
morning PEF and corticosteroid use reduced the specificity for FACET exacerbation by 
only 1%. 
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6.5.3.6 Corticosteroid use 
The use of corticosteroids was strongly predictive of all four definitions of exacerbation 
but especially TRUST and FACET definitions. Because of its predicti\"e propcrtie~ and 
because some exacerbations were classified by use of additional corticosteroids alone it 
was important to determine what predicted a course of corticosteroids. The strongest 
predictor for all courses of corticosteroids was an increase in daytime s:mptoms of two 
or more over baseline, table 6.20. Night time sJmptoms of two or more o\"er basdine 
resulted in a 2 fold increase in the odds of additional corticosteroids (OR 2.31 95% CI 
1.50 to 3.57) but increasing night time symptoms did not increase the odds of 
corticosteroids in the same way as daytime symptoms. An increase in da: time or night 
time symptoms had a greater effect on predicting a course of inhaled corticosteroids 
compared to oral corticosteroids. This suggests that patients may ha\"e increased 
treatment in response to symptoms. A reduction in both moming and evening PEF had 
a greater effect on the odds of a course of oral corticosteroids suggesting patients 
requiring oral corticosteroids experienced a more severe exacerbation. The increase in 
evening peak flow was not accompanied by a large increase in night time s:lnptoms. 
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6.5.4 Discussion 
The comparisons of the four different definitions of exacerbations highlighted both the 
similarities and differences between the definitions. 
The definition of exacerbation used by Wilding et al (l04) identified many episodes 
which may not have been serious changes in the underlying asthma because an increase 
in symptoms scores of only one or more over baseline resulted in an exacerbation. In 
contrast, the definition of exacerbation used by Taylor et al (105;107) was complicated 
and relied very heavily on changes in PEF, which meant that in this population of 
asthmatics very few exacerbations were identified. One of the main drawbacks of this 
definition was the number of days with changes in symptoms that could not be classified 
because they were not accompanied by changes in PEF. The definition assumed that the 
diary card variables were closely correlated with one another. 
The "ideal" definition of exacerbation would seem to lie somewhere between the 
TRUST and FACET definitions of exacerbation. The FACET definition of 
exacerbation seemed to underestimate the number of periods of worse asthma because 
the criteria included oral corticosteroid use and PEF only. The sensitivity and specificity 
analyses demonstrated there was a great deal of overlap between the definitions. If the 
FACET definition was used as the gold standard then the TRUST definition had a very 
high sensitivity and specificity, that is those patients who experienced a FACET 
exacerbation were also very likely to experience a TRUST exacerbation. 
The regreSSIon analysis of the diary card components of all four definitions of 
exacerbation yielded similar results in spite of the differences in the definitions. Use of 
corticosteroids, daytime symptoms and change in morning PEF of 100 l/min or more 
were the most important variables in terms of their ability to predict an exacerbation 
according to the four definitions in tum. A measure of exacerbation using just 
corticosteroid use and daytime symptoms was highly sensitive and specific if the 
TRUST or FACET definitions were used as the gold standard. Use of corticosteroids 
and a reduction in morning PEF of 80% were highly sensitive and specific for both 
TRUST and FACET. 
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An increase in daytime symptoms strongly predicted a course of corticosteroids and was 
not included in the FACET definition of exacerbation. To include an increase in 
daytime symptoms would make the FACET definition more complete by providing an 
objective reason for commencing corticosteroids. The most useful diary card 
components to measure would be corticosteroid use and daytime symptoms, adding 
morning PEF «80%) increased the sensitivity by 1.5% and reduced the specificity by 
<1 % but the number of days when morning PEF fell to 800/0 or less than baseline were 
relatively few «2% of days). The advantage of a measure relying on daytime symptoms 
and corticosteroid use may be improved compliance with diary card completion in long 
term trials of asthma therapy. 
In conclusion, in future trials of long or short acting inhaled ~2-agonists it would be 
possible to measure exacerbations using additional use of corticosteroids and daytime 
symptoms of two or more over baseline without morning PEF. Clear guidelines should 
be given to the patients and clinicians about when to commence additional 
corticosteroids. 
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Chapter 7 - Discussion 
The aim of this project was to compare the outcome measures identified from a 
systematic review of randomised controlled trials of inhaled ~ragonists with the 
TRUST definition of exacerbation, using the TRUST dataset. This analysis identified a 
standard primary outcome measure for use in trials of long and short acting inhaled ~2-
agonists that may be relevant to clinical practice. 
7.1 TRUST 
The regular use of salbutamol in mild to moderate asthmatics did not result in worse 
asthma control in TRUST. The exacerbation rate was similar between the two treatment 
groups and the confidence intervals overlapped. There were significant improvements 
in symptom free days and evening PEF but there was no difference in morning PEF. 
The TRUST result was particularly important because the patients were representative 
of the majority of asthmatics in the UK (160), treated in the primary care setting with 
over 90% taking concurrent inhaled corticosteroids. The results extended those of 
Drazen et al (95) who reported no difference between regular and as needed albuterol in 
patients without concomitant inhaled corticosteroids. The results also complemented 
the results of the trials of long acting ~2-agonists (52;72-77;79-82;84;86;89-
91 ;96;97;99; 101; 103-106; 1 08-112) which demonstrated the benefits of their use in 
moderate to severe asthma. The results contrasted with those earlier trials which 
suggested that inhaled ~2-agonists resulted in worse asthma control (50;51 ;53-55). 
The advantage of TRUST was that the sample size was sufficient to detect a difference 
of at least 15% in the exacerbation rate between the two treatment groups whereas some 
of the earlier trials of ~2-agonists were often small and lacked power. The trial was 
carned out in primary care where the majority of asthmatics are managed in the UK. 
The study was pragmatic in that there was no attempt to standardise other anti-asthma 
treatment and stabilise asthma control during the run-in period. Instead, patients were 
stratified according to their inhaled corticosteroid use. The trial was managed and 
monitored to a very high standard. There was regular communication between the co-
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ordinating centre and the practices, quality control procedures were in place and 
additional training was given when necessary. There was an MRC Trial Steering 
Committee and Data Monitoring and Ethics Committee that met regularly to monitor 
progress. 
The disadvantage of TRUST was that because the trial was large it was not feasible to 
use electronic PEF meters or Diskhalers, which would have allowed for a closer 
assessment of compliance. 
The results of TRUST will inform the most appropriate use of short acting ~2-agonist in 
the latest asthma management guidelines due to be published in 2002. 
7.2 Comparisons of the primary outcome measures 
The results of the analysis of the primary outcome measures identified by the systematic 
review suggested that the use of additional corticosteroids or an increase in daytime 
symptoms of two or more over baseline score was a suitable primary outcome measure 
for use in trials of long and short acting ~2-agonists. A fall in morning PEF of 20% or 
more from baseline was strongly predictive of all definitions of exacerbation but lacked 
sensitivity. Surprisingly an increase in night time symptoms was not a strong predictor 
of all definitions of exacerbations. 
As expected, simply averaging the diary card variables over the period of follow-up did 
not allow for the fluctuations in asthma and did not reflect the degree of change seen 
with the TRUST definition of exacerbation. This was most marked with mean PEF, 
which may be more suitable for monitoring long-term decline in lung function. 
Of the four definitions of exacerbation identified, there was most agreement between the 
TRUST (123) and FACET (101) definitions of exacerbation and less agreement 
between TRUST and the definitions proposed by Wilding (104) and Taylor (105; I 07). 
The FACET definition was very specific for change but lacked sensitivity for TRUST 
exacerbations because courses of increased inhaled corticosteroids were not included in 
the definition of exacerbation and there were very few days when morning PEF fell to 
70% or less of baseline. Much of the agreement could be explained by the role of 
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additional corticosteroids in the definitions of TRUST and FACET exacerbations. 
There was poor agreement with the Wilding definition because the one-unit increase in 
day or night time symptoms over baseline resulted in many days classified as 
exacerbation. Additional corticosteroids were less important in the Wilding definition 
because they had to occur in combination with a change in symptoms or PEF. The 
definition proposed by Taylor assumed that changes in PEF were the most important 
factor therefore many days with increased symptoms were not classified as an 
exacerbation because there was no accompanying fall in PEF. Because the diary card 
variables were poorly correlated, increased asthma symptoms did not occur on the same 
day as fall in PEF and many days when asthma appeared worse were not classified as an 
exacerbation. 
Most of the definitions of exacerbation identified had been developed with the 
assumption that changes in morning PEF and symptoms would reflect changes in the 
underlying asthma simultaneously. Because the diary card variables were poorly 
correlated in TRUST and other trials, forcing them together in a definition of 
exacerbation meant some days with apparently worse asthma were not classified as 
exacerbation. A requirement for additional corticosteroid treatment was clearly a sign 
that asthma control was worse and the most important factor motivating patients to seek 
treatment was an increase in day or night time symptoms and not a fall in PEF. This 
could have been because symptoms preceded the fall in PEF (161-163) or because 
symptoms and PEF measure different aspects of the disease. 
The most important components of exacerbation, from all four definitions identified, 
will now be discussed in tum. 
7.2.1 Oral and inhaled corticosteroids 
Many definitions of asthma exacerbation incorporated the use of additional 
corticosteroids (54;101;104;105;107;109;111;121-123). The inclusion of U a clinical 
need for oral or increased inhaled corticosteroids" was included in the TRUST 
definition of exacerbation to allay the fears of the general practitioners, patients and 
LRECs. It enabled those patients in danger of experiencing a rapid and potentially fatal 
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worsening of their asthma to receive additional corticosteroid treatment without waiting 
for a change in symptoms or PEF to occur on two or more consecutive days. \Vhilst 
there were obvious safety and ethical advantages to the inclusion of this criterion 
inevitably it led to courses of corticosteroids with neither a fall in PEF nor an increase in 
symptoms. A total of347 (40%) TRUST exacerbations were classified according to use 
of additional corticosteroids (oral and inhaled) alone. For FACET the proportion of 
exacerbations classified by corticosteroid use alone was between 42 - 77% depending 
on whether those patients with use of unknown corticosteroids were included. Those 
patients with a FACET exacerbation classified by oral corticosteroid use tended to have 
smaller changes in PEF and symptoms than did those patients with exacerbations and no 
corticosteroid use (101;164). This pattern was also observed with TRUST 
exacerbations because patients may have started treatment in anticipation on further 
worsening of their asthma. 
Use of corticosteroids was logically linked to exacerbation because their use 
automatically resulted in the classification of an exacerbation. Because of this logical 
link, including them in the regression models for exacerbation distorted the role of the 
remaining diary card variables. It was important to understand what predicted 
corticosteroid use because of their link with exacerbation. The regression analysis 
identified an increase in daytime symptoms followed by a 100 Ilmin fall in PEF as the 
most important predictors of corticosteroid use. This reflected the results of other 
studies that suggested patients modified their treatment in response to symptom changes 
rather than PEF (161; 165-167). The regression analysis used in this project was a 
simple between-patient multivariate logistic regression comparing corticosteroid 
exacerbations with days without corticosteroids, and may have oversimplified the 
relationship between PEF, symptoms and corticosteroid use. More complicated models 
have been used on the TRUST data (Chris Frost, unpublished work). A nested case 
control analysis of the TRUST and FACET data was undertaken; periods of 
corticosteroid use were matched with periods without corticosteroid use within the same 
patient and compared using regression analysis. Using this method, the strongest 
predictors for corticosteroid use in TRUST data were night time and daytime symptoms, 
with adjusted odds ratios of 2.22 (95% CI 1.47 to 3.34) and 1.95 (95% CI 1.39 to 2.73) 
respectively. A similar analysis using FACET data produced similar results. The odds 
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ratios from the matched case control analysis were higher than those obtained using the 
simpler analysis, presented in section 6.5.3.6, because they were within-patient 
comparisons and identified what had resulted in a course of treatment on one occasion 
but not another. Once again this added to evidence, which suggested that corticosteroids 
were used in response to changes in symptom scores rather than PEF (161; 164-167). 
Corticosteroid use was by definition a TRUST exacerbation because it represented a 
change in the underlying asthma control that resulted in increased treatment. However, 
the disadvantage of using courses of corticosteroids to identify exacerbations was that 
some patients might have started treatment in anticipation of an exacerbation, which 
without treatment may never have progressed. Clinicians and patients were given clear 
guidelines for the use of additional corticosteroids but 40% of TRUST exacerbations 
were not accompanied by a change in symptoms or PEF in spite of the quality control 
procedures designed to reduce this. Restricting corticosteroid use to oral treatments 
only may have reduced the proportion of exacerbations with no symptom or PEF 
changes because patients would have had to visit their doctor before starting treatment. 
It was unlikely that doctors would have recruited mild to moderate asthmatics to trial 
with such a design. Patients were successfully recruited to the TRUST pilot study 
where exacerbations were treated with oral corticosteroids alone but the protocol was 
modified for the main trial because of the impact of the British Thoracic Society 
guidelines (134) suggesting that exacerbations could be treated with increased inhaled 
corticosteroids. 
In future trials, the protocol for the use of oral or increased inhaled corticosteroids 
would need to be very clear. The evidence suggested that the guidelines for the use of 
corticosteroids should be based on an increase in symptoms (daytime and night time) of 
two or more units over baseline for two or more consecutive days. 
7.2.2 Morning PEF 
Ambulatory PEF is frequently used in clinical asthma trials because it provides an 
objective measurement of airflow limitation; the meters are cheap and the readings 
correlate well with those from spirometers. PEF correlates well with FEV I (143-
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145;168) and ambulatory PEF is believed to be a useful measure of asthma control 
because it measures the daily fluctuations that would be missed if measurements were 
restricted to clinic visits. The main disadvantages of PEF are the potential for reduced 
patient compliance with the measurements over time (142;169-171) and its poor 
correlation with asthma symptoms (137;144;161;163;167;172-175) both when making a 
diagnosis of asthma and monitoring change over time. PEF is effort dependent and of 
limited use in unmotivated individuals (161; 174). Many patients are poor perceivers of 
reduced PEF during experimental conditions such as bronchial provocation tests. Using 
a visual analogue scale for symptom severity, patients were found to be relatively poor 
at detecting a fall in PEF (167). 
Averaging PEF over the entire follow-up period reduced the benefits of ambulatory 
monitoring from a trial viewpoint. Infonnation on sharp daily fluctuations was lost. A 
fall in morning PEF of 100 1 / min was a strong predictor of exacerbation but it lacked 
sensitivity and few TRUST exacerbations were associated with a fall in PEF of 20% or 
more. Several detailed analyses of PEF reported the events leading up to and after an 
exacerbation (159; 176). Both papers described a gradual decline in PEF in the days 
leading up to an exacerbation followed by a sharp fall and then recovery. The average 
fall in PEF from baseline was 27% (159) and (to separate 45% as belonging to FACET) 
45% of FACET exacerbations had a fall in PEF of 30% or more (176). Studies of 
asthma self-management plans reported conflicting results regarding the use of PEF. 
Some suggested that a change in asthma symptoms was as effective as a change in PEF 
to guide treatment (166; 177), others that change in PEF alone was an effective guide 
(178), other studies were to small to show a benefit (165) and another demonstrated an 
effect but a fall in PEF to 15% of baseline was the trigger for increasing treatment (166). 
Ambulatory PEF may provide a useful physiological method of airflow limitation but 
this project highlighted the poor relationship between a change in PEF and the 
definitions of exacerbation. A fall in PEF of 200/0 or more was specific for all 
definitions of exacerbation but it was not sensitive. Because a fall in PEF was specific 
and strongly predicted an exacerbation it was a useful measure but the poor compliance 
and relatively few episodes when PEF fell to 80% of baseline or less meant it may have 
more limited uses. 
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7.2.3 Symptoms 
An increase in daytime symptoms of two or more over baseline was the strongest 
predictor of all definitions of exacerbation after corticosteroid use. As the daytime 
symptoms increased above baseline the odds of exacerbation was even greater. It was 
surprising that night time symptoms were less important in defining an exacerbation 
because they were strongly predictive of a course of corticosteroids. An increase in 
daytime symptoms was a strong predictor of exacerbation both independently and 
because it strongly predicted a course of corticosteroids. The FACET definition of 
exacerbation did not include daytime symptoms, but an increase in daytime symptoms 
identified 15 - 20% of all FACET exacerbations because of the strong association 
between an increase in daytime symptoms and corticosteroid use. 
The symptoms score used in TRUST was a simple six-point scale that concentrated on 
the frequency of all symptoms during the day. The different components of asthma 
symptoms such as cough, wheeze and breathlessness were not assessed separately. It 
was felt that because patients were completing diary cards for 12 months the 
components of the diary card should be kept simple. 
Several symptoms scores or symptom questionnaires have been developed for use in 
clinical trials (139;140;179;180). Burdon et al (168) first tested scales such as the 
modified Borg scale in the assessment of dyspnoea. The scale ranges from 0 to 10 and 
classifies the perception of breathlessness according to a series of descriptions and was 
found to be a useful s~bjective tool. Most of these questionnaires were not suitable for 
use on a daily basis for measuring change because of their complexity 
A simple six point symptom score was used in TRUST and an increase of two or more 
above baseline was found to be very strongly associated with all definitions of 
exacerbation. Future work might involve the development of the symptom score used in 
the TRUST dairy card to improve the identification of exacerbations. 
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7.3 Summary 
There have been three recent papers reporting the analysis of exacerbations in an 
attempt to identify the most suitable measures for use in clinical trials (161-163). The 
earliest study was published in 1996; Chan-Yeung et al studied 120 patients (adults and 
children) taking part in a nested case control study of viral exacerbation and 41 % of 
patients experienced an exacerbation. They compared days of follow-up to baseline 
levels and identified exacerbations. They found that symptoms started to increase two 
days before the first day of exacerbation and that this occurred before the PEF fell. PEF 
rarely fell to 30% or less than baseline. The authors concluded that a symptom diary 
identified exacerbations earlier than PEF changes. 
The most recent papers report the results of much larger studies. In 2001 Shingo et al 
(162) investigated the correlation between asthma diary card variables of 1500 patients 
participating in two I-year clinical trials. Within patient pairwise correlations of the 
diary card variables were made. The diary card variables were poorly correlated with 
one another although all comparisons were significant. The authors concluded that PEF 
or FEY 1 and symptoms or rescue ~2-agonist use measured different aspects of the 
disease and that all aspects should be included in any outcome measure. The final study 
published in 2001 by Leone et al (163) utilised data from 313 patients recruited to two 
large randomised controlled trials. Receiver operating characteristic (ROC) analysis of 
diary card variables was carried out to determine their ability to predict periods when 
FEY l fell to 80% or less of baseline. None of the variables predicted this reliably. 
The results of this project extend the results presented in these three papers. The 
relationship between the diary card variables in TRUST was weak. Symptoms, and in 
particular daytime symptoms were the strongest predictors of exacerbation along with 
corticosteroid use, which was logically linked to exacerbation. Asthma is a 
multidimensional disease measurable in different ways and the measures are poorly 
correlated with one another. Defining exacerbations by requiring two or more diary 
card variables to occur together may underestimate the number of exacerbations because 
the diary card variables are poorly correlated and therefore less likely to occur together. 
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A composite measure for measuring exacerbations of disease is possible when the 
components are well correlated. 
7.4 Strengths 
TRUST was a well-designed trial with an adequate sample size and the results provide 
important infonnation regarding the use of inhaled ~2-agonists in mild to moderate 
asthma. The trial was well managed and monitored ensuring good quality data. The 
analysis of the components of exacerbation made use of all the TRUST data; over 200 
000 observations, a total of 983 patients compared with previous work on exacerbations 
which have been in small studies with short periods of follow-up. The results of the 
analysis may have implications beyond a use in clinical trials. Patients are frequently 
asked to monitor their asthma as part of self management plans and if symptoms are 
strong predictors of corticosteroid use and exacerbations, self management plans could 
be simplified and patients may not need to make twice daily PEF measurements which 
may improve compliance with treatment. 
7.5 Weaknesses 
The main weakness of this project was that the variables that predicted exacerbations 
were often part of the inclusion criteria for the definition of exacerbation. Therefore, by 
definition, the exacerbations were going to be dependent on them. This was 
unavoidable in this type of study but the important result was that we know which of 
those explanatory variables were the most important. The examination of predictors for 
corticosteroid use may have been too simplistic and underestimated the true result. The 
nested case control method (Chris Frost, unpublished work) was better because the 
comparisons were within-patient and enabled the events leading up to a corticosteroid 
course to be compared with those not leading to corticosteroids in the same patient. 
This approach could not have been used with the exacerbations analysis because it 
would not have been so different from comparing exacerbations with baseline. 
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7.6 Conclusion and future work 
The most recent large, well designed randomised controlled trials (95; 123) have 
confirmed that the use of short acting inhaled ~2-agonists is safe in mild to moderate 
asthmatics. Analysing TRUST using the different primary outcome measures identified 
by the systematic review did change the results. Mean daytime symptoms and mean 
evening PEF demonstrated a small but significant improvement in favour of regular 
treatment whereas the Wilding definition of exacerbation suggested a small but 
significant worsening with regular treatment. 
The results of this project suggest that exacerbation of asthma in clinical trials could 
best be measured by recording use of additional corticosteroids, according to strict 
guidelines, and an increase in daytime symptoms of two or more over baseline. A fall in 
morning PEF of 20% or more both for two or more consecutive days was specific for all 
definitions of exacerbation but lacked sensitivity because of the relatively few days 
when this occurred. The inclusion of morning PEF would not justify the additional 
work expected from the patients and its inclusion may result in reduced compliance. 
Peto argued that in large randomised controlled trials such as TRUST the focus should 
be on a small number of very simple outcome measures (181) and in this case it would 
be sufficient to use corticosteroid use and an increase in daytime symptoms or two or 
more over baseline alone. This was reinforced by the fact that the diary card variables 
were poorly correlated. 
This modified definition of exacerbation is likely to be most suitable for use in 
randomised controlled trials or observational studies where the outcome of interest is 
asthma control such as trials of long and short acting ~ragonists or leukotriene 
antagonists. It would not be a suitable measure for trials designed to assess airway 
remodelling where lung function would be more appropriate. It is important to test this 
modified definition of exacerbation in another clinical trial or prospective observational 
study. 
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Firat author Year Drugs Treatment time Sample Result 
P.W. Trembath 1979 fenoteroll terbutaline 2 x4 weeks 22 for tern 
G.L. Shepherd 1981 salbutamoll placebo not dear 18 for salb 
K.B. Beswick 1986 salbutamol 12 months 17 for salb 
A. Ullman 1988 salmeteroll salbutamol 1 days 8 slam> salb 
A.S. Vathenen 1988 terbutaline (500",g 12mg) I placebo 1 day and 15 days 8!against terbutaline 
P.R Hekking 1990 formoteroll salbutamol 2 week crossover 301 form>salb 
M.R. Sears 1990 fenoteroll placebo 24 weeks 64 against fenot 
A. Ullman 1990 salmeteroll salbutamol 2 x2 weeks 12 for salm 
A. Wallin 1990 formoteroll salbutamol 2 x4 weeks 16 form> salb 
P. Arvidsson 1991 formoteroll salbutamol 1 year 18 against form 
S. Kesten 1991 formoteroll albuterol 3 months 145 form>salb 
C.P. Van Schayck 1991 salbutamoll atrovent (reg or exac only) 2 year 223 against salb 
M.G. Britton 1992 salmeteroll salbutamol 3 months 667 salm> salb 
H.A. Kersljens 1992 terbutaline IICSI atrovent I placebo 2.5 years 274 for tern + Ics 
J.B. Palmer 1992 salmeterol_(50 or 100",g} 3 months 283 for 100 mg 
O.S. Pearlman 1992 salmeteroll salbutamoll placebo 12 weeks 234 salm>salb 
W. Castle 1993 salmeterol I salbutamol 16 weeks 180 salm>salb 
B. Lundback 1993 salmeteroll salbutamol 12 months 388 salm>salb 
O.R. Taylor 1993 fenoteroll placebo 24 weeks 64 !against fenot 
I. Wahedna 1993 albuterol I broxaterol I placebo 3 WeEl<S 11 !agalnst fenot 
K.R. Chapman 1994 salbutamol I placebo 2 week crossover 341 for salb 
G.E. O'Alonzo 1994 salmeteroll albuteroll placebo 12 weeks 322 salm>salb>p 
M. Heino 1994 J32-agonists 2x1week 54 for J32-agonists 
K.P. Jones 1994 salmeterol I placebo 6 weeks 427 for salm 
C.S. Wong 1994 terbutaline 1 budesonide I placebo 2 t04 weeks 37 terb and budes 
O.E. Aldrey 1995 salbutamoll BOP 3 xwekks 22 both>either 
RA. Nathan 1995 salmeterol! albuterol ! placebo 12 weeks 556 salm > alb> p 
O.S. Pearlman 1995 salmeterol! albuterol 12 weeks 556 for salm 
I. Steffensen 1995 formoteroll salbutamol ! placebo 12 weeks 304 form>salb>p 
C.P. Van Schayck 1995 salbutamol ! atrovent (reg or exac only) 4 years 83 for salb 
O.H. Yates 1995 salbutamol 
A.J. Apter 1996 albuterol 15 week crossover 17 for albuterol 
J.M.Orazen 1996 albuteroll placebo 16 weeks 255 no diff 
P. Leblanc 1996 salbutamol! salmeterol 12 weeks 367 salm>salb 
P Faurschou 1996 salmeterol ! salbutamol 6 weeks 190 salm>salb 
A. Woolcock 1996 salmeteroll BOP 24 weeks 738 salm + BOP 
L. Boulet 1997 salmeterol I salbutamol 12 weeks 228 salm>salb 
A. Ganassini 1997 broxateroll placebo 3 weeks 24 no diff 
RA. Pauwels 1997 formoterol I budesonide 1 year 852 form + budes 
V.J. Tormey 1997 salbutamoll oxitropium bromide I placebo 3 x4 weeks 12 no diff 
T. van der Molen 1997 formoteroll placebo 24 weeks 239 for form 
P. Wilding 1997 salmeterol! placebo 6 month crossover 101 for salm 
RD. Taylor 1998 salbutamoll salmeteroll placebo 24 week crossover 157 salm > salb > p 
T. Ekstrom 1998 formoteroll terbutaline ! placebo 12 weeks 343 form> terb > p 
RJ. Hancox 1999 budesonide I terbutaline ! both 6 weeks crossover 47 both>either 
J.A. van Noord 1999 salmeterol I fluticasone 12 weeks 362 salm > flutic 
J.J. Condemii 1999 salmeteroll fluticasone 24 weeks 437 salm > flutic 
F AA.M. Vermetten 1999 salmeterol! budesonide 12 weeks 233 salm > budas 
A.E. Tattersfield 2001 formoteroll terbutaline 12 weeks 362 form> tern 
S.C. Lazarus 2001 salmeterol 1 inhaled corticosteroids (ICS) 28 weeks 108 ICS > salm 
, 
----
Tlble 1.1 Randomsled controlled trials of Inhaled Iz-agonists In asthma. 
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Inhaled betaradrenoreceptor agonists are the most effective treatment for the relief of 
asthma symptoms and the most widely prescribed anti-asthma therapy. Recently, 
however, the safety of this form of treatment, particularly when given regularly and 
in high dose has been questioned and causal links between beta-agonists and 
increased asthma morbidity and mortality have to be considered. 
An increase in asthma mortality and treatment with beta- agonists was first suggested 
in the 1960's when the introduction of isoprenaline-containing inhalers coincided 
with a marked rise in asthma mortalityl,2 which fell to 'pre-epidemic' levels after a 
possible association between excessive use of these inhalers, partiCUlarly those 
containing high doses of isoprenaline, and the increase in asthma mortality was 
made3• Recently, several studies have demonstrated that regular treatment with 
inhaled beta2 agonists is associated with an unexpected increase in airway hyper-
responsiveness4-8. The most commonly used beta-agonists, salbutamol, terbutaline 
and fenoterol have all been incriminated as potential causes of increase in bronchial 
hyper-responsiveness when used regularly; fenoterol being linked with the increase in 
asthma mortality in New Zealand in the 1980's9. The association of fenoterol and 
increased asthma mortality in New Zealand could be related to the fact that fenoterol 
was supplied in canisters which delivered approximately twice the effective 
bronchodilator dose of salbutamol lO• This is supported by the demonstration in a 
recent epidemiological study of a dose related increase in the risk of death or near-
death from asthma with both fenoterol and salbutamol which was almost identical 
when assessed at equivalent doses ll . 
The demonstration that regular use of inhaled fenoterol compared with on demand 
only use is associated with worse control of asthma has created much concern with 
regard to the use of inhaled beta-agonists and their possible association with 
increased morbidity and mortality. The finding that regular use of salbutamol, and 
ipratropium bromide for two years is associated with a greater annual decline in lung 
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function than with on demand treatmentS adds more concern about the problems 
which might be associated with the regular use ofbeta2-adrenoreceptor agonists. 
Recent controversies now surround the safety of long-term regular use of betar 
agonists l2 and withdrawal or reduction of such treatment in some patients is now 
being advocated 13. The evidence which most incriminates regular betar 
adrenoreceptor agonist therapy as being harmful is the pUblication from New 
Zealand7 which indicates that regular treatment with fenoterol results in worse 
control of asthma than when fenoterol is used on demand. This paper has caused 
much debate, both professional and public, about beta-a6onist therapy in general, and 
regular use in particular. The use of an inhaled beta-agonist on a regular basis is now 
not recommended for the treatment of most patients with chronic asthma 14. 
However, when on-demand treatment is necessary more often than twice daily it may 
well be associated with similar adverse effects as regular six-hourly therapy. It is 
known that regular twice daily treatment with terbutaline in low dose for two years is 
not associated with increased bronchial hyper-reactivity or any adverse effects in 
patients with mild asthma1S • No data generated from well designed studies are 
available, however, to refute the evidence that regular beta2-agonist therapy makes 
asthma worse7• There is also no evidence to support the hope and assumption that 
inhaled steroid therapy protects against any adverse effects of inhaled beta2-agonists. 
Indeed, in the New Zealand study of regular versus on-demand fenoterol adverse 
effects occurred even in patients taking inhaled steroids 7 but the total number of 
patients in this subgroup was too small for definite conclusions to be drawn. 
The general concern about beta-agonist therapy and its possible association with 
increased asthma morbidity and mortality observed recently in several countries l6, 
including the UK17, stimulated the formation of a national Task Force on Asthma in 
July 1991, under the auspices of the National Asthma Campaign. A Therapy 
Working Group was set up to identify important problem areas and to plan and 
initiate research projects. The Working Group was of the opinion that the use of 
inhaled beta2-agonists was the most important topic to address initially, and that with 
regard to regular versus on-demand inhaled beta2-agonists a large multicentre study 
had to be perfonned which would address the following important issues:-
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1. Does regular inhaled beta2-agonist therapy result in worse 
control of asthma than when used on-demand? 
2. Does current use of regular inhaled corticosteroid therapy 
influence the effects of regular or on-demand inhaled beta2-
agonist? 
3. If inhaled corticosteroid therapy influences any adverse 
effect(s) of treatment with an inhaled beta2-agonist therapy 
result in an increase in bronchial hyper-reactivity? This 
could only be assessed in a study restricted to a small 
number of centres in order to standardise t\!chnique. 
4. Does regular inhaled beta2-agonist therapy result In an 
increase in bronchial hyperreactivity? This could only be 
assessed in a study restricted to a small number of centres in 
order to standardise technique. 
CHOICE OF INHALED BETA2-AGONIST FOR STUDY 
Salbutamol has been chosen as the study drug since it is the most commonly used 
inhaled bronchodilator in the UK and in most other developed countries. A positive 
decision not to use fenoterol, as in the Sears study7 has been made in order to assess 
whether the effects attributed to fenoterol were idiosyncratic to that drug or 
manifestations of a beta2-agonist drug class effect. 
Dry powder salbutamol will be used in the study to avoid any possible adverse 
effects of regular inhalation of Freons/surfactants/lubricants contained in pressurised 
metered dose aerosols 18. 
STUDY PLAN 
Objective 
To determine whether regular treatment with inhaled salbutamol has any adverse 
effect(s) on the control and progression of chronic asthma compared with salbutamo1 
taken on-demand (as required for symptom relief). 
Design 
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Randomised double-blind parallel group study of one year's duration. 
Treatments 
1. Salbutamol 400 ~g four times daily from Oiskhaler 
2. Salbutamol placebo four times daily from Oiskhaler 
All patients entering the study will already be using a bronchodilator metered dose 
inhaler (MDI) which will be used on an as necessary basis for symptom control 
throughout the study period. 
Run-in period of? weeks 
PATIENTS 
Two groups of patients with chronic asthma will be studied: 
Group I 
Group 2 
Asthmatic patients whose only treatment is an inhaled beta2-agonist 
Patients requiring inhaled steroids for control of their symptoms in 
a dose range of 0.4-2.0 mg per 24 hours. 
Bronchial asthma will be defined as a diurnal variation in peak expiratory flow (PEF) 
of greater than 15% on at least 3 days per week during the run-in period and an 
improvement in PEF or forced expiratory volume in one second (FEV 1) of 15% or 
more after an inhaled bronchodilators. 
GROUP 1 PATIENTS 
Adults (over 18 years). Patients with asthma of at least one year's duration who have 
been using a bronchodilator MOl efficiently, and who have not been treated with 
inhaled steroids at any time, or oral steroids within 6 weeks of study entry. All 
patient should be using a bronchodilator MOl at least twice in every 24 hour period. 
Patients taking sodium cromoglycate, nedocromil sodium, ipratropium bromide, 
theophyllines, long-acting inhaled and any oral beta2-agonist preparation will not be 
eligible for study. 
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Number of patients to be studied: 150-200? 
GROUP 2 PATIENTS 
Adults (over 18 years). Patients with asthma of at least one year's duration who have 
been using a bronchodilator MDI efficiently and who have been on treatment with an 
inhaled steroid in a constant daily dose for 6 months within the dose range of 0.4-2 
mg per 24 hours. Patients who have been treated with oral steroids within six weeks 
of study entry will not be eligible. 
Patients taking sodium cromoglycate, nedocromil sodium, ipratropium bromide, 
theophyllines, long-acting inhaled and any oral betaragonist preparation will not be 
eligible for study. 
The dose of inhaled steroid will be kept constant throughout the study period. 
Number of patients to complete the study. 150-200? 
EXCLUSION CRITERIA 
* 
* 
* 
* 
* 
* 
* 
* 
* 
• 
Treatment with oral steroids within six weeks of study entry. 
Admission to hospital because of asthma within six weeks of study entry 
Inhaled steroid treatment for less than 6 months (Group 2 patients) 
Other significant lung disease or concomitant major illness 
Asthma requiring bronchodilator therapy less often than once/twice daily? 
Inability to use an MDI and a Diskhaler efficiently 
Treatment with sodium cromoglycate, nedocromil sodium, ipratropium 
bromide, theophyllines, long-acting inhaled and any oral beta2-agonist 
preparation 
Patients unable to use a peak flow meter and complete a diary card 
Patients who might move to another area of the country within the next 
year . 
Pregnancy 
EXCLUSION CRITERIA AFTER ENTRY 
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• Pregnancy 
• Need for drugs (for illnesses other than asthma) which might affect study 
end points 
• Need for oral prednisolone on most days for 2 months 
ASSESSMENT 
Exacerbations 
The primary end-point will be the number of exacerbations of asthma. 
\ 
Exacerbations could be defined as anyone of the following:-
1. Increased use of rescue beta2-agonist (more tharl 4 puffs per 24 hours) 
2. Decreased PEF (more than 300/0 of baseline or actual decrease of greater 
than 50 L per minute) 
3. Increased symptoms (greater than one point on a four point scale symptom 
score over one week) 
4. Increase in disease severity which results 10 the general practitioner 
prescribing extra treatment 
5. Treatment with oral prednisolone. 
Secondary end-point measurements will be peak expiratory flow variability, 
symptom-free days, days lost from work because of asthma, changes in symptom 
score, changes in use of rescue bronchodilator MOl. 
Patient Diary Card 
Twice daily measurement of PEF. Best of 3 to be recorded prior to the first dose of 
trial medication in the morning and immediately before the last dose in the evening. 
Number of puffs of rescue bronchodilator - to be recorded once or twice daily? 
Record of sleep disturbance by asthma 
Symptom assessment -? 4 point scale to be decided 
Record of all additional treatment and any new treatment for conditions other than 
asthma 
Number of days off work because of asthma 
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Clinical Assessment 
All patients will be seen and assessed clinically every four weeks. At these times 
diary cards will be checked and new ones issued. Unused trial drugs for the previous 
month will be collected (5 week supply will be provided for each 4 week period) and 
new trial drugs will be issued. clinical assessment of asthma - ? 4 point scale to be 
decided. 
FEV 1 and vital capacity and? reversibility test 
Bronchial reactivity will only be measured if the study ~an be performed in a small 
number of centres. If bronchial reactivity is measured it will be after randomisation 
to the two treatment limbs, and the technique will be standardised. 
Treatment of Exacerbations 
The dose of prednisolone for the treatment of exacerbations will be standardised. 
The actual dose has yet to be decided. If a treatment which involves return of peak 
flow to previous baseline etc. is used the total amount of prednisolone used in 
milligrams will have to be calculated. An alternative would be to use a standard 
treatment of 30 mg daily for 10 days 
For Group 2 patients an increase in dose of inhaled steroid for the control of a minor 
exacerbation of asthma will not be used. 
Ethical approval will be obtained from the Ethics Committee of all the participating 
hospitals. Written informed consent will be obtained from all patients. 
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[ PROTOCOL ) 
f 1 Iitk 
1.1 Short title 
A randomised controlled trial to assess the risks and benefits of long-tenn regular use of 
salbutamol. 
1.2 Purpose 
1.3 The main objective of the proposed randomised controlled trial is to detennine the 
effects of regular treatment with inhaled salbutamol on the control and progression of 
chronic asthma compared with the effects of salbutamol taken only when required for 
symptom relief. 
1.4 A second objective is to detennine whether the effect of salbutamol is modified by 
concomitant steroid use. 
2 Background 
Asthma is one of the commonest chronic diseases in industrialised countries. The 
population prevalence in the UK is around 10% in children and 5% in adults and mortality 
and morbidity continue to rise in the UK and in many other parts of the developed world. 
Since asthma is incurable and often persists throughout the life of the patient it has become 
a major public health concern. The health burden imposed is enonnous. Care of asthmatics 
consumes around 2% of the UK health budget and accounted in 1987/88 for 7 million days 
lost from work. Identification of the most appropriate and effective treatment for asthma is 
of critical importance (1). 
2.1 The recognition of asthma as a chronic inflammatory disease has led to earlier and more 
widespread use of inhaled steroids, with short-acting bronchodilators being 
recommended for symptom relief. Inhaled B2-agonists are the most effective 
bronchodilators for the relief of asthma symptoms and the most widely prescribed 
anti-asthma therapy. Recently, the long-term safety of B2-agonists, particularly when 
given regularly and in high dose, has been questioned and causal links between 
132 -agonists and increased asthma morbidity have been suggested. 
2.2 An association between increased asthma mortality and treatment with bronchodilators 
was first suggested in the 1960s. The introduction of isoprenaline-containing inhalers 
coincided with a marked rise in asthma mortality (2,3) which fell to 'pre-epidemic' levels 
after a possible association between excessive use of these inhalers, particularly those 
containing high doses of isoprenaline, and the increase in asthma mortality was made 
(4). There was, however, no evidence for a causal relationship between isoprenaline and 
the increase in asthma mortality, one possibility being that the symptomatic relief 
experienced by patients taking isoprenaline had resulted in delays in seeking necessary 
anti-inflammatory treatment when the underlying asthma had worsened, so that when 
such treatment was given it was ineffective. In the 1980s the 132-agonist fenoterol was 
linked to an increase in asthma mortality in New Zealand but again no causal 
relationship was established (5). As for isoprenaline, one explanation for increased 
mortality is that patients and doctors had become overdependent on fenoterol, the 
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effective symptom relief masking an underlying disease progression and resulting . 
delay in seeking or prescribing anti-inflammatory therapy. Fenoterol had been used ~~ 
canisters which delivered approximately twice the effective bronchodilator dose and it 
I was suggested that the findings could not necessarily be extrapolated to other 
B2-agonists recommended for use in lower doses. However, a recent case-control study 
showed a dose-related increase in the risk of death or near-death from asthma with 
fenoterol and salbutamol, the effects being almost identical when assessed at equivalent 
doses (6). 
2.3 The effect of 62-agonists on bronchial hyper-responsiveness is not clear, some studies 
reporting an increase and others no effect. Two studies cite salbutamol, terbutaline or 
fenoterol as potential causes of increased bronchial hyper-responsiveness when used 
regularly (7,8,9) but although statistically significant increases were found, the effects 
were extremely small and of doubtful clinical relevance. Haahtela et al (10) reported 
that regular twice daily treatment with terbutaline for two years did not increase 
bronchial hyper-responsiveness in mild asthmatics although the drug was used in an 
unconventionally low dose. Van Schayck, using information from his own and from 
other studies, concluded that 62-agonists alone do not increase bronchial 
hyper-responsiveness (11). 
2.4 Of more clinical relevance are the studies which have included measurements of decline 
in lung function. In a randomised single-blind study Van Schyak compared treatment 
with regular versus on-demand bronchodilator therapy using salbutamol and the 
anti-cholinergic, ipratropium bromide, in a crossover design. 144 patients completed a 
two year study and a statistically significant but small decline in lung function was 
found in those taking regular therapy. However, only 50 of the trial patients were 
asthmatics, and only 8 of these were randomised to regular therapy (12). 
The study most frequently quoted as evidence that regular treatment with 62-1 agonists 
results in worse control of asthma than when used on demand is the Sears study using 
fenoterol (13). In a double-blind placebo controlled crossover study 64 patients were 
randomised to fenoterol, 0.2 mg four times a day, or placebo with both groups being 
allowed fenoterol, salbutamol or terbutaline on-demand for relief of symptoms. 
Treatment was in two 24 week blocks and results were expressed in terms of overall 
control of asthma. In 7 patients there was no difference in overall control during the two 
treatment periods; better overall control was achieved in 17 patients with regular 
fenoterol and in 40 with placebo. The main criticism of this study is the lack of 
definition of asthma control. Various markers were used to assess worsening of asthma 
and in the overall assessment it is not clear what weight each individual marker was 
given or how apparently inconsistent effects on different markers were dealt with. 
2.S The Sears study (13,14) also attempted to look at whether the effect of f~noter~l w~ 
influenced by concomitant steroid therapy but the total number of patients In thiS 
subgroup was too small for definite conclusions to be drawn. Van Schyak has reported 
that in 28 asthmatics previously treated only with bronchodilators who had shown a 
decline in lung function, additional treatment with beclomethasone dipropionate slowed 
further decline (15). 
• , 
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2.6 Despite the paucity of evidence from experimental studies the safety of long-term 
regular use of J32-agonists is now being questioned (16) and withdrawal or reduction of 
such treatment in some patients is being advocated (17). The use of an inhaled 
62 -agonist on a regular basis is no longer recommended for the treatment of most 
patients with chronic asthma (18), but patients are still advised to use inhaled ~ 
-agonists as required for relief of symptoms. When on-demand treatment is necessaQ' 
more often than twice daily it may well be associated with similar adverse effects as 
reiu1ar six-hourly therapy. 
2.7 The general concern about J32-agonist therapy and its possible association with increased 
asthma morbidity and mortality (19,20) stimulated the fonnation in the UK of the 
National Asthma Task Force in July 1991, under the auspices of the National Asthma 
Campaign. The Royal Colleges, the regulatory agencies, the Department of Health, the 
British Thoracic Society (BTS), and interested GP grou?s are all represented on the 
Task Force. A Task Force Therapy Working Group set up to identify important 
problem areas and to plan and initiate research projects agreed that priority should be 
given to well designed studies to confinn or refute the evidence that regular B2-agonist 
therapy makes asthma worse (13). The Group proposed that a large, multicentre, 
randomised trial should be perfonned to address the following important issues:-
Main objective 
"Does regular inhaled B2-agonist therapy result in worse control of asthma than 
when used on-demand?" 
Secondary objective 
"Does concurrent' use of regular inhaled corticosteroid therapy influence the effects 
of regular or on-demand inhaled B2 -agonists?" 
2.8 Salbutamol was chosen as the trial drug since it is the most commonly used inhaled 
bronchodilator in the UK and in most other developed countries. 
2.9 The trial design involves randomisation of patients to treatment which does not fully 
accord with the guidelines issued by the BTS. It should therefore be emphasised that the 
BTS guidelines are only recommendations and that one aim of the proposed trial is to 
provide accurate experimental evidence to infonn the revision of those guidelines. The 
BTS is represented on the National Asthma Task Force and fully endorses this trial. 
3 Feasibility study 
3.1 Feasibility studies have been completed in the General Practice Research Framework 
(GPRF) providing infonnation on acceptability, recruitment, withdrawal and 
exacerbation rates. 
4 fe[5onnel and responsibilities 
4.1 Steering Committee 
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4.1.1 The ~rotocol has been de~eloped by a trial Steerin~ Committee from the Therapy 
I Working Group of the NatIOnal Asthma Task Force In collaboration with the GPRF 
Co-or~inating Centre ~nd with advice fro~ general practitioners. The steering 
comnuttee would contInue throughout the tnal and would seek advice from other 
members of the Therapy Working Group as required. 
4.1.2 Professor Tak Lee would have overall responsibility for the trial and 
Dr Madge Vickers would co-ordinate the trial in the GPRF. Ms Sarah Dennis would 
be responsible for the conduct of the trial on a day-to-day basis, liaising with the 
participating general practices and with the Therapy Working Group. Statistical 
input would be provided by Mr Christopher Frost working with 
Professor Stuart Pocock. Clinical advice would be provided on a day to day basis 
from the Unit by Professor Tom Meade and if necessary by other members of the 
Therapy Group, Dr Graham Crompton in particular. 
4.1.3 In each general practice one clinician would be responsible for the conduct of the trial 
and a research nurse for day-to-day trial management and data collection. All the 
research nurses would receive thorough training in the management of asthma. The 
MRC training nurses would be the first point of contact for nursing queries and 
would be responsible for quality control during the study. 
5 Ethical approval 
5.1 Each participating practice would seek ethical approval from its Local Research Ethics 
Committee. Approval for the feasibility study was obtained from the 4 LREC's covering 
the 5 practices taking part. 
5.2 Approval for the study is also being sought from the Royal College of General 
Practitioners Clinical Research Ethics Committee. 
6 Study design 
6.1 The design is a randomised, double-blind, placebo controlled trial of salbutarnol 400 J.1g 
four times daily. This choice of design minimises the potential for bias in the study. A 
(non-randomised) observational study comparing regular users of salbutamol with 
controls could be biased because controls would tend to have less extreme asthma. A 
crossover study (where each patient receives both salbutamol and placebo for a period of 
six months each with the order of treatments being randomised) could possibly be hard 
to interpret if the effect of one treatment persists into the period of time where the 
participant was on the other treatment. 
6.2 The trial would recruit mild to moderate asthmatics: those whose asthma was controlled 
only by B2-agonists and those currently taking inhaled steroids. Unstable asthmatics and 
those who rarely require anti-asthma treatment would be excluded. 
6.3 Patients would be recruited from 70-80 general practices in the GPRF. Practices from 
rural, urban, inner-city and industrial areas would be included in an attempt to. cO~'er 
variations in pollution and distribution of pollen and other allergens. The contl~umg 
recruitment to the GPRF means that there are a large number of practices avadable 
particularly for recruiting the patients on B2-agonists only. 
, 
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6.4 All patients will then be randomised to receive salbutamol or placebo. Those taki 
inhaled steroids will continue to do so throughout the trial. All patients will continue ~g 
have their usual bronchodilator, for emergency use when it is important to have; 
inhaler containing a known bronchodilator. 
6.5 Patients would be treated for one year thus covering any seasonal variation in the 
severity and control of their asthma. 
7 patient selection 
7.1 Males and females aged 18 years and over. 
7.2 Asthma of at least one year's duration. 
7.3 Current use of a bronchodilator MDI at least twice in a week. 
7.4 No oral steroids within 6 weeks of study entry. 
7.5 Ability to use a MDI and a Diskhaler efficiently. 
7.6 Bronchial asthma will be defined as a peak expiratory flow (PEF) greater than 50% of 
the predicted normal with 15% diurnal variability and an absolute minimum peak flow 
variability of 60 litres per minute. This may be confirmed by previous documentation in 
the medical notes or during the three week run-in period. 
8 patient exclusion at entry 
8.1 Treatment with oral steroids within six weeks of study entry. 
8.2 Patients taking inhaled steroids at a dose of greater than 2 mg per 24 hrs. 
8.3 Admission to hospital because of asthma within six weeks of study entry. 
8.4 Asthma not requiring at least twice weekly bronchodilator therapy. 
8.5 Treatment with sodium cromoglycate, nedocromil sodium, ipratropium bromide, 
oxitropium bromide, theophyllines, long-acting inhaled and any oral beta2-agonist 
preparation. 
8.6 Other significant lung disease or concomitant major illness. 
8.7 Pregnancy and risk of pregnancy. 
8.8 Inability to use an MDI and a Diskhaler effectively as determined by the nurse. 
8.9 Inability to use a peak flow meter and complete a diary card. 
8.10 PEF less than 50% of the predicted normal value. 
9 Treatment regimens . 
9.1 Allocation of treatment. . 
Patients would be stratified according to inhaled steroid use; with three bands 
comprising none, low (100 J,lg-800 J,lg daily) and moderate (between 800 J,lg and 2 mg 
daily) dose inhaled steroids. Allocation to active or placebo treatment would be at 
random with numbers equally balanced in each stratum between randomised groups 
which would be achieved by undertaking the randomisation at the co-ordinating centre. 
Randomised treatment will be double blind, neither the patient nor the nurse and OP 
knowing the treatment being received. Patients would be asked whether they thought 
they had been taking active or placebo and their reasons for their decision at the final 
assessment. Arrangements for breaking the codes have been made for 24 hours cover. 
9.2 Regular inhaled salbutamol. 
The adult dose of salbutamol is 400J,lg four times daily from a Diskhaler .. Dry ~wder 
salbutamol would be used to avoid any possible adverse effects of regular mhalatlon of 
freonslsurfactants/lubricants contained in pressurised metered dose inhalers. 
.----
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9j Patients currently on regular inhaled steroids. 
Patients would continue to take their current inhaled steroid preparation, the dose ran e 
would be from 0.4 to 2.0 mg daily but for individual patients would be kept const!t 
I throughout the study period. 
9.4 Placebo 
Salbutamol placebo preparation would be prepared specially by Glaxo and would be 
identical to the formulation used but would lack the active ingredient. 
10 Trial procedures 
10.1 Potential participants would be identified by a search of GP held patient records, 
contacted by post and invited to attend the surgery to discuss the study with the trial 
nurse. 
10.2 Those patients who attend would be given a full explanation of bronchial asthma, the 
treatments used, the rationale for the proposed trial, the trial itself including details of all 
procedures involved and possible long and short term risks and benefits of participation 
in the trial. At the interview, current health, medical history and eligibility for the trial 
would be assessed by the nurse-administered assessment forms. This would provide 
baseline information on all patients including those who would not be entering the 
study. Those patients who were eligible on the basis of the assessment would be invited 
to consider participating in the trial and would be given clear written explanation of the 
points covered in the interview. Informed consent would not be sought at this stage but 
patients who are interested would be invited to attend for a medical examination 2 to 3 
weeks later. 
10.3 Prior to a medical examination, patients would be invited to participate in the trial; the 
nurse would ensure that they understood the procedure for the trial and that they were 
able to use a MDI and a Diskhaler efficiently. Those who were eligible and willing to 
participate would be asked to sign the consent form. 
10.4 At entry a general medical examination would be carried out including a specific 
symptoms questionnaire and spirometry, to include peak expiratory flow (PEF). The 
nurse would explain how the diary cards were to be completed and how to measure and 
record diurnal PEF. All patients would be supplied with a mini- Wright peak flow 
meter. 
The patient would also be issued with clear instructions on the action to take in case of 
any worsening of their asthma and would be given the telephone number of the surgery 
so that they may obtain advice at any time. 
10.5 Patients would be asked to complete the diary card for an initial run-in period of 3 
weeks durina which time they would continue with their usual medication. At 3 weeks 
they would return to the surgery and the nurse would assess the stability of their asthma 
by reference to the diary cards. 
If eligible the patient would be admitted to the trial, stratified (no current inh~led 
steroids, low (100 J.1g-800 J.1g daily) and moderate (between 800 J.1g ~nd. 2 mg da.tlY~ 
dose inhaled steriods) and randomised to a treatment group. Trial medIcation and dlar~ 
cards would be issued. 
---
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Follow up checks would be undertaken at 4 weekly intervals. The trial nurse would 
assess the patient's asthma by reference to their completed diary cards noting in 
, particular diurnal variation in PEF, changes in symptom score, use of rescue 
bronchodilator and use of oral prednisolone. The asthma assessment fonn and the 
withdrawal from randomised treatment questionnaire would be completed as 
appropriate. Patients withdrawing from randomised treatment would be asked to give 
their consent to follow up through their medical notes. New diary cards and trial 
medication (5 week supply) would be issued. 
Quality of life would be measured at entry and at 6 and 12 months using the 
St. George's Respiratory Questionnaire. In addition, one or more generic health status 
questionnaires would be used, either the Sickness Impact Profile and/or the SF-36. 
Health economic data would be collected either on a daily basis on diary cards or at the 
regular four-weekly follow-up visits and would include: 
i) days lost from work or college whether self-certified or GP-certified 
ii) days unable to continue with usual activities 
iii) use of medication, prescribed and over the-counter 
iv) use of all NHS services. 
Costs of medication, service use, and estimates of the costs of time lost would be 
calculated for each treatment group. 
Compliance would be measured by counting used salbutamol and placebo disks. 
Consideration has been given to measurement of drug concentrations in urine and to the 
use of inhalers with micro-chips capable of recording number and time of inhalations 
but in a large trial such methods are prohibitively costly. At the inital assessment it 
would be established how many reliever inhalers the patient has and the prescription 
data would be used in an attempt to validate compliance with rescue inhalers. In 
previous GPRF trials the good relationship developed between the research nurse and 
participants has been an important factor in maintaining high levels of compliance. 
Patient safety would be ensured by all patients carrying a card with infonnation about 
the study and indicating when they should seek medical help, with the name of the GP 
and practice nurse responsible for the study in that practice. A similar card with details 
of the study and the medication used would be inserted into the patient's medical notes 
for the duration of the study. 
11 Outcome measures 
The main outcome of the trial would be any change in the underlying disease. 
11.1 In the main trial the primary marker of this would be the number of exacerbations, 
fulfilling the criteria in 12.1 over a one year period. If any patient required three 
separate courses of treatment for exacerbation they would be withdra\\n from the study. 
I 
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11.2 Secondary markers of the severity of the asthma would be: 
i) Use of rescue beta2-agonist. 
ii) Diurnal variation in PEF. 
iii) Symptom score. 
iv) Days lost from work/normal activities. 
v) Use ofNHS services - including GP and hospital consultations. 
vi) Changes in overall score on the quality of life questionnaire 
12 Exacerbation 
12.1 Definition of exacerbation 
For the purpose of the trial the onset of a exacerbation is defined as the patient 
demonstrating a clinical need for oral corticosteroids or experiencing two or more of the 
following: 
i) Fall in morning peak expiratory flow, PEF, to <80% of baseline reading on 2 or 
more consecutive mornings. 
ii) Increase in the need for rescue B2-agonist to 3 or more occasions per 24 hours on 
2 or more consecutive mornings. 
iii) Increase in night time score of 1 or more above baseline on 2 or more consecutive 
nights. 
iv) Inrease in daytime symptom score of 1 or more above baseline on 2 or more 
consecutive mornings. 
Recovery from an exacerbation would be defined as. 
i) Return to baseline symptom score QI symptom score stable at new baseline for 7 
days. 
ii) Morning PEF returned to baseline or morning PEF stable at new baseline for 7 
days. 
Management of exacerbation 
12.2 If a patient suddenly and rapidly deteriorates, i.e. brittle asthma; they should be treated 
immediately. 
12.3 Once a patient has experienced an exacerbation, treatment would be at the discretion of 
the GP. Suggested treatment regimens would be to increase the dose of inhaled steroid 
or to prescribe a short course of oral prednisolone. 
12.4 Increase inhaled steroid. 
Double the dose of the inhaled steroid until the morning PEF and symptoms return to 
baseline, and continue for the same number of days again before returning to the 
previous dose. The patient should be seen by the GP at this stage to ensure they are safe 
to return to the previous dose, and do not require further treatment. If after 2 weeks of 
increased inhaled treatment there is no improvement then they should start oral 
prednisolone. 
Under no circumstances should the dose of inhaled steroid be increased before an 
exacerbation in order to prevent its occurrence. 
171 
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12.5 Oral prednisolone 
Oral pre<!nisolone at a dose of 30 mg daily for 7 days. If longer than 7 days treatment 
was reqUlred, extra treatment days would be assessed as sevenths of a course, eg: 1 day 
I t and 5 days or ~ etc. 
13 Withdrawal from randomised treatment 
Patients may withdraw from randomised treatment whenever they wish for whatever reason 
they wish. In addition the following events would precipitate tennination of participation 
in the trial. 
i) Three exacerbations requiring additional treatment or 30 days continuous oral 
prednisolone treatment. 
ii) Any other serious illness at the discretion of the general practitioner. 
14 Data handling and analysis 
14.1 It is proposed that the main trial would involve 1000 patients. The main analysis will 
compare the 500 participants randomised to regular salbutamol with the 500 participants 
randomised to placebo salbutamol. This would give the trial high statistical power to 
detect reductions of the order of 15-20% (the order of minimum reduction that would be 
clinically important) in the average number of exacerbations per year between those 
receiving regular salbutamol and those receiving salbutamol placebo. For example the 
study would have 98% power to detect a decrease of 20% in the nwnber of 
exacerbations and 86% power to detect a decrease of 15% in the nwnber of 
exacerbations if the average number of exacerbations per year in those patients not on 
salbutamol is 1.5. If the number of exacerbations is lower, say 1 exacerbation on 
average per year, the power of the study would still be substantial: 92% power to detect 
a decrease of 20% in the number of exacerbations and 69% power to detect a decrease of 
15% in the number of exacerbations. 
A comparison of the effects of salbutamol on patients taking inhaled steroids and those 
not on inhaled steroids would be possible only if the difference between the two groups 
was large. 
Analysis 
The effect of regular versus on-demand salbutamol would be assessed by comparing the 
average number of exacerbations in the participants randomised to regular salbutamol 
with those randomised to salbutamol placebo. 
In the analysis, the exacerbations would be categonized according the severity, with 
three grades of severity:-
Severe - requiring hospitalization 
Moderate - requring oral conticosteroids 
Mild - fulfilling 2 or more of criteria (i) to (iv) 
. . . h . I al approximations would be Due to the large number of participants In t e tna norm· 1 
. . . ethods for ( lC 
• , 
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analysis of ordered categorical data would also be used as would survival analysis 
techniques for the analysis of time to first occurrence. 
15 Compensation for injury 
The MRC does not hold insurance against claims for compensation for injury caused by 
participation in clinical trials. However, as with other government funded bodies, 
including the NHS, claims resulting from the MRC sponsored trials will be given 
sympathetic consideration and will be dealt with through the appropriate government 
channels. These arrangements are fully in accord with recommendations 6.15 and 6.16 of 
the Medicines Commission in its advice to Ministers on healthy volunteer studies. 
16 Dissemination of results 
16.1 A report would be submitted to the Medical Research Council, the full UK Asthma Task 
Force and the National Asthma Campaign. 
16.2 Papers would be submitted to the appropriate scientific journals. 
16.3 The results would be reported to all practitioners taking part in the study and a 
presentation would be made at the annual MRC GPRF Conference. 
16.4 Consideration would be given to other channels of communication e.g. presentation at 
meetings, reports to RHAs, interested lay bodies and the general media. 
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Appendix 2.4 
In confidence 
Date 
Dear 
In collaboration with the Medical Research Council, the doctors in this practice 
are undertaking a trial into the use of regular inhaled bronchodilators (salbutamol and 
terbutaline) in the treatment of asthma. It is known that these drugs make breathing 
easier in the short - term, but it is not clear how they affect the severity of your asthma. 
The study we are doing will indicate how best to treat asthma patients in the long - tenn. 
We need to recruit adults who have had asthma for more than one year and who 
use their bronchodilator at least twice a week. We need two groups of patients; those 
who take inhaled steroids (beclomethasone and budesonide) and those who do not. 
We should like to invite you to the surgery to find out more about asthma and 
what the trial would involve. If you decide that you do not want to take part in the trial 
you will be under no obligation to do so. This will not affect your future medical care or 
your relationship with any medical staff. 
Please complete the attached questionnaire and return it to the surgery whether 
you wish to take part in the trial or not. If you do not wish to take part we will not bother 
you again. All infonnation will be treated in the strictest confidence and used for 
statistical purposes only. 
Thank you for your time. 
Yours sincerely 
Dr 
General Practitioner 
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MRC Epidemiology and \Iedical Care Cnit 
ASTHMA STUDY 
In Confidence 
1 [Name and address label] 
2 If you are considering the trial, please write your telephone nnmber below ~~) that 
the nurse can contact you 
3 How long have you had asthma? 
Less than I year 
Between 1 and 5 years 
Between 5 and 10 years 
More than 10 years 
4 How many times do you usually use your bronchodilator or reliever inhaler 
(e.g. Ventolin or Bricanyl) ? 
Less than twice a week 
2 or 6 times a week 
Every day 
More than once a day 
5 When was the last time you needed to have a course of steroid tablch or a 
nebuliser? 
6 a) 
Less than 6 weeks ago 
Between 6 weeks and 6 months 
More than 6 months ago 
Never 
Are you taking an inhaled steroid or preventer inhaler 
(e.g. Becotide or Pulmicort)? 
Yes 
b) If yes, how long have you been taking them': 
Less than 6 months 
Between 6 months and 1 year 
More than a year 
7 \\'ould you like to come to the practicl' to tind out more about 
the asthma trial? Yes \ 0 
Thank you for answering the questions. 
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TRUSTl ASTHMA - SCREENING 
PERSONAL DETAILS 
Trial number U~~--1~--1--1 I I 
N8J1le ................. · ...... ······ .. · ........ · .. ·····1 01 21 
Date of birth 1--1--11--1--11--1~ 
Age 
Sex 
Date of screening 
MorF 
I I 11--1--1I_I~ 
CURRENT MARITAL STATUS 
Married or living with partner = 1 
Single, never married =2 
Divorced = 3 
Separated = 4 
Widowed = 5 I~ 
EDUCATION 
1 
10 
12 
18 
20 
21 
27 
ETHNIC GROUP 
Black (Afucan) = 1 
Black (other) = 3 
Chinese = 5 
Pakistani = 7 
White (other) = 11 
Black (Caribbean) = 2 
Bangladeshi = 4 
Indian = 6 
White (British, Irish) = 10 
Other Ethnic Group = 12 
LLI 35 
SMOKING 
Do you smoke"! Yes 0 NoO 
If yes, how many per day? 1 1 1 
If no, have you ever smoked? 
YesO NOO 
When did you stop? 1 1 U~ 
month year 
Are you regularly exposed to other 
peoples smoke? 
YesO NoO 
37 
38 
40 
41 
45 
If Yes Tick !2l Home 0 Work 0 46 
What age were you when you left school or college? 
16 years or YOlmger = 1 
7-19 years old = 2 
20 years old or older = 3 I_I 
EXERCISE 
28 Do you take part in vigorous exercise at least once 
per week? 
Since leaving school or college have you had any 0 
more fuU-time or part-time further or higher Yes NoO 47 
education? If yes, list exercise 
Yes 0 NoD 29 
OCCUPATION 
paid employment = I self-employment = 2 
IIDCmployed =3 housewife = 4 
student = 5 retired = 6 
IIOD-disabled = 7 other = 10 
I I I 30 
Details oflast or current employment 
EMCUCODES 
1_1_1 32 
if··· .. · ........ ·· ................ ·········· .. · .. ·· .. · .. ·· .. ·· .. · 
SC3 manual = 1, non-manual = 2 I~ 34 
r:.._~ 
• ••••••••••••••••••••••••••••••••••••••••• •••• ••••••••••••••• ,--I ----.. 
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 1..-1 ~ 
48 
50 
............................................................. I 52 
CURRENT MEDICAL PROBLEMS 
(other than asthma) EMCU CODES 
....••....•.............................• 
........•.............•••...............• 
•...••••.•.••..........................•. 
••••••••.............•.•••..•.......•..•. 
Time of asthma diagnosis 
I I 
U,-,---,--
I I 
LJ,-'------I 
I I /I J 
month year 
54 
58 
62 
66 
70 
I 01 31 11 
CURRENT MEDICATION EMCU CODES 
.,.~ .. , 
................................. ··· ...... ·· ...... I_LI 12 
......................... ·· ....... ·· .... 1 I I 14 
................. --
................. · ......................... 1 I I 16 
.............. --
............................................ 1 I I 18 
............. --
...................................... · ........... · ...... 1_1_1 20 
How often do you usually use your reliever inhaler? 
1_1_1 times 22 
Tick r2I I_I day I_I week 24 
Total daily dose of inhaled steroid 
1_1_1_1_lllg 25 
ASTHMA ASSESSMENT 
What tends to trigger your asthma? 
(enter Y or N in the boxes) 
Exercise I_I 
Housedust mites I_I 
Cold air I_I 
Respiratory infection 
Emotion 
Cough/sneeze 
Laugh 
Work 
Animals 
Smoke 
Seasonal 
I_I 
I_I 
I_I 
I_I 
I_I 
I_I 
I_I 
I_I 
specify season................... I_I 
Other I_I 
specify .............................. I_I 
Height 
Weight 
............................... I_I 
1_1_1_lcm 
1_1_1_1 kg 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
47 
Peak expiratory flow I_I_I_II/min 50 
% predicted nonnal 1_1_1_1.1_1 % 53 
,-
.n'" 
How ~ften during the last month have you 
expenenced the following symptoms? 
(Not at all = 1, less than four times a week = ., 
4-6 times a week = 3, every day/night = 4, -, 
more than twice a day/night = 5) 
Wheeze 
Cough 
Breathlessness 
Chest tightness 
Waking at night because of asthma 
I_I 
LJ 
U 
I~ 
I_I 
Inability to take part in usual activities U 
EXCLUSION CHECK LIST 
(enter Y or N into the boxes) 
Asthma less than 1 year LI 
Inhaled steroid use < 6 months I_I 
Dose of inhaled steroid 
> 2 mg per day LI 
Other anti-asthma medication I~ 
PEF < 50% predicted normal value I_I 
Oral steroids in last 6 weeks I_I 
Hospital admission for asthma 
in last 6 weeks 
f32-agonist use < 2 per week 
Other lung pathology 
Other major illness 
Suspected or known pregnancy 
Is patient eligible? 
Yes 0 
If NO, state reason 
.................................................... 
...................................................... 
I_I 
LI 
I_I 
I_I 
I_I 
I 01 41 
NoD 
I_LJ 
1_1_1 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
10 
12 
13 
15 
Date of next appointment LULI_II_U 17 
Appendix 2.6 
MRC Epidemiology and Medical Care Unit 
TRUST 5 
ASTHMA STUDY 
BACKGROUND INFORMATION 
It bas recently been suggested in the national press that drugs such as Bricanyl (terbutaline) 
and Ventolin (salbutamol) may cause asthma to deteriorate if used regularly. These drugs are 
still very important in bringing rapid relief to the asthmatic in the event of an attack. What is 
not clear is what effect these drugs have on the underlying disease; i.e. what effect they have 
on the lungs over a long period of time. 
Some studies suggest that reliever inhalers either help or do not change the course of the 
asthma. Other studies have linked the use of reliever inhalers with a worsening of asthma in 
individual patients, a general increase in the number of attacks and the number of deaths from 
asthma. 
It is important that we find out what effect the regular use of reliever inhalers has on asthma 
control so that doctors can decide the best combination of relievers and preventers for their 
patients. 
The only way to do this is to carry out a trial. 
The study will compare the effects of taking salbutamol regularly with 
taking salbutamol only when necessary to relieve 
the symptoms of asthma. 
The Aim of the Study 
The main aim of the study is to establish what effect salbutamol (ventolin) taken regularly has 
on the control of asthma. We will also be able to see whether taking inhaled steroids 
(preventers) alters the effect of salbutamol on asthma control. 
This information can only be obtained from doing this sort of clinical trial. The r~sul.ts will 
enable doctors to be sure that they are prescribing the most effective combmatlOn of 
treatments for your asthma. 
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TRUST S 
What it Would Involve 
We want people who have had asthma for more than one year and currently take either 
inhaled steroids (preventers) and inhaled bronchodilators (relievers) or inhaled 
bronchodilators (relievers) only to control their symptoms. We want to monitor you for 
one year while you continue to take your inhaled steroid and either salbutamol four 
times a day or placebo (a dummy inhaler, i.e. containing no effective medication) four 
times a day. We do not know whether salbutamol will be better than inactive inhalers in 
its effects on the control of asthma in the long term, so you would not be missing out on 
treatment known to be effective if you were given the inactive inhaler. You will still 
have your usual bronchodilator to relieve your symptoms should you need to. Everyone 
has an equal chance of being allocated to either of the treatments. The doctor and the 
practice nurse will not know whether you are taking the active drugs or the placebo and 
nor will you. 
AU patients will continue to have their usual bronchodilator (reliever) inhaler for 
use when needed (rescue inhaler). 
AU people taking part in the study would: 
Have a thorough asthma assessment. 
Be given either salbutamol or salbutamol placebo. 
Be given a Mini-Wright peak flow meter. 
Complete a diary card with details of peak flow, symptoms, drugs taken and days 
off work or when you have needed to see a doctor. 
Return to the practice nurse for reassessment every four weeks for ~ year ~he~ a 
new diary card will be issued and also the next month's supply of tnal medIcation. 
Be given advice about what to do in the event of an asthma attack. 
Be given concise infonnation about asthma and its treatments. 
Be given advice on smoking, exercise and diet ifnecessary. 
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TRUST 6 
:\IRC Epidemiology and Medical Care L nit 
ASTHMA STUDY 
CONSENT FORM 
Patient's Name 
Study number 
The doctors in this practice are working with the Medical Research Council and the 
National Asthma Task Force on a study to investigate the long - term effects of regular 
inhaled salbutamol on the severity of asthma. The stud~T will investigate the long-term 
effects on the control of the asthma, in particular the effects on the number of asthma 
attacks, peak flow, symptom severity and quality of life, and whether this effect is 
changed with the use of inhaled steroids. Salbutamol and inhaled steroids are the most 
commonly used drugs to treat asthma, but the study should identify \\'hich is the most 
effective combination. 
On entering the trial you will be given salbutamol or no salbutamol (placebo) inhalers. 
If you currently take inhaled steroids (preventers) you will continue to do so as directed 
by your doctor, and you will also have your usual bronchodilator for symptom relief 
when necessary. Neither you nor the research nurse will know whether you are on the 
active treatment. Whatever your treatment allocation, during your participation in the 
study you will be kept under regular medical supervision and will see the research nurse 
at four weekly intervals. Should you develop an illness while you are in the study you 
will be given appropriate medical care and withdrawn from the trial if necessary. 
You are free to decide whether you do or do not take part in the study. If you do take 
part, you wilL of course, be free to withdraw from the trial at any time and for any 
reason, if you wish, and if you do so this will affect neither the future medical attention 
that you receive nor your relationship with any medical staff. 
Please would you sign below to indicate that you are willing to participate in the ~hthma 
trial. 
PATIENT'S CONSENT 
I have read the above explanation and the information leatlet. The trial has been 
explained to me orally and I have had the opportunity to ask questions. It is on the h,l-;i' 
of the information from these sources that I agree to participate in the asthma tnal. 
Signed _____________ _ Date 
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GENERAL PRACTITIONER'S AGREEMENT 
I am the general practitioner of the above patient and in my opinion there is nothing in 
his or her medical history to contraindicate entry into the trial. The patient would enter 
the trial with my consent. 
S igned ___________________ D ate 
1 S.~ 
now TO TELL WHEN YOUB ASTHMA IS WQRSE 
SYMPTOMS OF ASTHMA ARE: 
COUGH 
WHEEZE 
BREA 1"I-aESSNESS 
WAKING AT NIGHT WITH BREATHING PROBLEMS 
If any of these symptoms are worse tha" usual, if is a sign that 
your asthma is gelling worse. 
OTHER THINGS TO CHECK: 
USING YOUR RELIEVER INHALER 3 OR MORE TIMES A DAY 
AND GEl liNG LESS BENEFIT FROM IT 
PEAK FLOW READING BELO\V 
DOD 
IF YOU NOTICE ANY OF THESE CHANGES IN 
YOUR ASTHMA 
CONTACT YOUR GP OR PRACTICE NURSE 
CONTACT ______________________ _ 
naEPHONENUMBER ______________ __ 
MEDICAL RESEARCH COUNCIL 
ASTHMA STUDY 
PEAK FLOW DIARY CARD 
PATIENTNAME _____________ _ 
TRIAL NUMBER 
DATE STARTED 
CHART NUMBER 
PEAK FLOW 
000000000 
DDDDDD 
DO 
DOD 
'--, 
f 
e: 
>< 
IV 
00 
1 
J)dlc !>Iartcd till::' diary carel ,_,_, l-.-l~ I~_J 
S~lIIptUIII Scorc 
N u/IIlJcr ur purrs or 
rciie,"er inhaler 
nz: I E\tRinz: I Nlz:ht time I ()a~t1l11c I Night limc I Daytime 
--.-----
I 
I 
I 
"-1---~ . ---1 
Days 
orr 
work 
(mark 
wilhX) 
Visit GJ> Vislt to 
ror 1151hllla A&E ror Stcruld 
(mark wilh astluna tablets or 
A) (mark wilh change In 
For ulher A) Inhaled 
(lIIa/"k wilh For other sleroids 
0) (mark wilh (mark 
0) with X) 
~···-I--
I 
~-----t --
-- ---I -- ---1---- ----+---~ 
-t 
I 
---+-- ---1- " 
i 
. -" 
I 
I 
- + ~ I-I 
- L-
__ 1 
~. -- ~ ----l 
I 
------·~"---~-t-----+_---_j 
19 
20 
21 
22 
23 
24 
25 
26 
21 
28 
29 
30 
31 
32 
33 
3~ 
~~ --- r~---1 t 
--1----l35 
I 
--.-
36 
0- ~ 
--
--, ~---1- ---1 1 ____ "_ I 
Peak Flow Reading 
Uerorc In.haler 
Morning Enning 
I 
1 
I 
, 
; 
Hslt GI' Hslt to 
ror A&E for SIc:roid 
asthma aslhma tablets or 
{mark (mark chan&cln 
Number or purrs of Days orr wilh A) "ilh A) inhaJed 
S~TllptO"' Score rcUc\"Cr inhaler ,,"ork For other For olhtr steroids 
Night tunc Da)1lnlc Night tlnu~ Da)11mc (mark {mark (muk (mark 
"ith X) with 0) "ith 0) "ith X) ~ 
--
- ~" 
-
- --- ------ ---~-
-
- ~ ------
----
"-
--
-- --~ 
-
--- -. - -~ " 
------ " "- --
- ~--~-
- "-
-----
~"------
----- "-- --- --
_._- - --- ~---- f------
----
-
----_ .. _------
I 
t -
"-
I 
t ------~-t - -- ----- ------------
I I ! I L __ u. --- -- - - -I 
"-- - " " - ---- ----- --
J I j 
------ ---"-
I'kA\C 11,1 <&n\ oIlier dru~'\ pl"orrilJcd fur ~ou "lid tal,cll by you this month (please include the name, the dose, the routc, the date started and fini~hnJ "herc necessary). 
, 
'Na" HUC770NJ!l FOR <:C> ........ ~a ""'-"&.PEAK FL<>'VV D.ARV CARD 
Please read (he insuuc::tJons c:an:ftdly before starting (0 complete the diary. The iruonnation you 
supply in Ihis asthma dialy is important in enabling us to dctenninc how well your asthma is 
being controlled by the trial medication. The diaries from all the asthmatics taking part in tbe 
study "'ill be used to determine which is the most effective treatment. We would therefore 
appreciate your accuracy in completing this form. 
PEAK FLOW MEASUREMENTS 
Always record your peak flow reading every morning and every evening before using your trial 
inhalers. Stand up to take your peak flow. and carefully record the best of3 readings in the 
correct box. If you forget to record your peak flow. leave the box blank. If you enter a made-up 
value it \\ill spoil the results for the trial. 
SYMPTOM SCORE . 
Enter the number that best describes your symptoms for that day or night in the correct box. 
NIGHT-TIME SYMPTOMS 
This should be assessed each morning immediately after awakening. (Symptoms are chest 
tightness. wheezing. breathlessness and cough.) 
o = No symptoms during the night 
1 = Symptoms on waking but not causing you to wake early 
2 = Symptoms causing you to wake once or to wake early 
3 = Symptoms causing you to wake twice or more (including waking early) 
-' == Symptoms causing you to be awake most of the night 
5 = Symptoms so severe that you did not sleep at all 
DAYTIME SYMPTOMS 
This should be assessed each evening. just before going to bed. (Symptoms are chest 
tightness, wheezing. breathlessness and cough.) 
o - No symptoms during the day 
1 - Symptoms for one short period during the day 
2 - Symptoms for two or more short periods during the day 
3 - Symptoms for most of the day which did not interfere \\ith usual daytime activities 
.. - Symptoms for most of the day which did interfere with usual da}1ime activities 
5 - Symptoms so severe that you could not perform your usual daytime activities 
DAYS OFF WORK/COLLEGE 
•• _~ •• ..: ....... _..yt ___ .. ,.... ••• _ •• "" ___ • _ •• __ .1 ..... _ ..... ____ " ___ L ... ____ . r •• 
.-~ 
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ASTHMA - TRUST STUDY TRUST 8 
FOLLOW-UP 1-13 
Trial number I-'_I_I_LJ_I~~_I 
NaJDe ................................... · ... ·······1 01 61 
1 01 21 
Date of birth I~_II_I~I_I_I 
Age 1_1--' 
Date of assessment LJ~I--'~I~-' 
Assessment number 1_1-' 
CURRENT MEDICAL PROBLEMS 
(other than asthma) 
Any new medical problems? 
YesD NoD 
If yes, specify 
1 
10 
12 
14 
20 
22 
28 
30 
.......................................... ....... I_LI_I_I 3 1 
................................................. LI_I_I--' 
Iffemale, do you have any reason to believe 
that you may be pregnant 
YesD NoD 
Any change in current medication? 
YesD NoD 
If yes, specify 
......................................................... I~-' 
"........................ .... ............ ............... 1 I I 
_--1 
Have you visited the hospital because of 
WOrsening asthma in the last 4 weeks? 
YesD NoD 
Have you taken a course of steroid tablets 
~ the last 4 weeks? 
YesD NoD 
Have you increased the dose of inhaled steroids 
in the last 4 weeks? 
• YesD NoD 
llf''yestto any of the above questions, 
r llleasecomplete TRUST 16 
I 
i 
35 
39 
40 
41 
43 
45 
46 
47 
SMOKING 
Do you smoke? YesD 
If Yes, how many per day? 
Are you regularly exposed to other 
people's smoke? 
YesD NoD 
If Yes, Tick ~ HomeD workD 
ASTHMA ASSESSMENT 
Height I~-'-'cm 
Weight I_U-' kg 
Peak expiratory flow I~-'.-I llmin 
% predicted normal 1_1.-1-'·1-'% 
How often during the last month have you 
experienced the following symptoms? 
(Not at all = 1, less than four times a week = 2, 
4-6 times a week = 3, every day/night = 4, 
more than twice a day/night = 5) 
Wheeze I_I 
Cough 1-' 
Breathlessness U 
Chest tightness 1-' 
Waking at night because of asthma U 
Inability to take part in usual activities U 
COMPLIANCE 
How many unused blisters? 
How many should be unused? 
1 01 71 
1 0121 
1 1 I 
1-'-' 
48 
49 
51 
52 
53 
56 
59 
62 
66 
67 
68 
69 
70 
71 
10 
12 
14 
16 
Date of next appointment LLILU,-I -,,-,I 18 
Final assessment only. 
Do you think you were taking 
salbutamol 
Placebo 
Reasons ................................ . •.....•.• 
.•.•.................................•.•.• 
u 
U 
LJ 
LJ 
24 
2S 
26 
.,., 
.. ' 
« 
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TReST 11 
MRC Epidemiology and Medical Care Coit 
ASTHMA STUDY 
WITHDRAWAL FROl\f RA1\l)O~lISED TREAT:\IE:\T 
Trial number 
Name 
----------------------------------------
! 01:2 12 
Date of withdrawal from raodomised treatment 14 
REASONS FOR \VITHDRA WAL FROl\f RANDOl\USED TREAT\IE:\T 
I. Four serious exacerbations YorN 2() 
2. Requiring additional treatment for asthma YorN 21 
3. Development of a major illness Y or \: 
4. Persistent poor compliance Yor~ 
1 "\ 
--' 
5. Moved away Y ur \: 24 
6. No longer wishes to participate Y or \' 
10; 
7. Pregnancy Y or \: 2h 
8. Other, please spcci t~' reasons Y or:- '27 
Appendix ~. 1 1 
TRl'ST 12 
:\lRC Epidemiology and ~ledical Care Unit 
ASTHMA STUDY 
CO~SENT FOR'I 
Patient's Name 
Study number 
Although you have been withdrawn from the Medical Research Council asthma study 
and will be no longer taking the trial medication. we would like your pennission to 
follow your progress for the duration of the trial through your medical records. Any 
infonnation obtained would only be connected \\·ith your asthma and no other hL'alth 
problems, and all infonnation would be treated with the strictest confidence. 
The infonnation to be obtained would be the number of asthma attacks in the remaining 
part of the study year. and any visits to the doctor or practice nurse. 
If you do not wish to be followed up for the remaining part of the study year your future 
medical attention and your relationship with the medical staff will not be atlected. 
Please would you sign below to indicate that you are willing to take part in the follow -
up. 
PATIENT'S CONSENT 
I have read the above explanation and the method of follow - up has been fully 
explained to me. It is on the basis of the infonnation from these sources th.1t I ,1:-:rt:C tl) 
participate in the follow - up. 
Sibrned ________________ _ 
Date 
------- .---
IS9 
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Synthesising and evaluating outcome measures for asthma in 
adults and children. 
Background 
The health status of patients with asthma, and thus the effectiveness of treatment fnr 
asthma, have traditionally been measured by lung function, typically peak eXpir3tl)ry 
flow rates. Although this approach is entirely feasible in the context of hu~y clinical 
practice, it suffers from two main shortcomings. First it takes no account of the very 
different ways in which the same loss of pulmonary function affects the ditTerent 
patients. Secondly it provides no basis for choosing between asthma and other patients 
in the allocation of scarce health care resources, a responsibility that falls to all 
purchasers in the new NHS. 
Justification 
Increasing acceptance of the limited value of pulmon3I)' function as the only outcomc 
measure for asthma has led to proposals for alternatives. These have rangcd from 
asthma specific scales that examine the effect of the condition on daily li\ing 1.2 through 
patients centred scales for respiratory illness in general 3 to general scales that eO\'cr ~!I1 
conditions but may not be responsive to subtle variations in pulmonary function .15. 
This diversity has led to those seeking to evaluate alternativc models llf care for asthma 
to use ad hoc combinations of existing measures 6. Thus the key issues to be ~lddn:"sed 
within the R&D priority are how valid. reliable, responsi \c and gcncralisabk 7 arc the"l' 
measures? \\!hat optimal combinations of measures can be recommended tt)f lise in 
three different contexts - normal clinical practice. routine audit and monitt)rin~ and 
rigorous evaluation of alternati\e policies'? 
Description of research 
. . . . "t' a't11111a rCl:Ol!nitlOll "hould he \\ hen syntheslsmg and e\aluatmg outcome measuro t)r S • ... 
made of different clinical scttings and the purpt)scs to whiL'h the outC(lll1e will h· PUl 
Appendi\ .! I 
Reliable outcome measures are needed to evaluate disease status treatment mod' t~ . 
• 1 lcath.1n 
and prognosis in routine clinical settings, in single modality therapeutic r~'L\lr-:h and 
health services research, such as long tenn disease modification and the ~l'~~"sme:~: of 
the effectiveness of health care systems. 
Outcome measures that should be considered are: 
• Indices of lung function impainnent: the relative sensitivities llf measures of airtll1\\ 
obstruction and their likely variable sensitivity in relation to the ,,~\erity of asthma 
and the type of intervention, could be evaluated by a systematic review l)1' puhlishL'd 
randomised control trials. 
• Diary cards have neither been standardised nor formally e\aluated. The concept (If a 
"symptom-free day" is increasingly used but has not been validated. Primary 
research in this area would be of interest. Many definitions have been used for acute 
episodes and a systematic review could examine their relatin~ utility. 
• Health status measurements specific for asthma have been de"igned. tho"e in adult~ 
being better validated than those for children, for whom a better questionnaire ma~' 
well be needed. The research needs to be focused on \\'hether the existing me,hun:s 
of health status can be used to measure improvements in care and outcome in a 
reliable and specific way. 
Resource use: outcome measures of days off (work or school). (j P, hospital ,tltendancc. 
admissions and prescribing need to be standardised, unbiased and simple, and the 
validity of data collection and recording requires validation. 
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Appendix .: ~ 
Medline Search Strategy 
Database: All Medline Segments < 1966 to latest> 
Set Search Rrsuits 
001 randomized controlled trial.pt. 1 ~(1~54 
002 randomized controlled trials.sh. 19914 
003 random allocation.sh. 44() _~ 3 
004 double blind method.sh. h62SS 
005 single blind method.sh. 6010 
006 1 or 2 or 3 or 4 or 5 2 1 ()l)44 
007 animal.sh. 323() 1 ~_~ 
008 human.sh. 74224;-\6 
009 7 not (7 and 8) 2537172 
010 6 not 9 199423 
011 clinical trial.pt. '1~"';;'7 - 1_-
012 exp clinical trials/ 1256~;-\ 
013 (clin$ adj3 trial$).ti,ab. 61959 
014 «singlS or doubl$ or treb$ or tripS) adj3 (blindS or maskS).mp. 639()3 
015 placebos.sh. 210'7() 
016 placebo$.ti,ab. 6S643 
017 random.ti,ab. 6004: 
018 research design.sh. 2S54h 
019 1 1 or 12 or 13 or 14 or 15 or 16 or 1 7 or 18 478870 
020 19 not 9 45625, 
021 20 not 10 267317 
022 comparative study.sh. l)()4SS 1 
023 exp evaluation studies/ 4()1894 
024 follow-up studies.sh. 24564S 
025 prospective studies.sh. 137796 
026 (control$ or prospectiv$ or volunteerS).ti,ab. 11 S I (1(,lI 
027 22 or 23 or 24 or 25 or 26 ~4~2714 
028 27 not 9 1 S3()l)l)5 
029 28 not (10 or 21) 151 )_~30() 
030 asthma.sh. 554-5 
031 asthma.ti,ab. 4«~ 7S 
032 30 or 31 h4_~ 14 
033 bronchodilator agents.sh . S -;'()5 
..... 10 1114 034 adrenergic beta agonists.sh. 
035 inhaled.ti,ab. 155_~4 
036 33 or 34 Ijl17b 
037 36 and 35 
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038 32 and 37 I! " I 
039 38 and (10 or 21 or 29) lOSS 
l) l) " 
040 limit 39 to english language 
r ,~l) 
041 limit 40 to all adult < 19 plus yl'ar~ (l41 
042 limit 41 to abstracts 
1l)3 
Appendix 4.3 
Data collection sheet 
Author 
Article title 
Source 
InstitutionalafftHation 
Refman ID 
Aim 
Primary outcome 
Secondary outcomes 
Intervention 
Number of interventions 
Condition 
Other treatment allowed 
Subjects 
Duration of intervention 
Method of collection 
Consent 
RCT 
Was it truly random? 
Was randomisation blinded? 
How complete follow-up? 
Data from losses to follow-up? 
Assessers blind to treatment? 
Comparable baseline data? 
Groups otherwise treated 
indentically? 
Target population 
Inclusion criteria 
Exclusion criteria 
Characteristics - age 
sex 
Time interval 
First and second 
First and last 
Analysis 
Statistics test 
To be included 
If no: reasons 
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Reason for exclusion First stage Second stage 
Challenge 94 3 
Pathology 86 
ICS 71 
Mechanisms 56 
Device \ 47 1 
Epidemiology / HSR 37 
Severity 26 
--Theophyllines 22 
Dose Response 20 1 
Safety / efficacy 17 1 
Other 16 4 
Sport / exercise 14 
Reviews 12 
Leukotrienes 11 
COPD 10 
QOL 9 
Health Economics 8 
Nocturnal 8 2 
Nedocromil 7 
Age 6 
Guidelines 6 
CVS side effects 5 
Pregnancy 5 
FEV1 0 4 
Table 3.4.2 0 2 
Serial lung function 0 7 
Total 593 25 
Table 4.1 
Reasons for exclusion for papers identified by Medline search. 
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Reasons for exclusion First stage Second stage 
Pathology/mech 73 
Challenge 66 
Device 49 
Severity 22 
Steroids 22 
Other 21 1 
Theophyllines 19 
Language 18 
Dose Response 10 
Side effects 9 
Sport / exercise 9 
Serial lung function 9 9 
Leukotrienes 7 
Nedocromil 6 
Nocturnal 6 
QOL 6 
Oral b2-agonist 6 1 
Open 4 
Epidemiology / HSR 2 
Health Economics 2 
Safety / efficacy 2 1 
Pregnancy 1 
Total 369 12 
Table 4.2 
Reasons for exclusion for papers identified by CCTR search. 
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Appendix 6.1 
6.1 Regression analysis for the relationship between TRUST 
exacerbation and mean PEF. 
The last three weeks of the run-in period were used to calculate the baseline mean values 
for morning, evening and daily PEF. Mean values for each of the PEF variables in tum 
were generated for the whole follow up period and also for each month of follow-up in 
tum. In addition for each patient, the dataset also contained the dates on which they entered 
and left the study, follow up time, number of days taking additional corticosteroids, 
treatment allocation and the total number of exacerbations according to the TRUST 
definition. 
Two basic regression models were used; the first model was a logistic regression model that 
assessed the degree to which change in a variable such as mean morning PEF, adjusted for 
baseline morning PEF and length of follow up, could predict whether a patient experienced 
an exacerbation or not. The second model was a Poisson regression model that assessed the 
degree to which change in a variable such as mean morning PEF, adjusted for baseline 
morning PEF and length of follow up, could predict the rate of exacerbations experienced. 
6. 1. 1 Logistic Regression Model 
log odds( ex) = Po + PI amdiff + plampefl 
Where "ex" was the binary variable for the presence or absence of an exacerbation, 
uamdiff' was the change in mean morning PEF between baseline and follow up and 
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"ampefl" was mean baseline morning PEF. EXP(~I) represented the odds ratio for having 
an exacerbation per unit increase in "amdift", adjusting for baseline. The model was 
implemented in STAT A as: 
logistic ex amdiff ampefl. 
In order to examIne whether the relationship between TRUST exacerbation and the 
difference in mean PEF between baseline and follow up was linear; "amdiff' was divided 
into five 50 IImin groups. The reference group included all patients with a change in mean 
morning PEF from baseline of < -50 I/min. The likelihood ratio test was used to compare 
the earlier model with one where the categorical indicators were added. If the latter showed 
no statistically significant improvement at the 5% level, the simpler linear trend model was 
used. 
6. 1.2 Poisson Regression Model 
log A = po + PI amdiff + ~2ampef 
Where A. was the rate of exacerbations per unit follow-up time. STAT A calculated this 
from the total number of exacerbations experienced by each patient and the total amount of 
follow up for each patient. EXP(Pl) represented the rate ratio of exacerbation per unit 
increase in "amdiff" adjusted for baseline. Because patients could experience more than 
one exacerbation during the follow up period and because exacerbations do not necessarily 
occur independently of one another the model was adjusted for clustering of exacerbations 
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on patient study number in addition to follow up; this inflated the standard errors 3ccording 
to the degree of clustering. The model was tested for linearitv as with the logistic 
regression model. The model was implemented in ST A TA using: 
glm totex amdiff ampefl, fam(pois) link(log) Inoffset(followup) scale(x2) eform 
The generalised linear model is the same as the Poisson model but the standard error is 
inflated by a factor of the square root of the Pearson chi-square statistic diyided by the 
residual degrees of freedom, in order to compensate for the over-dispersion due tll the 
within person clustering (1). Using "gIm" the distribution of the dependant \'ariabk must 
be specified, in this case it is Poisson, "lnoffset" specifies the person years follow up, 
scale(x2) sets the scale parameter to Pearson chi-squared and "eform" means that the 
coefficients are displayed as rate ratios. 
References 
(1) McCullagh P, NeIder JA. Generalised Linear ~lodels. London: Chapman and Hall, 1989. 
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6.2 Regression analysis for the relationship between TRUST 
exacerbation and mean symptoms. 
The last three weeks of the run-in period were used to calculate the baseline mean values 
for day and night time symptoms. Mean values for each of the variables in tum \\'Cre 
generated for the whole follow up period and also for each month of follow-up in tum. In 
addition for each patient, the dataset also contained the dates on which they entered and 
left the study, follow up time, number of days taking additional corticosteroids, treatment 
allocation and the total number of exacerbations according to the TRUST definition. 
Two basic regression models were used; the first model was a logistic regression model 
that assessed the degree to which change in a variable such as mean daytime symptoms. 
adjusted for baseline daytime symptoms and length of follow up, could predict whether a 
patient experienced an exacerbation or not. The second model was a Poisson regression 
model that assessed the degree to which change in a variable such as mean da)1imc 
s)lnptoms, adjusted for baseline daytime symptoms and length of follow up, could 
predict the rate of exacerbations experienced. 
6.2. 1 Logistic Regression Model 
lo~ odds(ex) = ~o + ~Idysdiff + ~2d~'s 1 
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Where "ex" was the binary variable for the presence or absence of an exacerbation. 
"dysdiff' was the change in mean daytime symptoms between baseline and follow up and 
"dys 1 " was mean baseline daytime symptoms. Exp(~ 1) is the odds ratio of exacerbations 
per unit increase in symptom change from baseline, adjusted for baseline. Linearity was 
examined as described in Appendix 6.1. "Dysdiff' was categorised into fiyc groups 
differing by one unit. The reference group included all patients with a change in mean 
daytime symptoms from baseline of < 2.5 11. 
6.2.2 Poisson Regression Model 
log A, = ~o + ~ldysdiff + ~2dysl 
As described earlier, A is the rate of exacerbations. The explanatory variables included 
the difference in mean daytime symptoms between baseline and follow up, "dysdiff', and 
the baseline value for mean daytime symptoms, "dys 1". As described earlier the model 
was adjusted for clustering of exacerbations on patient study number in addition to tt )llow 
up. The model was tested for linearity described in Appendix 6.1. The model was 
implemented in STAT A using: 
glm totex dysdiff dysl, fam(pois) Iink(log) Inoffset(followup) scalr(,,2) {'form 
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Appendix 6.3 
6.3 Regression analysis of exacerbations on diary card 
variables. 
Logistic regression was used to assess the effect of the diary card variables on the odds of 
experiencing a TRUST exacerbation. The crude regression model \\"as a univariate 
model adjusting only for baseline values. The adjusted odds ratio was obtained using a 
multivariate model that adjusted for age, sex, inhaled steroid level, baseline values and 
clustering on patient study number. 
For each of the four definitions of exacerbation in tum the logistic regression analysis 
was repeated for days of exacerbation and linked periods of exacerbation when standard 
errors were adjusted for clustering on patient study number. The model was: 
Log odds (exacerbation) = ~o + ~I(ampet) + ~2(ampef1) 
\\"here "ampef' was morning PEF and '4ampefl" was baseline morning PEF. The saml' 
model was repeated for e\"ening PEF, diurnal variation, daytime s)mptoms, night time 
s:lnptoms and rescue P2-agonist use singly and together in a multi\ariate model. 
Appendix 6.4 
6.4 Analysis of use of additional corticosteroids on diary card 
variables. 
Logistic regression was used to assess the effect of the diary card variables on the odds of 
starting a course of additional corticosteroids. The crude regression model was a 
univariate model adjusting only for baseline values. The adjusted odds ratio was 
obtained using a multivariate model that adjusted for age, sex, smoking, baseline \'alues 
and clustering on patient study number. 
log odds (corticosteroid exacerbation) = ~o + ~I(ampef) + ~2(ampef1) 
\\'here "ampef' was morning PEF and "ampefl" was baseline morning PEF. The same 
model was repeated for e\'ening PEF. diurnal variation, daytime symptoms, night time 
symptoms and rescue Pragonist use singly and together in a multi\'ariate model. The 
regression analysis was repeated to investigate the relationship between the diary card 
\'ariables and courses of oral or increased corticosteroids and inhaled cortiet)steroids 
separately. 
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